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ABSTRACT 
REID AUSTIN ROBERTS: Harnessing What Lies Within –  
Programming Immunity with Biocompatible Devices to Treat Human Disease 
(Under the direction of Jenny Ting, PhD and Joseph DeSimone, PhD) 
 
Advances in our mechanistic insight of cellular function and how this relates 
to host physiology have revealed a world which is intimately connected at the macro 
and micro level.  Our increasing understanding of biology exemplifies this, where 
cells respond to environmental cues through interconnected networks of proteins 
which function as receptors and adaptors to elicit gene expression changes that 
drive appropriate cellular programs for a given stimulus.  Consequently, our deeper 
molecular appreciation of host homeostasis implicates aberrations of these 
pathways in nearly all major human disease categories, including those of infectious, 
metabolic, neurologic, oncogenic, and autoimmune etiology.   
We have come to recognize the mammalian immune system as a common 
network hub among all these varied pathologies.  As such, the major goal of this 
dissertation is to identify a platform to program immune responses in mammals so 
that we may enhance our ability to treat disease and improve health in the 21st 
century.  Using advances in materials science, in particular a recently developed 
particle fabrication technology termed Particle Replication in Non-wetting Templates 
(PRINT), our studies systematically assess the murine and human immune 
response to precisely fabricated nano- and microscale particles composed of 
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biodegradable and biocompatible materials.  We then build on these findings and 
present particle design parameters to program a number of clinically attractive 
immune responses by targeting endogenous cellular signaling pathways.  These 
include control of particle uptake through surface modification, design parameters 
that modulate the magnitude and kinetics of biological signaling dynamics that can 
be used to exacerbate or dampen inflammatory responses, as well as particle 
designs which may be of use in treating allergies and autoimmune disorders.  In 
total, this dissertation provides evidence that rational design of biocompatible nano- 
and microparticles is a viable means to instruct therapeutic immune responses that 
may fundamentally improve how we treat human disease. 
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CHAPTER 1 
INTRODUCTION 
This dissertation seeks to define a platform for programming immune 
responses in order to fundamentally improve how we treat disease in the 21st 
century.  It is our tenet that therapeutically relevant instruction of the immune system 
will require extremely modular and biocompatible systems capable of providing a 
range of biological signals on the physical scale at which cellular networks 
communicate.  These nano- and micro-scale devices will thus be capable of 
programming host biology in defined manners.   
The research presented herein spans the fields of cell signaling biology, 
immunology, materials science and bioengineering.  To this end, I first provide 
background of relevant information for each of these fields to frame this dissertation.  
Subsequent chapters will expound in more detail work performed and findings 
uncovered.  While not exhaustive, this introductory overview of immune system 
function from a cellular network perspective provides the framework from which I 
pursued this dissertation.  Immune cells precisely sense their environment in order 
to elicit appropriate responses.  These responses are required to defend against 
infectious diseases but also drive pathology in the setting of non-communicable 
diseases (NCD) if uncontrolled.  Because the vast majority of the world’s population 
are susceptible to microbial infection and NCD, manipulating immune system   
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function in a targeted manner should become a key intervention in the clinician’s 
arsenal.   
 
1.1 CELLULAR FUNCTION FROM A NETWORK PERSPECTIVE 
In order to fully appreciate what is required for a human to maintain health over 
the course of an average modern lifespan of 67.2 years [3], it is worthwhile to first 
understand what constitutes a human body at the cellular level.  There are trillions of 
human cells specialized for their functional purpose, be it detoxifying substances in 
the liver, perceiving light in the retina of the eye, forming memories in the brain, 
providing structural support as bone, or patrolling the body for signs of infection to 
name but a few examples [4].  Yet all these trillions of cells emerged from a single 
union between a sperm and an egg, and thus divided and specialized throughout 
development to fill all the niches required for a functioning human being.   
While the details of development and niche specialization are complex, 
unique and beyond the scope of this dissertation, suffice to say that some simple 
repeating themes emerge that we can use to guide our understanding of human 
biology.  Most critical of these themes is the overarching principle that a cell 
responds to environmental cues in order to ensure the survival of the organism it 
constitutes, be it unicellular or a multicellular organism.  This response is dictated by 
signal transduction pathways that first emerged in unicellular organisms responding 
to intracellular signals picked up from the environment and then was expanded to 
extracellular detection in order to support the complexity of higher order multicellular 
species that are distant ancestors of humans [5,6].   
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At its most basic, signal transduction requires a cell to sense information 
encoded in its environment and then relay that information to immediate response 
networks such as G-protein coupled receptors as well as the nucleus of the cell, 
where expression of genes can be modulated in order to better adapt the cell to its 
current state of experience.  A common example is the metabolic response of 
humans to glucose, a nutrient taken in from the environment in the form of dietary 
sugar consumption.  Specialized cells in the pancreas - beta cells - bind glucose with 
glucose receptors and in response, upregulate expression of insulin and trigger its 
release into the bloodstream.  Systemic insulin can then bind cell-surface bound 
insulin receptors throughout the body which coordinate uptake of glucose from the 
bloodstream for immediate or long-term energy use depending on the needs of the 
organism [7].  Using this simplified example, we can see all the hallmarks of signal 
transduction and network coordination of an appropriate response: 1) sensing of the 
environment; 2) relaying that information to the nucleus; 3) turning on appropriate 
gene programs; and 4) production of proteins that enable downstream functions 
required for the homeostasis of the organism at large, including secretion of host-
derived environmental cues out of a cell.   
We must also acknowledge that the human organism is not only integrating 
signals from its ~10 trillion human cells, but also must maintain order with the 
estimated 100 trillion bacterial cells which cohabit each of our bodies [8].  This latter 
insight has only come to the forefront of scientific knowledge in the past decade but 
has already transformed our understanding of the human body: we are not separate, 
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isolated entities in the world at large, but more of an ecosystem of multiple species 
that shifts depending on the geographic and dietary environment [8-14].   
With this basic theme of cellular response to environmental cues in mind, let 
us now discuss how the human immune system maintains homeostasis of the 
organism as this information can enable more selective and integrated therapeutic 
interventions for the panoply of health ailments that afflict modern man.  While we 
will delve into more explicit details from hereon, it is of utmost importance to recall 
the underlying theme that an organism’s survival depends explicitly on its ability to 
respond appropriately to its environment.  As we will see, an appropriate response 
often requires involvement of numerous signaling pathways and biological networks 
within and between cells. 
 
1.2 THE IMMUNE SYSTEM: PROVIDING CONTEXT, BRANDING RESPONSES 
While there are thousands of signal transduction pathways in human cells, we 
will restrict ourselves to discussing some pathways which comprise major network 
hubs for function of the immune system.  Abundant evidence suggests the immune 
system has profound effects on mammalian biology and is intimately involved in our 
maintenance of health through interactions with all major organ and tissue types 
[2,15-18].  Thus, clarifying our understanding of signal transduction principles in the 
immune system will frame our research directions in subsequent chapters. 
Generally speaking, the main duty of the immune system is to differentiate 
self from non-self and mount appropriate cellular responses according to that 
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differentiation.  This principle task is a hallmark of our evolutionary history which 
required cells to fend off attack by microbes such as fungi, bacteria and viruses in 
order to survive using the innate immune system.  As multicellular organisms 
became entrenched on Earth and expanded in size and complexity, higher order 
immune systems became necessary, as is evidenced by the development of an 
adaptive immune system in jawed vertebrates over 500 million years ago [19].  
However, as we have recently come to appreciate, the simple story of the immune 
system as defense against infection is only one aspect of the complex role this 
interconnected network of cells and soluble mediators plays in host homeostasis.  
To begin to appreciate this complexity, we will briefly outline major players of the 
mammalian immune system. 
 
1.3 INNATE IMMUNITY: PROVIDING CONTEXT TO EXPERIENCE 
In order to respond appropriately to an environmental encounter, innate 
immune cells much first identify whether the stimulus is self or non-self.  This occurs 
through numerous classes of receptors located on the surface and within the cell.  
While beyond the scope of this dissertation, we briefly mention the critical role of T 
cell receptors (TCR) and B cell receptors (BCR) in immune system function as these 
receptor signaling networks constitute some exciting clinical advances for treatment 
of cancers and autoimmune disorders as will be highlighted later in this chapter.   
More germane to our studies are Pattern Recognition Receptors (PRRs) which have 
evolved to recognize conserved microbial structures, such as bacterial or fungal cell 
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wall components and viral nucleotides.  This occurs through direct binding of these 
structures or through sensing intracellular responses to microbes, like the production 
of metabolites specific to infection with a virus [20,21].  Upon activation of PRRs 
within a cell, unique gene programs are turned on that result in expression and 
secretion of soluble mediators that alert other cells to both the presence and quality 
of the engaged stimulus [22,23].  These mediators, such as cytokines and 
chemokines, drive not only movement of cells into and out of tissues spaces, but 
also program stimuli-appropriate responses based on the combination of mediators 
present.   
While many non-immune cells throughout the body have various PRRs, 
innate immune cells such as macrophages (M0) and dendritic cells (DC) are two of 
the primary effectors of innate defense.  These innate cells have the capacity to eat 
microbes in a process termed phagocytosis that serves two purposes: 1) remove the 
offending stimuli from the body where it can do more harm, and 2) process the 
stimuli so that an adaptive immune response can be elicited against it [24-26].  A key 
point is that depending on the context of the stimuli, innate immune cells instruct 
other cells as to the quality of the stimuli encountered.  Thus the innate immune 
response to a viral infection is qualitatively different than that to a bacterial infection 
or encounters with fungi [20,27].  This contextualization of environmental stimuli 
drives stimuli-appropriate tissue and adaptive immune responses as will be 
discussed in more detail shortly.  There are a number of other cell types which also 
play critical roles in innate immunity but we will restrict ourselves to discussing M0 
and DC as these are the cell types which are passively targeted by both 
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nanoparticles and microparticles and thus serve as the frontline for programming 
immunity in mammals. 
Our understanding of innate immunity has come a long way since PRRs were 
first proposed to exist by Charles Janeway, Jr. in 1989 [28].  Since his prescient 
prediction of PRRs, we have identified not only multiple classes of PRRs but have 
increasingly refined our molecular understanding of these receptor families.  There 
are currently four major classes of PRRs - Toll-like Receptors (TLRs), Nod-like 
Receptors (NLRs), C-type Lectin Receptors (CLRs) and RIG-like Helicases (RLHs) – 
though other individual PRR have recently been identified [29,30]. 
 
1.4 THE LESSONS OF TLRS AND NLRS 
TLRs are the best studied PRR class and serve as a model for which we 
understand the function of other PRRs.  Of the 10 TLRs identified in humans, 9 have 
known functions, with five being cell surface bound and four localized to intracellular 
compartments termed endosomes [31].  This distribution in various cellular 
compartments correlates with function; cell surface TLRs bind microbial motifs 
present on the surface of microbes whereas endosomal TLRs bind microbial nucleic 
acid motifs that are unmasked after successful degradation [32].  Upon binding 
cognate ligand, TLRs undergo post-translational modifications such as 
phosphorylation and relocalization in the cell, thus enabling downstream adaptors to 
interact with these receptors and trigger signaling pathways to drive gene expression 
changes commensurate with the microbe encountered [20,27,32-34].  For example, 
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triggering of TLR3 in the endosome by viral double stranded RNA results in 
activation of the TRIF adaptor and subsequent translocation of two transcription 
factors to the nucleus, NF-κB and IRF3, where they drive gene expression of pro-
inflammatory cytokines and anti-viral interferons [27].  In summary, the location of 
the TLR corresponds to where its microbial ligand is perceived and the subsequent 
gene programs elicited are appropriate for the microbe encountered.   
Whereas TLR signaling pathways have been well characterized, the NLR 
family of PRR are far less well known, in part due to their initial identification only in 
the early 2000s [35].  There are 22 human NLRs which are grouped as a family 
based on their structural homology, with C-terminal Leucine rich repeat (LRR) 
regions, a central nucleotide binding domain (NBD) and a N-terminal effector domain 
that is thought to confer unique properties among the NLR members [36,37].  As a 
beautiful example of convergent evolution, plants defend themselves with the NB-
LRR receptor family using very similar protein domain architecture as human NLRs 
[38].   
Most NLRs are believed to reside in the cellular cytosol, though some 
members have been found at the inner leaflet of the plasma membrane (NOD1 and 
NOD2) or localized to the outer membrane of the mitochondria (NLRX1) [39-41].  
Since their initial discovery, NLRs have been shown to play a broad role in host 
immunity (Figure 1-1).  NLR functions include transcriptional control of MHC class I 
and II expression, modulation of autophagy, inhibition and activation of pro-
inflammatory pathways including NF-κB-mediated transcription, as well as a 
subclass of NLRs which form inflammasomes - multi-protein complexes which cause 
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activation of the cysteine protease caspase-1 and subsequent maturation of the pro-
inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18) [42-45].   
NLRs have been implicated in the innate immune responses to fungi, bacteria 
and viruses, with concomitant effects on ensuing adaptive immune responses [46-
56].  Two NLRs, NOD1 and NOD2, have clear roles in the autophagic response to 
bacteria and subsequent loading of antigen in MHC class II complexes [40,57,58].  A 
separate means by which NLRs control adaptive immune responses is through 
upregulating expression of MHC I and MHC II genes via NLRC5 and CIITA, 
respectively [59-67].   As antigen-specific adaptive immune responses are critically 
dependent on MHC peptide presentation, these NLR members are thus placed at a 
central hub in initiating adaptive immunity.   
As discussed shortly in more detail, the quality of an adaptive immune 
response is dependent not on just the antigen but also on the context in which that 
antigen is presented.  Context is encoded in part through soluble messengers 
termed cytokines which greatly augment the quality of adaptive immune responses.  
One major type of adaptive immune response involved in defense against fungi and 
autoimmune pathology, termed Th17, is thought to be at least partially dependent on 
activation of inflammasome forming NLR proteins, such as NLRP3.  Release of the 
potent pro-inflammatory cytokine IL-1β from innate immune cells with activated 
inflammasomes can initiate Th17 adaptive immune responses.  Evidence supporting 
this comes from studies in mice deficient in inflammasome components which are 
more susceptible to fungal infection or protected from Th17-mediated pathology in 
settings of experimental autoimmune encephalitis [46,68-70].  Because of the potent 
10  
effects on Th17 immune responses elicited from NLRP3 inflammasome activation,  
designing vaccines which can trigger this PRR is an avid area of research in the 
nanomaterials field and one we will study in more detail in subsequent chapters [71-
75]. 
 
Figure 1-1. NLRs are sensors of the Intracellular Environment. 
While not exhaustive, this schematic overview presents cell locations and functions 
for NLR family members based on published literature.  Of note, NLRs reside 
throughout the cell, from the inner leaflet of the plasma membrane (NOD1 and 
NOD2) to the mitochondria (NLRX1), the cytosol (inflammasome forming NLRs) and 
in the nucleus for those with known transcriptional functions (NLRC5 and CIITA). 
while some NLRs may be pro-inflammatory, others inhibit these same pathways. 
11  
Based on work we and others have published, NLRs mediate these wide-
ranging immune effects in part through interactions with receptors involved in other 
innate immunity signaling pathways, such as the TNF receptor associated factor 
family (TRAF) [76-79].  Through the network nature of NLR effects on innate 
immunity, they have also been implicated in modifying the host microbiota [80-83].   
Disease susceptibility to metabolic syndrome and cancer is modified by a number of 
NLR receptors based on studies using mice deficient in NLR genes [63,80,84-92].   
Genome-wide association studies have also uncovered a powerful role for mutations 
in NLRs in a range of human disease, including bare lymphocyte syndrome, Crohn’s 
disease, auto-inflammatory disorders such as Muckle-wells and Blau syndrome, and 
autoimmune disorders such as vitiligo [37,45,93-104]. 
We have highlighted the NLR family in detail to serve as an example of how 
immune sensors can potently augment human physiology, with either beneficial or 
detrimental effects depending on the intact nature of these signaling networks.  
While this dissertation focuses on nanomaterial interactions with mammalian 
immunity, it is worthwhile to note that simultaneous research into the basic molecular 
functions of immune signaling networks will be crucial to broadening and enhancing 
the therapeutic potential of immunoengineering.  To this end, we note our own 
research efforts to further molecular understanding of the NLR family via 
biochemical studies and bioinformatics approaches that are beyond the scope of this 
dissertation [76,88,105,106] (and unpublished data). 
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1.5 ADAPTIVE IMMUNITY: BRANDS OF RESPONSE 
 Perhaps one of the more astounding features of human biology is how unique 
immune responses are orchestrated for specific classes of microbes.  We have 
already discussed the role of innate immune cells and PRRs such as TLRs and 
NLRs in contextualizing environmental encounters but how this context drives 
appropriate adaptive immune responses is equally fascinating.  At root, an 
appropriate cellular response to its environment is elicited through networked 
orchestration of signal transduction pathways and the immune system is perhaps the 
clearest example of this concept.   Here, we will attempt to synthesize a tremendous 
amount of immunology research into a few simple concepts reflecting this notion 
[2,15,16,18,20,23,24,32,33,56,107-115]:   
1) innate immune cells, in particular dendritic cells (DCs), encounter microbes 
and process them according to the PRR that are triggered  
2) the sum total of PRR signaling pathways triggered within the DC and 
surrounding tissues will elicit a unique milieu of cytokines and cell surface 
receptors that provide context to other cells and regional tissues in order to 
mount appropriate responses  
3) within regional lymph nodes, DCs instruct T cells to mount adaptive 
immune responses to specific antigens presented by DC on MHC class I and 
II receptors to drive either CD8+ or CD4+ T cell effector responses 
appropriate to the microbe encountered (e.g., intracellular virus or 
extracellular bacteria) 
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4) the quality and quantity of T cell responses to an antigen depends on the 
context in which it is presented by a DC, which is encoded in the cytokine 
milieu initially triggered by PRRs within the DC and affected tissues 
5) these cytokines drive specific T cell gene programs that qualitatively shift 
the class of effector T cell response to tailor it for the task at hand, in part 
through inhibiting production of cytokines associated with inappropriate 
classes of T cell effector responses 
6) in a similar fashion, B cell antibody responses are appropriately tailored 
through B cell-intrinsic PRR signaling, sampling of antigens, and sensing of 
the cytokine milieu elicited by innate immune cells and effector T cells 
7) in the absence of PRR signaling, anergic or tolerogenic T cell responses 
are generated, such as would be the case to self-antigens 
Over the course of mammalian evolution, the end result of this immune symphony is 
the generation of general classes of microbe-specific adaptive immune responses as 
listed in Table 1.1 and visualized in Figure 1-2. 
Table 1.1 – General Description of Adaptive Immune Responses. 
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Figure 1-2. G
eneration of Adaptive Im
m
une C
lasses. 
A) M
icrobes activate unique sets of PR
R
 on D
endritic C
ells w
hich trigger production of cytokines and cell surface 
receptors appropriate to the m
icrobe encountered.  This contextualizes the threat at hand during antigen presentation 
to T cells, thus driving gene expression program
s hallm
arked by class-specific transcription factors (listed under T 
cell type) and subsequent T cell production of class-specific cytokines (listed to right of T cells). B
) An im
m
une 
hierarchy perspective enables appreciation for all levels of coordination, from
 signaling pathw
ays activated by PR
R
s 
to cell-cell com
m
unication that m
odulates the tissue environm
ent and vice-versa. Figure adapted from
 [ 2] w
ith 
perm
ission from
 N
ature Publishing G
roup. 
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1.6 A CALL FOR IMMUNOTHERAPY 
With this molecular understanding of innate immunity and the generation of 
adaptive immune responses, we have gained unheralded insight into the 
pathogenesis of both infectious diseases and those of non-microbial origin (termed 
non-communicable diseases, NCD).  For infectious diseases, this can enable the 
production of more efficacious and microbe-specific vaccines.  By designing 
vaccines that activate innate immune pathways normally elicited during the course of 
infection with a pathogen , we can generate adaptive immune responses appropriate 
to the pathogen we are trying to vaccinate against [18].  For example, we now know 
that a Th17 response is required to clear infection with the fungus Candida albicans 
so efforts are underway to design vaccines which elicit anti-fungal Th17 responses 
[116-120].    Similarly, using recent gains from immunology research a number of 
pathogens with high morbidity and mortality around the world for which there are 
currently no vaccines are being targeted.  These include malaria, Dengue virus, HIV 
and cholera [121].  As we will discuss, many of these vaccines will rely on 
nanomaterials designed specifically to augment appropriate innate immune signaling 
networks for a given pathogen [74,122-124].  
Non-Communicable Diseases – Our Modern Epidemics 
A potentially transformative research direction made available through our 
understanding of immunological networks is the ability to entirely change how we 
treat non-communicable diseases (NCD).  These illnesses – including heart disease, 
cancer, chronic obstructive pulmonary disorders and diabetes – have the highest 
morbidity and largest economic burden in the United States and other developed 
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societies [125-127].  It is estimated that 63% of deaths worldwide are due to NCD 
and the global economic output lost due to NCD over the next 20 years is predicted 
to reach over $30 trillion [127].  While NCD have behavioral risk factors that should 
be first line intervention strategies, specific aberrations in immune function correlated 
with these diseases are potential therapeutic targets that have yet to be fully 
addressed.  Immunotherapies for NCD may show better efficacies at lower cost than 
currently used non-specific treatment approaches. 
Cancer is one example of a NCD with immune therapeutic options.  Cancer, 
at its core, is a cell which no longer recognizes its rightful place in the host organism 
and proliferates without concern for the body by co-opting its microenvironment 
[128,129].  It more recently has come to light that this co-opting of the 
microenvironment includes broad immune suppression in the tumor area as a 
means to keep the body’s own defenses at bay [17].  This occurs in part through 
modulating the cytokine milieu to promote suppressive polarization of innate immune 
cells while enhancing regulatory T cell responses to aid the cancer in hiding its true 
danger from the body [130-132].  The current standards of care to treat cancer 
include systemic chemotherapies that kill all rapidly dividing cells, radiation therapy, 
and systemic administration of antibodies or small molecules that target potent 
signaling pathways involved in both cancer and normal cellular function.  These 
arduous and expensive treatment approaches can be debilitating to the patient and 
often non-curative [133-136].  Thus, alternative treatment approaches are 
desperately needed.   
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An avid area of current research is the concept of modulating the immune 
environment of cancers to reawaken the body’s own defenses and harness the 
inherent power of the immune system to then eradicate the cancer [137].  Multiple 
approaches are being pursued, with some involving antibody-based activation of 
cancer-dampened T cells already showing promise in the clinic [136].  Cancer cells 
also upregulate CD47, a cell surface receptor that serves as a ‘don’t eat me’ signal 
to macrophages [138].  Recent evidence suggests that blocking this receptor with 
antibodies is sufficient to enable macrophage clearance of cancers in mouse models 
[139].  The long-sought goal of generating cancer vaccines is also progressing, in 
part through immunoengineering approaches using nanomaterials as will be 
discussed in more detail below.  With recent evidence indicating a Th1 immune 
response induces growth arrest in mouse and human cancers through the cytokines 
TNF-α and IFN-γ, targeted modulation of the immune environment could become a 
standard of care for cancer treatment [140]. 
Another NCD with immunotherapy potential that is now a world-wide epidemic 
is type 2 diabetes.  Unlike type 1 diabetes which is of autoimmune origin (and 
amenable to immunotherapy), type II is caused by diet-induced metabolic and 
immune alterations which render patients insulin-resistant, thus mimicking the 
pathology of type 1 diabetes [7].  With increasing populations of the world eating 
high-fat and high-sugar diets, the levels of obesity are reaching staggering 
proportions and obesity is a primary risk factor for type 2 diabetes.  With obesity 
prevalence rates at over 35% of US adults and 16% of US youth, the current and 
future economic costs to our health care system are recognized as unsustainable 
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[141-143].  While behavioral choices and policy changes to our food system are 
clearly important interventions that need to be pursued to stem these alarming 
obesity rates, augmenting the immune system is a potential therapeutic approach for 
those patients who have already become diabetic.   
As an example of the intimate relationship with immune function and 
metabolic homeostasis, it is now clear that Th2 type immune responses - hallmarked 
by the cytokines, IL-4, IL-5 and IL-13 (Table 1.1) - are critical to the maintenance of 
metabolic function in adipose and hepatic tissues and are required for glucose 
homeostasis.  Mice deficient in any of these cytokines are more susceptible to high-
fat diet induced insulin resistance and hyperglycemia [144-146].  Conversely, pro-
inflammatory Th1 cytokines like IL-1β are known to cause insulin resistance 
[89,147].  From a therapeutic approach, infection with intestinal helminths, which 
induce Th2 immune responses, have also been shown to restore normoglycemia 
and insulin sensitivity in otherwise diabetic mice [145,146].   
As stated at the start of this chapter, immune cells precisely sense their 
environment in order to elicit appropriate responses.  These responses are required 
to defend against infectious diseases but also drive pathology in the setting of non-
communicable diseases if uncontrolled.  Because the vast majority of the world’s 
population are susceptible to microbial infection or NCD, programming immune 
system function in a targeted manner should become a key intervention in the 
clinician’s arsenal.  To that end, we now turn to a discussion of our current state of 
knowledge regarding nanomaterial interaction with mammalian biology and efforts 
undertaken to use these materials to program immune responses. 
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1.7 NANOMATERIAL INTERACTIONS WITH BIOLOGICAL SYSTEMS 
As the thrust of this dissertation is the analysis of the innate immune 
response to nano- and micro-scale particles, it is of use to first provide a background 
on the current state of our understanding as regards biocompatibility with materials 
in these size ranges.  The overriding supposition is that by first understanding how 
size, shape and composition of particle parameters affect immune outcomes, we can 
then more appropriately design particles for a range of therapeutic interventions, in 
particular those which aim to modulate the host immune response in defined 
manners.  Herein, we use the term nanoparticle (NP) to refer to particles that are 
less than 1 micron in all dimensions and microparticles (MP) for those that are 
greater than 1 micron in any single dimension.  When discussing both nanoparticles 
and microparticles as a generalized group, we will refer to them as NMP. 
 Historically, studies of nanomaterial interactions with mammalian biology 
have occurred with no real field standards but recent efforts have been made to 
establish general assays for toxicology and immunological properties of 
nanomaterials [148].  This is in part due to the complexity of carrying out controlled 
experiments to delineate differences between nanomaterials based on fine 
alterations of size, surface charge or composition, all of which clearly impact the 
mammalian immune response [148-150].  As an example, by altering the size, 
surface charge, surface hydrophobicity or surface-exposed functional groups, the 
quantity and quality of proteins adsorbed to NMP can be greatly affected [151-153].    
Yet to give a sense of the disparity between in vitro nanoparticle studies and in vivo 
relevance, recent papers have shown that studies which fail to use serum surrogates 
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during in vitro analysis likely have little functional relevance to what occurs during in 
vivo experiments [154].    
A relevant example for translational applications is the use of targeting NP to 
specific cell subsets by decorating antibodies for specific receptors on the surface of 
NP.  One group recently found that NP targeting specificity to the transferrin 
receptor, which is upregulated in some cancers, was completely abrogated when 
switching in vitro assays from phosphate buffered saline media to one that was 
serum replete to more closely resemble host biology [155].  Remarkably, many NP 
studies do not use serum-containing media so this seemingly predictable result not 
only calls in to question numerous previously published findings but also serves as a 
wake-up call to the nanomaterials community at large as regards the translational 
relevance of experimental design.  This example also serves to bolster the position 
we took during the NMP studies detailed in this dissertation: well-controlled, 
biologically relevant studies are needed to characterize nanomaterial interactions 
with mammalian immune system. 
Admittedly, a difficulty in drawing broad conclusions regarding how particle 
design features such as size, shape, composition and surface charge affect host 
biology is due to major differences in NMP fabrication techniques, materials sourcing 
and experimental assays within and between labs [148,156].  Common NMP 
fabrication techniques include water-oil-water emulsion or spray-drying methods, yet 
particles fabricated in this manner can range in size by many hundreds of 
nanometers and have heterogenous shapes within the same batch [73,157,158].   
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Thus careful analysis of the role of size or shape on biological responses to 
nanomaterials using standard fabrication methods is difficult at best.   
Composition Considerations of NMP – The Inflammasome Example 
A remarkable example of the sensitivity of innate immunity to nanoscale 
details is how modifying the surface and composition of NMP can modulate 
activation of the NLRP3 inflammasome.  As a reminder, the NLRP3 inflammasome 
is a multi-molecular protein complex that is formed in response to a variety of 
environmental triggers, ultimately resulting in the activation and secretion of pro-
inflammatory cytokines, IL-1β and IL-18 [29,159].  Because particulate matter such 
as asbestos, silica and monosodium urate crystals are known to activate the NLRP3 
inflammasome, it is expected that NMP may also trigger this innate immune 
response.  There are many uses for NMP where it would be disadvantageous and 
clinically unacceptable to use particles that induced inflammation, such as diagnostic 
and drug-delivery applications.  Conversely, activating the NLRP3 inflammasome by 
NMP is a potential vaccine adjuvant and thus the design principles controlling this 
response is an avid area of study.  Through the work of a number of groups, we are 
starting to gain insight into how NMP can activate the NLRP3 inflammasome. 
Work by the Tschopp group identified composition of metallic nanoparticles 
as the prime factor in triggering IL-1β release.  Titanium dioxide and silica dioxide 
NP caused inflammasome activation while comparable sized zinc oxide particles did 
not [75].  Another group focused entirely on silica particles in the nano and micron 
range and found a size-dependent effect on IL-1β release.  Fascinatingly, both 
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inflammasome activation and associated inflammatory signaling changes induced by 
these particles was inhibited simply through modifying the chemical groups exposed 
on the surface of particles [160-162].   
While these findings have relevance to consumer products and environmental 
toxiciology, the literature regarding inflammasome activation by NMP composed of 
polymers more relevant to biomedicine applications is inconsistent.  Perhaps the two 
most commonly used polymers for biomedical applications are poly(lactide-co-
glycolide (PLGA) and polyethylene glycol (PEG).  These biocompatible polymers are 
approved by the Food and Drug Administration (FDA) and have a long, safe history 
of clinical use [163,164].  Yet when the biodegradable polymer PLGA is formulated 
into NMP, groups report differences in its inflammasome activating potential [71].  
One report shows in vitro and in vivo evidence for inflammasome activation by PLGA 
NMP that is contradicted by another study [72,73].   However, recent evidence 
suggests these literature discrepancies could be due to fabrication differences 
among groups, as simply a non-smooth NMP surface is sufficient to induce 
inflammasome activation by particulate matter [165].  We have studied the issue of 
inflammasome activation by NMP at length, as will be discussed in subsequent 
chapters.  Because composition is so clearly a factor in NMP interactions with 
human biology, we focused our studies on PLGA and PEG polymers as they have 
the most relevance for eventual clinical use given their safe history. 
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Physical Parameter Considerations of Particle Uptake 
Though particle parameters such as size, shape and composition do impact 
host biology, field-wide conclusions regarding any one design feature is currently not 
possible.  For example, while surface charge has been associated with cell uptake, if 
one modulates the size of the particle then conclusions regarding surface charge 
and uptake are not necessarily consistent [166-168].  Similarly, the mechanism by 
which cells uptake NMP is dependent on a variety of features, including size, shape 
and surface charge.  Whereas mannose-coated NP are taken up by macrophages 
through mannose-receptor dependent phagocytosis [169-171], lipid-coated NP can 
be taken in via complement-receptor dependent pathways [172].  Iron oxide NP 
uptake is scavenger-receptor dependent [173].  From an immunological perspective, 
these are critical design parameters as the phagocytic uptake pathway can have 
downstream pro- or anti-inflammatory effects [26].  Multiple other examples of the 
inconsistent nature of how design parameters augment the biological fate of NMP 
abound, serving ultimately to highlight the absolute sensitivity of mammalian biology 
to just about every particle feature one chooses to test. 
Separate from the specific phagocytic pathway used to ingest particles, the 
actual shape of the NMP plays a critical role in the initiation and successful 
completion of phagocytosis. A seminal study by the Mitragotri group identified the 
contact angle by which a macrophage encounters a particle as a critical parameter 
dictating successful phagocytosis of the NMP [174].  If the contact angle was greater 
than 45 degrees, then particle phagocytosis was unlikely to occur, likely due to 
physical difficulties of mobilizing the actin cytoskeleton to engulf particles in their 
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widest dimension (>500nm).  The Mitragotri group has used this finding to design 
high aspect ratio NMP with worm like shapes to inhibit phagocytosis by restricting 
uptake to only those phagocytes which happen to encounter particles at the tip 
(where the contact angle  <45 degrees) [175].  Such shape design considerations 
may be of use for therapeutic modalities requiring enhanced circulation times and/or 
extracellular release of cargo.   
 More recently, these researchers have identified shape as critically 
augmenting the targeting specificity of antibody-coated NMP through harnessing this 
initial contact angle finding.  By coating rod, spherous and disc shaped NMP with 
trastuzamab (a monoclonal antibody against HER2/neu receptors expressed by 
breast cancer tissue), the authors found rod-shaped NMP reduced non-specific cell 
uptake and reduced breast cancer cell line growth more efficiently than an 
equivalent dose of soluble trastuzamab [176].  These exciting findings point to an 
emerging theme in NMP studies whereby particularization of biological molecules 
(drugs, antibodies, ligands) confers unique properties not found with equivalent 
soluble forms of the same molecule, as will be discussed in greater experimental 
detail in Chapter 4.   
One plausible explanation for why NMP are capable of eliciting emergent 
properties from cells when coated with bioactive molecules may be due to formation 
of a phagocytic synapse that macrophages and dendritic cells use to sense intact 
microbes [1].  This has formally been proven by the Underhill group using both 
soluble and particulate forms of the fungal cell wall component, β-glucan, which is 
recognized by Dectin-1, a cell surface receptor belonging to the C-type lectin (CLR) 
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family of PRR.  Although both soluble and particulate forms of β-glucan are bound 
by Dectin-1, signaling is not initiated from the Dectin-1 receptor unless β-glucan is 
present in a particulate form (Figure 1-3).  This causes receptor clustering of Dectin-
1 and formation of a ‘phagocytic synapse’ that is able to physically exclude 
regulatory tyrosine phosphatases CD45 and CD148 from the site of phagocytosis 
[177].  In effect, immune signaling is not initiated from Dectin-1 unless an intact 
fungus (i.e., particulate form) is sensed.   This clever biomechanical control enables 
innate immune cells to restrain initiation of potent anti-fungal responses to only those 
instances when an actual fungal microbe is encountered, thus sparing spurious 
innate responses that may otherwise be detrimental to the host.  It is thus 
conceivable that coating of NMP with biologically active ligands, in particular 
antibodies or ligands which bind surface receptors, will result in emergent cellular 
responses through receptor clustering that soluble forms fail to elicit.  We present 
evidence supporting this hypothesis in Chapter 4.  Germane to this issue, there is 
abundant literature reflecting the role of surface-ligand density in downstream 
cellular responses to NMP [178-181].   
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Figure 1-3. Formation of a Phagocytic Synapse in response to 
Particulate Ligand.  
Consider Fungal β-glucan (orange) a bioactive ligand that can be either 
soluble or fabricated with nano- and micro-scale particles to appear as 
shown here (Russian doll outline). Receptor clustering afforded by 
particulation of ligand is one rationale for emergent properties seen with 
NMP. Figure is from [1] and used with permission from Nature Publishing 
Group. 
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The surface chemistry of nanomaterials used in NMP can also significantly 
impact the immune response to these particles.  It has been shown that certain 
primary hydroxyl groups or other surface nucleophiles on nanomaterials can react 
with complement factor C3 to form the active C3b product, thus triggering potent 
complement-mediated effects on innate and adaptive immunity [182-185].  As 
discussed previously, inflammasome activation by metallic NP depends on the metal 
used, whereas silica nanoparticle activation of the inflammasome can be augmented 
through modification of surface chemical groups [75,186,187].  In total, these studies 
highlight the need to address nanomaterial interactions with the immune system for 
every given particle size and composition, as the only thing we can predict is that the 
body is clearly capable of discriminating among minute details. 
Help Wanted: Control of Particle Design 
With this nanomaterial background in mind, it should be evident that a 
process to reproducibly fabricate particles with complete control over all physical and 
chemical parameters would be a great boon to the NMP research community.  In 
2005, such a fabrication method was developed in the lab of Joseph DeSimone, 
Ph.D., by fusing the precision and engineering control offered by lithographic 
techniques from the microelectronic industry with state-of-the-art synthetic chemistry 
in a modular platform.  The process – termed Particle Replication in Non-wetting 
Templates (PRINT) – is a top-down particle molding technology with unmatched 
control of the size, shape and composition of molded features.  PRINT templates 
can be molded with an unprecedented variety of materials, including pharmaceutical 
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compounds, small molecules, proteins, siRNA, and bioabsorbable polymers 
containing therapeutics or diagnostic cargos [188-194].   
An easy to grasp analogy is to consider PRINT molds as ice-trays with 
cubicles of defined size and shape that can be filled with solutions of one’s choosing.  
After PRINTing, the particles (ice cubes) can be popped out of the tray, resulting in a 
homogenous population of monodisperse particles of defined chemical composition 
(Figure 1-4).  Using PRINT, well-controlled experiments isolating the effects of 
specific particle parameters such as size, shape and chemical composition on 
mammalian immune responses can be reproducibly explored. 
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Figure 1-4.  Schematic of the PRINT fabrication process.   
Master templates (grey) are fabricated using advanced lithographic techniques to 
defined size and shape parameters. A liquid fluoropolymer (green) is poured on the 
surface of the master template and photochemically cross linked to generate a 
precise mold having micro- or nanoscale cavities (green).  A liquid solution 
comprised of user-specified components (red) fills the cavities in the mold through 
capillary forces. Once the liquid in the mold cavities is converted to a solid, the array 
of particles (red) are removed from the mold (green) through contact with a 
harvesting film (yellow). Free flowing particles or stable dispersions can be obtained 
by separating the harvesting film from the particles, often with water, thus enabling 
monodisperse particles to be used for downstream experiments. Figure adapted 
from http://www.desimone-group.chem.unc.edu. 
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To summarize this section, biological interactions with NMP fundamentally 
depend on the physical and chemical parameters of particles, though there are no 
overarching conclusions that can be drawn as regards all NMP for a given 
parameter.  This is perhaps unsurprising given that the body does not process 
information in discreet groups but instead tailors an appropriate response to the 
individual stimulus, as discussed earlier in this chapter.  Just as the body responds 
uniquely to various types of bacteria despite similarities in size, shape and genus, it 
follows that the response to NMP will also be context dependent.  For these 
reasons, a bulk of the work presented in chapters 2 and 3 of this dissertation 
pertains to careful analysis of the mammalian innate immune response to NMP 
through controlled experiments using PRINT particles of strictly defined size, shape 
and composition.  These fundamental studies are necessary in order to enable the 
rational design of NMP therapies for a range of health ailments that afflict 21st 
century society.  As evidence of the potential for NMP to fundamentally change how 
diseases are treated through modulation of the immune system, an overview of 
immunoengineering approaches using NMP will now be discussed. 
 
1.8 IMMUNOENGINEERING: WHERE WE ARE 
The basic principle of immunoengineering is to design NMP that deliver 
biological signals in a targeted manner in order to program immune responses. This 
is commonly done through incorporating biological ligands and receptors into or on 
the surface of NMP that mimic endogenous immune cell interactions.  The 
theoretical variety of immune signaling events that can be synthetically generated 
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through engineering approaches is rapidly approaching parity with the actual variety 
of immune interactions we know to occur in situ.  This is in part due to the broad 
range of commercially-available immune active molecules, such as cytokines and 
antibodies to immune receptors, which enable modular approaches to programming 
immunity.  We now present a survey of published immunoengineering studies which 
reflect the potential of this approach to treating human disease. 
NMP have been designed to release cytokines in order to elicit specific 
immune outcomes.  Modeling NMP after mast cell granules, the Abraham group 
complexed an immunostimulatory cytokine, TNF-α, into synthetic granules 
composed of heparin and chitosan in order to boost and direct the quality of  
immune responses [195].  These synthetic granules drained to the lymph node of 
mice and were able to enhance adaptive immune responses and survival to 
influenza more efficiently than soluble delivery of TNF-α.  Furthermore, the group 
showed that NMP delivery of IL-12 was capable of skewing the adaptive immune 
responses towards the Th1 class.  This simple yet powerful approach indicates 
artificial skewing of immune environments is feasible.  Though the broad therapeutic 
potential of this approach remains largely unexplored, evidence suggests 
appropriately designed NMP can skew adaptive immune responses between 
classes (i.e., Th2 -> Th1, Th17->Treg) [196,197]. 
In an in vitro system, the Fahmy group generated artificial antigen presenting 
cells (aAPC) by anchoring peptide-MHC complexes and co-stimulatory ligands to the 
surface of MNP composed of the biodegradable polymer poly(lactide-co-glycolide 
(PLGA) [198]. These aAPC MNP were loaded with the T cell stimulating cytokine IL-
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2 and incubated in culture with T cells to assess their potential to act as dendritic 
cells (DC).  The results show a size dependent activation of T cells, whereby 
microparticles 8µm in diameter were more efficient at stimulating proliferation of T 
cells than NP with 130nm diameter.  This was not due to differences in total amount 
of ligands or receptors present.  The study also found that particle encapsulated IL-2 
was 10x more efficient than soluble IL-2 in terms of T cell proliferation, suggesting 
high localized IL-2 concentrations between the aAPC and T cell mediated more 
robust signaling akin to that which would occur between DC and T cells.  This 
artificial system has relevance to ex vivo manipulation of T cells for clinical 
interventions, but also reveals how scaling biological interactions to the appropriate 
dimension (i.e., nano- and micrometer) confers broad enhancement of biological 
outcomes. 
Next-Generation Vaccines 
Perhaps the strongest illustration of the promise for immunoengineering with 
NMP is progress in vaccine development.  This is ironic, given that vaccination is 
one of the most successful and oldest examples of engineering immunity in human 
society.  Prior to the advent of vaccination in the late 18th century, the average 
lifespan was 35 years of age.  It is now approaching 80 years, in large part due to 
the success of worldwide vaccination campaigns [121].  With recent elucidation of 
the molecular mechanisms behind the efficacy of vaccines, researchers are now 
avidly pursuing the rational design of vaccines to promote more tailored immune 
responses to a pathogen of interest [18,107,110,121,199,200].  This is made 
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possible in large part through our understanding of innate immune activation by 
microbes through specific pattern recognition receptors (PRR).   
By coupling PRR activation to delivery of an antigen, antigen-specific 
adaptive immune responses can be generated with control over the quality of the 
adaptive response through judicious design of NMP [74,201].  As many ligands for 
PRRs are now known and commercially available, immunoengineers are rapidly 
incorporating these into NMP along with antigens of interest to improve the next 
generation of vaccines.   PRR ligands published with NMP include those for the 
majority of TLRs, as well as those which activate CLRs and the NLRs NOD1 and 
NOD2 [120,202-207].  The power of NMP from a vaccine perspective lies not only in 
the modularity afforded through selective or combinatorial PRR agonist inclusion, but 
also the ability to co-deliver innate immune agonists along with the antigen one 
desires an adaptive immune response towards.  This mimics the spatiotemporal 
immune activation that occurs during natural infections and couples innate immune 
activation to a specific antigen of interest.  In point of fact, NMP delivery of TLR 
agonists to mouse and human DC has been shown to be 100 times more effective 
than soluble delivery [206]. 
The Pulendran group recently used PLGA NP containing TLR4 and TLR7/8 
agonists to show a profound synergistic enhancement of antibody and cell-mediated 
adaptive responses to co-delivered antigens in both mice and non-human primates.  
Combinatorial activation of these TLRs through NP delivery elicited antibody 
responses that were orders of magnitude greater than individual TLR ligand 
containing NP or the currently used vaccine adjuvant alum [204].  This finding is in 
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line with others who have seen a profound enhancement in adaptive immune 
responses to synergistic TLR agonism [200,205,207].  An as yet unexplored area is 
the use of PRR ligands from multiple classes of PRR families for use in vaccines, 
NMP or otherwise.  It is our belief that combinatorial activation of multiple PRR 
classes, such as TLRs, NLRs and RIG-I-Lie receptors (RLRs), will likely result in 
even more profound enhancement of vaccine-induced immune responses as this 
can recapitulate the natural immune response to microbial infections which 
themselves trigger multiple PRR classes. 
Design Control of Nanomaterials 
A great strength of NMP approaches to vaccine delivery is the control over 
numerous biological parameters that can be designed into NMP and tailored to the 
clinical need at hand.  For example, production of CD4+ T cell responses is required 
for potent humoral immunity while anti-viral responses require CD8+ T cell effector 
responses.  These two responses depend on presentation of antigen through either 
MHC II (CD4+) or MHC I (CD8+), and the pathway to presentation is different 
between the two [208-210].  Class II peptides are acquired from the extracellular 
space as intact antigen and processed within the acidic environment of phagosomes 
into peptides that are then presented on MHC II receptors.  Conversely, Class I 
peptides are generally acquired from the cytosol of cells.  Thus, NMP vaccines with 
the goal of eliciting antigen-specific CD8+ T cell responses, such as those against 
viruses, must either avoid phagosomes entirely or be able to escape the phagosome 
once there.   
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Here, the materials science component of NMP design comes to play, with 
generation of polymers which are biologically responsive and thus can ensure 
cargoes within NMP are delivered to the cytosol.  One approach is the use of mulit-
lamellar liposomal NP.  These are highly sensitive to phagosomal phospholipases 
and thus rapidly degrade after endocytosis, releasing cargo (antigen) into the cytosol 
and potently enhancing CD8+ adaptive immune response [211].  An alternative 
approach for ensuring cytosolic delivery of NMP cargo makes use of the pH drop as 
phagosomes mature.  In this case, NMP are made with pH-sensitive polymers such 
as polypropyl acrylic acid that display membranolytic activity during acidification of 
the phagosome.  This disrupts the phagosome, releasing the NMP into the cytosol 
where MHC I presentation of antigenic cargo can occur to drive potent CD8+ T cell 
responses [212].  
 A key requirement for the success of immunoengineering approaches is the 
ability to target specific cells or regions of the body with NMP .  Because regional 
lymph nodes are the location of adaptive immune response generation, ensuring 
NMP can get to these areas is crucial.  NMP design affords a variety of approaches 
to this issue.  Through size selection (500-2000nm diameter), one can passively 
target antigen presenting cells, such as macrophages and dendritic cells, in the 
periphery where they then can traffic to regional lymphnodes.  Conversely, smaller 
particles (<100nm) will drain to regional lymph nodes on their own, where they can 
then be processed by resident immune cells [213].  For particles in the 200-500nm 
range, it is less clear whether they drain to lymph nodes or are passively trafficked 
by macrophages and dendritic cells [214].   
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 NMP can also be directly targeted to certain immune cell subsets through the 
use of surface conjugated ligands and antibodies.  DEC-205 is a cell surface 
receptor on a subclass of DC (CD8+) that are especially suited to priming CD8+ T 
cell responses.  Thus, decorating MNP with antibodies to DEC-205 has been used 
to specifically target particles to this immune cell subset [215,216].  Interestingly, one 
study found that varying the surface density of DEC-205 antibody on NP could 
modulate the ensuing innate immune response from targeted DC, with increasing 
antibody density correlating with heightened production of the anti-inflammatory 
cytokine IL-10 due to enhanced cross-linking of the DEC-205 receptor [178].   
Other studies targeting human DC through the DC-SIGN receptor showed 
that both the distance between the conjugated antibody and NMP surface and the 
size of the particle were critical parameters in ensuring targeted cell-specific uptake 
[217,218].  As evidence of how carefully coordinated the immune response is and 
how NMP design can both probe these basic mechanisms while offering 
therapeutically relevant tools, the Figdor group assessed uptake and antigen 
processing of NP targeted to either the carbohydrate recognition domain (CRD) or 
the neck region of the DC-SIGN receptor [219].  They found that NP which targeted 
the neck region of DC-SIGN were taken up through a clathrin-independent 
mechanism that led to prolonged retention in endosomes and enhanced MHC I 
cross-presentation of antigen as compared to the CRD-targeted NP.  The cross-
presentation of antigen using this strategy was 1000 times more effective than 
soluble antigen alone, again pointing to the power of biological scale imparted by 
NMP. 
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 Whereas most current vaccines are delivered via intramuscular or 
subcutaneous injections, NMP afford a variety of alternative delivery routes, such as 
inhalation, oral and transdermal microneedle.  Studies addressing route of NMP 
delivery have seen an impact on the quality of immune responses, with Th1 
response in particular being more sensitive to delivery route than Th2 responses 
[220].  Importantly, it is increasingly appreciated that tissue-specific immune 
responses are critical to controlling local infections [16].  This is perhaps best seen 
as regards immunity of mucosal organs, such as the lungs and digestive tract.  As 
the most common site of entry for infection, eliciting mucosal immunity via 
vaccination is a critical parameter to success [221-223].   
A powerful example of mucosal targeting is the induction of antigen-specific 
CD8+ T cells and production of a Th17 immune environment in the lungs following 
intranasal vaccination with a NP designed to target DC and release antigen into the 
cytosol of these cells [224].  Such responses are crucial to protecting against 
respiratory infections with bacteria and viruses, such as influenza.  The paradigm of 
inducing mucosal immunity also holds true for targeting mucosal tumors, whereby 
vaccination through the intranasal route is able to elicit anti-tumor CD8+ T cell 
responses while intramuscular vaccination fails to do so in orthotopic head, neck and 
lung cancers derived from the human papillomavirus 16 (HPV16) E7–expressing 
epithelial TC1 cell line [225].   
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Cancer Immunotherapy 
In addition to the use of NMP for microbial vaccination, immunoengineering 
with NMP offers entirely new approaches to cancer treatment while avoiding the 
systemic toxicity associated with soluble delivery of cytokines or antibodies [136].  
Similar to vaccines against microbes, a number of research groups are developing 
NMP-based cancer vaccines which incorporate PRR agonists and antigens 
associated with specific cancers [137,225-228].  While these approaches do show 
promise, a difficulty will be identifying cancer-specific antigens that don’t result in 
autoimmune pathology in healthy tissues.  Thus, modulating the immune 
environment of cancer is a potentially more viable option.   
As discussed earlier, cancers co-opt their microenvironment in order to hide 
from the immune system and divert nutrients towards their growth [130].  Therefore, 
some nascent anti-cancer NMP approaches involve blocking the mechanisms by 
which cancer quells immune responses in the tumor microenvironment. One 
example is through inhibiting the function of STAT3, a transcription factor 
upregulated in tumors that dampens production of Th1 cytokines while increasing 
secretion of immunosuppressive factors [229,230].  Designing NPs to carry siRNA 
against STAT3 has shown promise in shifting the immunosuppressive tumor 
environment towards one that enables immune surveillance and tumor clearance 
[231,232].  Another approach coupled NP-mediated delivery of IL-2, a T-cell 
activating cytokine, with a small molecule inhibitor of the immunosuppressive 
cytokine TGF-β.  This multi-pathway approach inhibited tumor growth, provided 
100% survival in mouse melanoma models and required NP delivery of both 
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molecules, as either compound alone or delivered in soluble fashion failed to protect 
mice [233].  This reflects a growing understanding in the cancer field that targeting 
multiple pathways at once will be required to avoid tumor resistance [234].  NMP are 
well suited to deliver multiple cargoes in this regard. 
 Due to clearance by innate immune cells as well as vasculature abnormalities 
in the tumor bed, it can be difficult to ensure NMP reach cancer regions at sufficient 
levels to exert therapeutic benefit in vivo [235].  Thus, modification of immune cells 
ex vivo prior to implantation back into the host is a ‘trojan-horse’ approach that relies 
on the intrinsic ability of immune cells to navigate to tumor sites in vivo.  A creative 
use of this concept was reported by the Irvine group where they conjugated NP to 
the surface of T cells ex vivo using free thiol groups present on the surface of T cell 
membranes.  By loading these NP with IL-15 and IL-21, potent T cell activating 
cytokines, these NP could in effect serve as paracrine signaling hitchhikers on T 
cells and greatly enhanced the T cell tumor killing capabilities in vivo [236].   
Hitchhiking Particles and Inflammation 
The ‘hitchhike’ tactic has been used by other groups in non-cancer 
applications to deliver NMP to sites usually occluded from particle transport.  For 
example, by feeding macrophages NP with antiviral cargo, researchers have 
enabled delivery of anti-virals to the brain after these NP-laden macrophages 
navigated through the blood-brain barrier [237,238].  Access to the central nervous 
system (CNS) is notoriously challenging so NMP approaches which enable 
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therapeutic delivery of drugs or immune-modulators to this region have a 
tremendous amount of clinical potential [239,240]. 
Inflammation itself is a driver of numerous pathologies, wreaking havoc in the 
CNS after stroke for example, so approaches to limit inflammation are promising 
areas for NMP [34,96,241].  While encapsulating anti-inflammatory small molecules 
like cyclosporine or glucocorticoids in NP is an effective means of dampening 
inflammation, more recent efforts make use of immune signaling pathways to 
broaden the impact of NMP interventions [242,243].  One means of targeting 
inflammation is the development of reactive oxygen species-sensitive (ROS) 
polymers [244].  ROS production is upregulated by cells during inflammation 
associated with cancer and infection, thus NMP designed with ROS-sensitive 
polymers may selectively degrade in targeted areas of inflammation and release 
therapeutic payloads only in these sites. 
A conceptually simple yet elegant approach to reduce inflammatory pathology 
is the passive targeting of monocytes with therapeutic NP that inhibit monocyte 
recruitment to sites of inflammation where they perpetuate and worsen disease.  
This can be done through encapsulating siRNA to CCR2 in NP, as CCR2 is a cell 
surface chemokine receptor required for recruitment of inflammatory monocytes.  
NP-delivery to these cells reduces upregulation of CCR2 and inhibits their ability to 
respond to inflammatory alarm signals because they are not able to sense it from 
their environment in the absence of CCR2.  In mouse studies, this approach 
attenuates the number of inflammatory monocytes in atherosclerotic plaques, 
reduces infarct size after coronary artery occlusion, prolongs insulin sensitivity in 
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diabetic mice after pancreatic islet transplantation, and reduces tumor volumes and 
the number of tumor-associated macrophages [245].   
Autoimmune Disorders – No Need to Fight the Self 
A last area we will discuss regarding immunoengineering approaches relates 
to autoimmune disorders.  Autoimmunity occurs when the immune system attacks 
the self, though the etiologies for these disorders still remain largely elusive 
[24,96,115].  Yet like so many aspects of human pathology, modulating the immune 
response can be a viable therapy in setting of autoimmunity.  The current standard 
of care is the use of systemic immunosuppressive drugs to shut down the entire 
immune system non-specifically.  Conversely, the immunoengineering approach 
uses NMP to deliver antigen-specific instruction to the immune system to either 
dampen the activity of self-targeted T cells or induce a regulatory T cell type of 
adaptive immune response [214,246,247].  These approaches rely on the same 
premise as microbial vaccines, but with the goal of inducing regulatory responses as 
opposed to effector T cells (Figure 1-2).   
One example is decorating NP with MHC-peptide complexes specific for self-
antigens in a NOD mouse model of diabetes.  Diabetic mice treated with these NP 
induced auto-regulatory memory T cells that were able to suppress immune-
mediated pathology and restore glucose homeostasis [248].  In analysis of the 
mechanism by which this regulatory T cell population was elicited, the authors 
believe the MHC-peptide conjugation to NP approach may work for any antigen that 
is targeted in autoimmune settings [249]. 
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More recently, mice with experimental autoimmune encephalomyelitis (EAE), 
which models the autoimmune disorder multiple sclerosis, were effectively cured of 
disease through a NMP treatment approach.  In this model, the autoimmune-
inducing antigen is a proteolipid protein (PLP), one of the most abundant proteins in 
the CNS.  Whereas delivery of soluble PLP exacerbated disease, simply conjugating 
PLP to the surface of PLGA NP was sufficient to dampen disease through shutting 
down the T cells responsible for mediating pathology [250].  While the mechanism is 
not fully clear, this finding suggests that antigen delivery by naked NP may mimic 
antigen presentation by dying self-cells, which results in tolerogenic immune 
responses.  We will explore engineering tolerance in more detail in Chapter 4. 
 
1.9 DISSERTATION OVERVIEW  
 Having presented a background on the role of signal transduction pathways in 
orchestrating immune responses as well as how NMP design parameters can be 
used to augment these functions for therapeutic aims, we will now turn to research 
performed during the course of this dissertation.  Throughout this work, we make 
use of the PRINT fabrication process to precisely address how particle size, shape 
and composition affect the mammalian immune response.  As has been detailed at 
length, the innate immune system is the prime driver of adaptive immune responses.  
Therefore, to help bring about the full potential of therapeutic immunoengineering 
pursuits, a baseline assessment of NMP interactions with the mammalian innate 
immune system is necessary.  The ultimate goal is to identify immunologically inert 
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particles that then can be designed to skew immune responses towards any and all 
immune classes. 
In Chapter 2, we focus on the murine innate immune system and address the 
potential for NMP particles to activate innate immunity through initiation of 
inflammatory responses in murine macrophages ex vivo, with a particular focus on 
particle-mediated inflammasome activation.  We then address the use of particles 
across the nano and miscoscale as inert programming devices for pulmonary 
therapeutics using direct instillation into murine lungs as our model.  Our results 
identify a cadre of particles across the nano- and micro-scale that can remain in the 
lungs for at least one week in an immunologically inert fashion. 
In Chapter 3, we move our NMP studies into a human monocyte cell line and 
primary human immune cells from healthy donors.  We assess the potential for 
these particles to activate inflammatory responses in human immune cells as well as 
carry out a broad cytokine screen to uncover other immune pathways that may be 
augmented by particle treatment.  We identify human immune cell subsets which 
preferentially take up NP and a chemical modification that can augment this 
response. We also identify heterogeneity in the magnitude of human immune 
responses to NP among donors that may help inform future clinical studies.  To lend 
further translational relevance to this work, we cross-validate these findings in a 
humanized mouse model to establish an in vivo system for future NMP studies with 
clinical applications. 
44  
In Chapter 4, we present a compilation of findings over the course of our 
studies that reflect not only the complexity of innate immune responses to NMP, but 
also highlight potential immunoengineering directions using rationally designed 
particles we have generated.  Studies address: 1) the role of surface modification on 
augmenting nanoparticle uptake into human immune cells; 2) particle design 
parameters to control the kinetics and magnitude of inflammasome activation; 3) 
anti-inflammatory NMP designs; and 4) NMP designs which may enable 
programming of immune tolerance through two separate pathways.  These findings 
have direct relevance to the development of microbial and cancer vaccines, reducing 
inflammatory damage in a range of disease settings, and offering new treatments for 
autoimmune disorders. 
 In Chapter 5, we conclude with an overview of the findings of this dissertation.  
Important lessons that may help guide future nanomaterials research in mammalian 
biology will also be highlighted.  Lastly, we offer thoughts on future directions and 
implications of immunoengineering approaches to human disease. 
 
 
 
 
 
 
  
 
 
CHAPTER 2 
ANALYSIS OF THE MURINE IMMUNE RESPONSE TO PULMONARY DELIVERY 
OF PRECISELY FABRICATED NANO- AND MICROSCALE PARTICLES1 
 
Nanomedicine has the potential to transform clinical care in the 21st century.  
However, a precise understanding of how nanomaterial design parameters such as 
size, shape and composition affect the mammalian immune system is a prerequisite 
for the realization of nanomedicine’s translational promise.  Herein, we make use of 
the recently developed Particle Replication in Non-wetting Template (PRINT) 
fabrication process to precisely fabricate particles across and the nano- and micro-
scale with defined shapes and compositions to address the role of particle design 
parameters on the murine innate immune response in both in vitro and in vivo 
settings.  We find that particles composed of either the biodegradable polymer 
poly(lactic-co-glycolic acid) (PLGA) or the biocompatible polymer polyethylene glycol 
(PEG) do not cause release of pro-inflammatory cytokines nor inflammasome 
activation in bone marrow-derived macrophages.  When instilled into the lungs of 
mice, particle composition and size can augment the number and type of innate 
immune cells recruited to the lungs without triggering inflammatory responses as 
                                                        1 Adapted for this dissertation from Roberts RA, Shen T, Allen IC, Hasan W, 
DeSimone JM, Ting JP. (2013) Analysis of the Murine Immune Response to 
Pulmonary Delivery of Precisely Fabricated Nano- and Microscale Particles. PLoS 
ONE 8(4): e62115. doi:10.1371/journal.pone.0062115  
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assayed by cytokine release and histopathology.  Smaller particles (80x320nm) are 
more readily taken up in vivo by monocytes and macrophages than larger particles 
(6µm diameter), yet particles of all tested sizes remained in the lungs for up to 7 
days without clearance or triggering of host immunity.  These results suggest 
rational design of nanoparticle physical parameters can be used for sustained and 
localized delivery of therapeutics to the lungs. 
 
2.1 INTRODUCTION 
The application of nanoparticles in medicine for disease treatment is a 
potentially transformative area of research.  The possibility of potent instruction and 
modulation of host physiology through nanomaterials has been abundantly 
demonstrated.  These efforts include modulation of cell-specific gene expression 
through delivery of antisense oligonucleotides, dose-sparing and targeted delivery of 
pharmacologics,  as well as enhanced multi-functional imaging diagnostics through 
nanoformulations [245,251,252].  Another area where nanotechnology may 
revolutionize clinical care is the ability to direct immune responses in defined 
manners.  The most obvious benefit is in the design of next-generation vaccines 
against microbial pathogens, whereby antigen specific immune responses can be 
elicited at levels far more potent than existing vaccines, commensurate with the 
immune response engendered by live organisms [123,204,253].  These latter 
advances owe much to our recent understanding of the critical role of innate 
immunity in contextualizing an appropriate adaptive immune response.  This context 
is triggered through endogenous host receptor signaling pathways, most well 
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characterized by the TLR family of pattern recognition receptors (PRR), but 
hallmarked by a panoply of such PRRs including C-type lectin receptors, RIG-like 
helicases and the burgeoning understanding of Nod-like receptors (NLRs) as 
sentinels of the intracellular environment [18].   
Researchers in the emerging field of immune-engineering are capitalizing on 
these exciting advances to open up the possibility to direct and instruct 
immunological outcomes to a variety of pathological conditions [246].  These include 
improving current pathogen vaccines, to the more nascent fields of cancer 
immunotherapy, tolerance induction in the setting of autoimmunity and organ 
transplantation, as well as general immunological rebalancing in diseased settings, 
such as the chronic inflammation associated with type 2 diabetes.  The implications 
of such technology are profound and potentially represent a paradigm shift in clinical 
practice across a broad swath of medicine.  However, efforts to use nanotechnology 
and material sciences engineering to modulate human biology in situ require a 
comprehensive understanding of the immune response, or lack thereof, engendered 
to introduced nanocarriers [148,150]. 
In order for the gamut of potential downstream therapeutic applications of 
nanomedicine to be realized, we must first understand how the physical properties of 
nanomaterials augment host immune responses.  These principles will then enable 
the appropriate design of nano- and micro-scale interventions for specific purposes.  
For example, the use of nanoparticles to deliver potent biological molecules, such as 
oligonucleotides or small molecules augmenting intracellular signaling pathways, 
may squander the regulatory opportunity to reach the clinic if the nanocarriers for 
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such entities initiate off-target events that activate host immune responses.  
Conversely, vaccines can be made more potent if nanocarriers are designed to 
activate the appropriate innate immune response to tailor adaptive immune 
responses to delivered antigens.  As an example, the current state of the art is to 
use Alum as a non-specific immunomodulatory adjuvant in vaccine formulations.  
This could explain, in part, why some of the most pressing pathogens do not yet 
have useful vaccines as Alum is known to engender a Th2-biased humoral immune 
response [254].  It is conceivable that nano-carriers designed to elicit the appropriate 
adaptive immune response to an antigen of interest - i.e., Th17 against fungal 
pathogens - may enable the generation of vaccine-induced immune responses that 
more closely mimic the natural immune response elicited by infection with a given 
pathogen as opposed the non-tailored immunity induced by Alum. 
A great issue in advancing nanotechnology from a laboratory pursuit into a 
component of clinical care is a robust understanding of how physical particle 
properties augment biological outcomes.  There is a wealth of literature promoting 
the use of nanotechnology in modern medicine, but much of this literature relies on 
particle fabrication methods, such as oil-in-water emulsion, that generate 
heterogeneous populations of particles that can vary widely between batches and 
across labs [255,256].   In addition, most studies related to biomedical applications 
of nanotechnology have not addressed the role of the immune system in the host 
response to particulate delivery, a critical issue that threatens to diminish the utility of 
such particles if these are rapidly cleared by innate immune cells and/or induce 
localized or systemic immune responses that pose unintended complications for 
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clinical development.  In cases where  the immunological parameters of 
nanotechnology are being addressed, great variance is seen based on size, 
composition and even surface modification of particles, highlighting the tremendous 
complexity and exquisite sensitivity of the immune system to nanoscale events  
[148-150].   
Most currently employed fabrication methods do not allow precise control 
over particle physical parameters, thus it is difficult to draw conclusions as to how 
size, shape and composition affect the innate immune response to particles in the 
nano and micron range.  To address this lack of knowledge, we employed our 
recently developed top-down nanofabrication technique termed Particle Replication 
in Non-Wetting Templates (PRINT) [157,188,194,257].  Using soft-lithography 
techniques adopted from the semi-conductor industry, PRINT enables the 
production of monodisperse nano- and microparticles with well-defined control over 
particle size, shape, composition, modulus and surface chemistry.  Therefore, the 
role of these physical parameters in augmenting biological responses can be 
reproducibly probed using PRINT technology.  
To lend both clinical and field relevance to our findings, particles were 
designed with either the F.D.A approved polymer Poly-lactic co-gloycolic acid 
(PLGA) or derivatives of the commonly published polymer polyethylene glycol 
(PEG).  While PLGA is an attractive polymer given its long history of clinical use, our 
study was aimed in part to clarify discrepancy in the literature as to whether particles 
made of PLGA trigger inflammation.  As our main purpose was to define the 
‘baseline’ status of whether particles of defined size, shape and composition 
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triggered inflammation, we did not augment particles in this study to include 
additional biologically active molecules, such as oligonucleotides, small molecules or 
adjuvants as previously published by our group and others [258-261].   To this end, 
we used in vitro assays with murine derived macrophages and in vivo delivery of 
particles to the lungs of mice to test the inflammatory potential of these particles.  
The lung is a highly desired site for therapeutic delivery of nanomedicine and we 
chose it for both clinical relevance and its sensitivity as an immunological organ 
[262].  Our findings imply that the delivery of PRINT nano- and micro-particles do not 
engender systemic or localized inflammatory responses and may not be impeded by 
host immune responses to the polymers used in this study. Future design strategies 
for the panoply of therapeutic opportunities made available by nanoenginneering are 
likely available, as particles across broad size ranges can thus be rationally 
designed from an inert state.   
 
2.2 MATERIALS AND METHODS 
Particle Materials 
Poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoetheyl 
methacrylate hydrochloride (AEM), Diphenyl (2,4,6-trimethylbenzoyl)-phoshine oxide 
(TPO), and  poly lactic co-glycolic acid (PLGA; 85:15 lactic acid/glycolic acid, MW= 
55 000 g/mol) were purchased from Sigma-Aldrich.  Tetraethylene glycol 
monoacrylate (HP4A) was synthesized in-house as previously described [263].  
Thermo Scientific Dylight 650 maleimide, PTFE syringe filters (13mm membrane, 
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0.220 µm pore size), dimethylformamide (DMF), triethanolamine (TEA), pyridine, 
sterile water, borate buffer (pH 8.6), Dulbecco’s phosphate buffered saline (DPBS) 
(pH 7.4), 1X phosphate buffered saline (PBS) (pH 7.4), acetic anhydride and 
methanol were obtained from Fisher Scientific.  Conventional filters (2 μm) were 
purchased from Agilent and polyvinyl alcohol (Mw 2000) (PVOH) was purchased 
from Acros Organics.  All PRINT molds used in these studies (80 nm x 320 nm, 1µm 
cylinder, 1.5µm and 6µm donuts) were kindly provided by Liquidia Technologies.   
PRINT PLGA Particle Fabrication 
The PRINT process for fabricating particles has been described previously 
[260,261].  Briefly, to fabricate PLGA particles, a preparticle solution containing 
PLGA was prepared in a DMSO (dimethylsulfoxide) / DMF (dimethylfluoride) / water 
solvent mixture (4:16:1) and cast on a poly-(ethylene teraphthalate) (PET) sheet 
(delivery sheet) using a #5 Mayer Rod (R.D. Specialties). The delivery sheet was 
placed in contact with a PRINT mold with desired features patterned (e.g., 80 × 320 
nm). The delivery sheet and mold were passed through a heated laminator (150 °C, 
5.5 × 105 Pa) and separated at the nip. This heating process enables the PLGA 
polymer solution to fill the molds, thereby forming nanoparticles of desired size and 
shape. Nanoparticles were then harvested from the PRINT mold by placing it in 
contact with a PET sheet coated with a layer (400 nm cast from water) of poly(vinyl 
alcohol) (PVA, MW = 2000 g/mol). This mold/PET-PVA ensemble was then passed 
through the laminator (150 °C, 5.5 × 105 Pa) to transfer the nanoparticles to the PVA 
sheet. Both laminator steps, the filling of the mold and transfer of particles onto the 
PVA-coated PET sheet, were performed at low humidity (∼20−30%). Particles were 
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released from the PET/PVA sheet by delivering ~1ml of sterile water via a bead 
harvester to dissolve the PVA layer and remove the particles from the PET sheet.  A 
typical yield of 80x320nm PLGA particles was ~0.4 mg particles/ft of PRINT mold, 
though this depended on the particle feature size of the mold.  To remove excess 
PVA and concentrate the particles, tangential flow filtration (TFF; Spectrum Labs) 
was used to concentrate particles in sterile water (1-2mg/ml). For later use in particle 
characterization assays and experiments, particles were lyophilized by adding 10× 
mannitol and 8× sucrose (10× and 8× to mass of particles) using a tree lyophilizer. 
Mannitol and sucrose were used as cryoprotectants.  
PRINT Hydrogel Fabrication 
The process of fabricating 80x320nm hydrogel particles was conceptually similar to 
PLGA fabrication, but with important differences. The pre-particle solution (PPS) 
contained a composition of 67.5 wt% HP4A, 20 wt% AEM (functional monomer), 10 
wt% PEG700DA (crosslinker), 1 wt% TPO (photo initiator) and 1.5 wt% Dylight 650 
maleimide. This composition was then dissolved at 3.5 wt% in methanol and drawn 
as a thin film using a # 3 Mayer rod (R.D. Specialties) onto a roll of corona treated 
PET using an in-house custom-made roll-to-roll lab line (Liquidia Technologies) 
running at 12 ft/min.  The solvent was evaporated from this delivery sheet by 
exposing the film to heat guns.  The delivery sheet was laminated (80 PSI, 12 ft/min) 
to the patterned side of the mold, followed by delamination at the nip.  Particles were 
cured by passing the filled mold through a UV-LED (Phoseon, 395 nm, 3 SCFM N2, 
12 ft/min).  A PVOH harvesting sheet was hot laminated to the filled mold (140 ºC, 
80 PSI, 12 ft/min).  Upon cooling to room temperature, particles were removed from 
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the mold by splitting the PVOH harvesting sheet from the mold.  Particles were then 
harvested by dissolving the PVOH in a bead of water (1 mL of water per 5 ft of 
harvesting sheet).  The particle suspension was passed through a 2 µm filter 
(Agilent) to remove any large particulates.  To remove the excess PVOH, particles 
were centrifuged (Eppendorf Centrifuge 5417R) at 14000 rpm for 15 min, the 
supernatant was removed and the particles were re-suspended in sterile water.  This 
purification process was repeated 4 times prior to lyophilization as detailed above. 
The 80x320nm particles were acetylated prior to experimental use to match negative 
charge of micron sized hydrogel particles. 
The 1.5 and 6 µm donut shaped hydrogel particles were fabricated using a 
dropcast method.  The pre-particle solution (PPS) was composed of 20% PEG700-
DA, 78% HP4A, 1% TPO (photoinitiator), and 1% Dylight 650.  The solution was 
spread onto a fluorocur mold and a poly(ethylene terephthalate) (PET) sheet was 
laminated on top of the mold and polymer mixture and run through a heated, 
pressurized laminator to fill the molds.  The mold was then cured with a UV LED 
lamp for 30 seconds.  Particles were transferred out of the mold onto a Luvitec 
harvesting layer by laminating the mold and Luvitec sheet together and running them 
through a heated laminator nip.  The mold and harvesting sheet was separated, 
leaving free particles on the harvest layer.  Particles were collected from the harvest 
sheet by bead harvesting with water and pelleted by centrifugation.  The particles 
were re-suspended in tert-butanol and lyophilized overnight. 
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Particle Characterization 
Thermogravimetric analysis (TGA) was used to determine stock particle 
concentrations (TA Instruments Q5000 TGA).  Briefly, 20 µL of the stock 
nanoparticle solution was pipetted into a tared aluminum sample pan. The sample 
was heated at 30°C/min to 130°C and held at this temperature for 10 minutes. The 
sample was then cooled at 30°C/min down to 30°C and held for 2 minutes.  A 
Hitachi S-4700 scanning electron microscope (SEM)was used to visualize particles.  
Prior to imaging, the SEM samples were coated with 1.5 nm of gold-palladium alloy 
using a Cressington 108 auto sputter coater.  Particle size and zeta potential were 
measured by dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern 
Instruments, Ltd.).   
Experimental animals 
All studies were conducted in accordance with National Institutes of Health 
guidelines for the care and use of laboratory animals and approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of North 
Carolina at Chapel Hill. All animals were maintained in pathogen-free facilities at the 
University of North Carolina at Chapel Hill.  
In vitro inflammation assays 
Bone marrow macrophages were isolated from the femurs of C57Bl/6 and 
BALB/c mice using standard procedures. Bone marrow-derived macrophages were 
cultured for six days in DMEM supplemented with 10% fetal bovine serum, L-
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Glutamine, pen/strep and 20% L929-conditioned medium prior to use in particle 
experiments.  Adherent cells were isolated and plated in complete Dulbecco’s 
Modifed Eagle Medium (Gibco) with 10% fetal calf serum, 1% penicillin/streptomycin 
and 1% L-glutamine at 200,000 cells per well in a 96-well dish for 24 hours prior to 
treatment with particles.  Some cells were primed with LPS (50ng/ml) for 24 hours 
prior to particle treatment to provide signal 1 for inflammasome activation.  MSU 
(300μg/ml; Invivogen) or ATP (5mM) was used as a positive control for 
inflammasome activation. Particles were resuspended in PBS prior to dosing at 
various concentrations.  After 24 hours of particle treatment in triplicate, 
supernatants were harvested and analyzed by murine IL-1β, TNF-α and IL-6 ELISA 
(BD Biosciences). 
Assessment of airway inflammation 
To assess whether PRINT particles induce airway inflammation, 10-12 week 
old female C57Bl/6 mice were anesthetized with isofluorane inhalation and particles 
were instilled via intratracheal (i.t.) administration.  50µg of particles were dosed in 
50ul of PBS.  Intratracheal administration of PBS (50ul) or LPS (20µg in 50ul PBS) 
served as negative and positive controls for airway inflammation, respectively, as 
previously described [264].  Mice were euthanized and airway inflammation was 
assessed 48 hours or 7 days post treatment.  
Serum was collected from animals by cardiac puncture and centrifuged at 
15,000 RPM for 10 minutes.  The serum supernatant was collected and used for 
ELISA analysis of inflammatory markers.  Bronchoalveolar lavage fluid (BALF) was 
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also collected to evaluate local leukocyte and cytokine levels in the lungs.  For this 
purpose, lungs were lavaged three times with 1ml Hanks Balanced Salt Solution 
(HBSS; Gibco).  After centrifugation at 1500 RPM for 5 minutes, cell-free 
supernatants were collected and used to assess cytokine levels of IL-1β, TNF-α and 
IL-6 via ELISA (BD Biosciences).   RBC were lysed via brief hypotonic saline 
treatment and the cell pellet was resuspended in PBS.  Total BALF cellularity was 
assessed with a hemacytometer.  The cellular composition was determined by 
cytospin of BALF aliquots onto slides and staining with Diff-Quik (Dade Behring) for 
differential cell counts. Leukocytes were identified based on the morphology of ≥200 
cells per sample. Following BALF harvest, the lungs were fixed by inflation (20-cm 
pressure) and immersed in 10% buffered formalin.   
Histopathological examination 
Inflammation was evaluated in 5µm sections of the left lung lobe after 
hematoxylin and eosin (H&E) staining.  Serial paraffin-embedded sections were set 
and cut to reveal maximum longitudinal visualization of the intrapulmonary main 
axial airway and inflammation was scored by one of the authors (I.C.A.) who was 
blinded to genotype and treatment.  As previously described, histology images were 
evaluated on each of the following inflammatory parameters and scored between 0 
(absent) to 3 (severe): mononuclear cell infiltration, polymorphonuclear cell 
infiltration, airway epithelial cell hyperplasia/injury, extravasation, perivascular 
cuffing, and estimated percentage of the lung involved with inflammation [48,265]. 
Scores for each parameter were averaged for a total histology score. 
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Particle uptake in BALF 
BALF aliquots from PEG treated mice were fixed in 2% paraformaldehyde and 
stained with DAPI (nuclei) and Phalloidin 488 (actin) and then viewed via 
epifluorescence microscopy for particle uptake (Dylight 650).  Five distinct fields of 
view (FOV) were captured for each slide.  The percentage of cell uptake was 
determined by dividing the number of cells showing particle internalization by the 
total number of cells in each field of view.  
Statistical Analysis 
GraphPad Prism 5 software was used to identify statistical significance.  
Single data point comparisons were evaluated by Student’s two-tailed t-test, 
whereas multiple comparisons were evaluated for statistical significance using 
Analysis of Variance (ANOVA) followed by Tukey-Kramer HSD post-test.  All 
cytokine and cell count data are presented as mean +/- standard deviation (SD) or 
standard error of the mean (SEM), respectively, with a p-value less than 0.05 
considered statistically significant. 
 
2.3 RESULTS 
PRINT enables the fabrication of monodisperse and homogenous particles 
We employed Particle Replication in Non-Wetting Templates (PRINT) in an 
effort to address whether particles of defined size, shape and composition trigger an 
inflammatory response in mice.  This fabrication platform enables production of 
57  
homogenous and monodisperse particles with user-defined physical parameters.  As 
a large amount of literature shows crucial biological differences depending on size 
and shape, the PRINT technique enables reproducible probing of basic cell biology 
with nearly complete control of design parameters [122,150,266,267].    
For the purposes of our studies, we fabricated particles across the nano and 
micron range to reflect biologically relevant sizes.  These include 80x320nm 
particles (commensurate with the sizes of small bacteria and large viruses), 1 µm 
and 1.5µm particles (commensurate with bacteria and platelets), and 6µm particles 
(akin to a red blood cell in size) [266,268].  To characterize the fabricated particles, 
we performed dynamic light scattering (DLS) and zeta potential measurements as 
shown in Figure 2-1A.  Note that DLS measurements are quantified based on 
particles with a perfect sphere shape, so that the size ranges detected are in line 
with non-spherous shapes of the molds used.  The poly-dispersity index (PDI), a 
measure of heterogeneity in a particle population, indicates we were able to 
fabricate monodisperse particles of the same size and shape.  This is further 
evidenced by scanning electron microscopy images (Figure 2-1B).  As the surface 
charge of particles has been shown to play a role in biological outcomes, such as 
protein adsorption and cell uptake, we measured the Zeta potential of particles to 
quantify net surface charge [267,269,270].  For all PLGA particles, surface charge 
was negative and decreased with increasing particle size (Figure 2-1A). 
While our initial studies used particles fabricated from the F.D.A-approved 
biocompatible and biodegradable polymer poly(lactic-co-glycolic acid) PLGA, we 
also incorporated studies using particles fabricated with derivatives of biocompatible 
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poly (ethylene glycol) (PEG).  Chemical modification of PEG is more feasible than 
with PLGA and thus it is often used to add increased functionality to nanocarriers, 
such as decoration of cell-targeting ligands, imaging agents, and pharmacologic 
cargo incorporation. Characteristics of fabricated PEG particles were similar to that 
of the PLGA particles, with low PDI and negative surface charge (Figure 2-1C) and 
monodisperisty as evidenced by SEM (Figure 2-1D).  These PEG particles were 
fabricated with a dye (DyLight 650) to enable fluorescent imaging of particles in 
downstream assays. 
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Figure 2-1. PRINT Particle Characterization. 
A) Dynamic light scattering (DLS) and zeta potential measurements of PLGA 
particles used in studies.  Particle charge decreases with increasing size for PLGA 
but this trend isn’t consistent across polymers. B) Scanning electron microscope 
(SEM) images of PLGA particles. C) PEG particle composition and characterization. 
D) SEM of PEG particles. 
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PRINT particles do not induce inflammation in murine macrophages 
Much work has been done in vitro to assess the potential use of PLGA 
nanoparticles in a variety of therapeutic modalities, from delivery of 
chemotherapeutics and siRNA to imaging agents for improved diagnostics to name 
a few.  However, less work has been done to characterize the innate immune 
response to such particles and whether physical parameters of particles can 
augment the immune response.  As a primary sentinel of host homeostasis, the 
innate immune system is tasked with identifying foreign matter in the body and 
initiating an appropriate response.  Subsequent activation of the innate immune 
response is hallmarked by release of soluble protein messengers like cytokines that 
serve to recruit other immune cells to the area to participate in defense and repair of 
the host [18].  This inflammatory response is initiated by release of pro-inflammatory 
cytokines, including TNF-α, IL-6 and IL-1β, from innate immune cells, such as 
macrophages.   
The field of environmental toxicology has long studied the role of 
nanoparticulates in inducing inflammation, in particular in the lung [271].  Attempting 
to synthesize work by other groups using a range of particle compositions and sizes 
suggest that there is no clear correlation between the physical parameters of a 
particle and the ensuing inflammatory response to it.  Generally speaking, the 
composition of a particle has greater bearing on the inflammatory response than its 
size or shape.  As an example, titanium dioxide and silica dioxide nanoparticles 
trigger inflammation, whereas zinc oxide nanoparticles do not, even though all 
particles were of similar size (15-20nm) [75].  Others have identified size-dependent 
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inflammation and cell death that could be inhibited simply with surface modification 
of silica particles with common chemical groups such as aldehydes [160-162].  
These findings highlight the sensitivity of the innate immune system as each particle 
may engender unique responses depending on its size, shape and composition. 
We initially tested the inflammatory potential of PRINT particles in an in vitro 
cell culture system with bone marrow-derived macrophages from C57BL/6 mice.  
We used a panel of PRINT particles that differed in composition and size (Figure 2-
1).  After either a 5 hour or 24 hour incubation with a panel of PRINT particles 
comprised of either PLGA or PEG derivatives, no detectable levels of any tested 
pro-inflammatory cytokine (TNF-α, IL-6, IL-1β) across a range of doses (1-100μg/ml) 
were found (Figure 2-2A and data not shown).  Lipopolysaccharide (LPS), a cell wall 
component of gram-negative bacteria, was used as a positive control for 
inflammation induction.  The lack of cytokine induction was in line with data from 
endotoxin assays indicating our fabrication process was endotoxin-free (Figure 2-
2B).  In addition, across all doses of particles tested, no particle-induce cytotoxicity 
was observed as measured by LDH assay (Figure 2-2C).  
Given the recent discovery of the inflammasome as a mediator of the innate 
immune response to particulate challenge, we also sought to address whether 
PRINT-fabricated PLGA particles could cause inflammasome activation [72,75,272].  
The inflammasome is a multi-protein complex that is formed in response to variety of 
environmental stimuli, including asbestos, silica and monosodium urate crystals, that 
results in the activation of caspase-1 and subsequent maturation and secretion of 
the pro-inflammatory cytokines IL-1β and IL-18 [43].  As our initial results did not 
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indicate any particle induction of IL-1β (Figure 2-2A), we next assessed whether 
priming macrophages with LPS would cause particles to induce inflammasome 
activation.  LPS priming is thought to provide signal 1 to inflammasome formation by 
upregulating the protein levels of pro-IL-1β and NLRP3, a main component of the 
inflammasome complex [273,274].  As assessed by IL-1β release, PLGA particles 
did not induce activation of the inflammasome in the presence or absence of LPS-
priming when tested in either BALB/c (Figure 2-2D) or C57BL/6 macrophages 
(Figure 2-2E).  Importantly, we tested particles across a range of doses (100ng-
3µg/ml) and sizes (80x320nm and 1µm cylinders).  These results suggest that PLGA 
particles across the nano and micron range do not synergize with TLR ligands (i.e., 
LPS) to induce inflammasome activation in vitro and lend further credence to the use 
of PLGA particles for in vivo applications. 
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Figure 2-2. PRINT particles do not cause inflammation in bone marrow-derived 
macrophages from BALB/c or C57BL/6 mice. 
A) Overnight stimulation with a panel of PRINT PLGA and hydrogel particles at 
100μg/ml does not cause TNF-α, IL-6, or IL-1β release from bone marrow-derived 
macrophages from C57BL/6 mice as measured by ELISA.  B) Both PLGA and 
hydrogel PRINT particles tested negative for endotoxin contamination using a 
Limulus amebocyte lysate assay.  C) PRINT particles are not cytotoxic in bone-
marrow derived macrophages as determined by lactate dehydrogenase (LDH) 
release. D) 80x320nm PLGA particles do not synergize with LPS to induce 
inflammasome activation as measured by IL-1β ELISA in BALB/c bone-marrow 
derived macrophages.  E) Neither 80x320nm nor 1µm PLGA particles synergize with 
LPS to induce inflammasome activation as measured by IL-1β ELISA in C57BL/6 
bone-marrow derived macrophages. MSU was dosed at 300μg/ml. *** = p<0.001.  
Experiments were performed in triplicate. Data shown are representative of at least 
three independent experiments. 
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PLGA particles do not induce lung inflammation 
Bolstered by our in vitro findings, we next were interested in whether PLGA 
particles could be delivered to the lungs of mice without causing overt signs of 
immune activation as hallmarked by inflammation.  The lung was chosen as a highly 
sensitive mucosal organ with clearly defined markers of inflammation that is the sight 
of numerous therapeutically relevant diseases, from allergies and asthma to chronic 
obstructive pulmonary disorder (COPD) and respiratory infections by microbial 
pathogens such as tuberculosis and influenza [262,275].  As such, therapeutic 
modulation of lung biology is a highly desired clinical goal with relevance to the vast 
majority of the human population.  We used intra-tracheal (i.t.) delivery to determine 
whether 80x320nm PLGA particles (50µg) caused inflammation in the lungs, with 
PBS (50ul) and LPS (20µg) used as negative and positive controls, respectively.  48 
hours after installation, mice (n=5 per group) were harvested and lung inflammation 
was assessed via field standards used in respiratory infection models [48,265].  
Broncheoalveolar lavage fluid (BALF) cellularity indicated no recruitment of immune 
cells to the lungs after particle treatment, as cell numbers were no different than the 
PBS control (Figure 2-3A).  LPS-treated mice revealed a robust accumulation of 
leukocytes as is expected during inflammatory responses.  Assessing the 
composition of leukocyte populations in the BALF revealed no significant recruitment 
of immune cells to the lungs of particle-treated mice.  Conversely, LPS-treated mice 
had high levels of both monocytes and neutrophils, key mediators of the innate 
immune system’s inflammatory response (Figure 2-3B). 
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While BALF cellularity is widely used as a marker of lung inflammation, lung 
histopathology enables a deeper understanding of inflammatory effects on the lung 
parenchyma.  Representative sections of histopathology slides of the main bronchi 
of the left lobe were examined to further delineate leukocyte infiltration around lung 
vasculature, parenchyma and the large and small airways (Figure 2-3C).  Whereas 
LPS treatment caused a clear accumulation of leukocytes throughout the lung, 
treatment with 80x320nm PLGA particles showed no difference as compared to PBS 
controls (Figure 2-3D).   To further verify the non-inflammatory nature of these 
particles, pro-inflammatory cytokine levels were assessed in the BALF and serum of 
treated mice.  No significant release of IL-1β (Figure 2-3E) or IL-6 (Figure 2-3F) was 
seen in the BALF.  Serum measurements for these same cytokines and TNF-α were 
undetectable (data not shown).  In total, these results are in agreement with the in 
vitro findings and suggest that 80x320nm PLGA particles can be delivered to the 
lungs without causing innate immune activation and inflammation. 
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Figure 2-3. 80x320nm PLGA particles do not cause lung inflammation in mice. 
Mice were challenged with either 50µg of 80x320nm PLGA particles or 20µg LPS i.t. 
and airway inflammation was assessed 48 hours post-challenge.  A) Total cellularity 
of bronchoalveolar lavage fluid (BALF) in treated C57BL/6 mice is no different after 
48 hours than PBS-treated mice and is significantly less than the inflammatory cell 
recruitment seen in LPS-treated mice.  B) PLGA particle treatment does not induce 
any appreciable immune cell recruitment to the lungs of mice, as opposed to the 
heightened levels of monocytes and neutrophils seen in the lungs of LPS-treated 
mice.  C) Histopathology revealed no significant differences in lung architecture 
between PBS- and 80x320nm PLGA particle-treated mice.  This is in stark contrast 
to the airway occlusion and significant innate immune cell recruitment seen in LPS-
treated mice. D) Histopathology scoring confirmed that no significant differences 
were seen between the lungs of PBS and PLGA particle treated mice. E-F) The 
increased lung levels of pro-inflammatory IL-1β and IL-6 seen in LPS-treated mice is 
not found in PLGA-treated mice. PBS, n=3; 80x320nm PLGA particle-treated, n=5; 
LPS-treated, n=3. ND = Not Detected.  * = p< 0.05, *** = p<0.001. Experiments were 
performed using 3-5 mice per group. Data shown are representative of at least two 
independent experiments. 
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Sustained deposition of hydrogel particles in lungs without inflammation 
To broaden the implication of our in vivo findings, we fabricated a series of 
particles using PEG polymers and their derivatives (hydrogels) that incorporated 
fluorescent dyes which enabled us to track them in vivo over time after lung 
instillation.  The hydrogel particles ranged in size from 80x320nm to 1.5µm and 6µm 
as characterized in Figure 2-1.  In vitro experiments indicated they did not elicit 
inflammatory cytokines or cell death from bone marrow-derived macrophages 
(Figure 2-2).  Using the same experimental approach as outlined above, 50µg of 
particles were instilled i.t. into C57BL/6 mice and lung inflammation was assessed at 
two time points, 48 hours and 7 days post-particle instillation.  As shown in Figure 2-
4A, total BALF cellularity does not increase in the presence of hydrogel particles as 
compared to PBS at 48 hours, which is in marked contrast to LPS-induced cell 
recruitment to the lungs.  Breaking down the BALF cell types revealed a similar 
number of monocytes in the lungs PBS and particle-treated mice, whereas LPS-
treatment induced a marked influx of both monocytes and neutrophils (Figure 2-4B).  
At 7 days post-particle treatment, there was no significant increase in the total BALF 
cellularity or composition in mice treated with any hydrogel particles (Figure 2-4C 
and 2-4D).  Histopathology analyses indicated neither lung architecture disruption 
nor leukocyte infiltration into the lungs or airways of particle-treated mice as 
compared to PBS controls at either the 48 hour or 7 day time point (Figure 2-4E and 
2-4F).   
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Figure 2-4. Hydrogel particles do not cause lung inflammation in mice. 
Mice were challenged with 50µg of hydrogel particles (80x320nm, 1.5µm, or 6.0 µm 
donuts) i.t. and airway inflammation was assessed 48 hours and 7 days post-
challenge.  A) BALF analysis indicated no increased cellularity 48 hours after 
hydrogel particle treatment, whereas a significant cellular influx was seen in LPS-
treated controls.  B) At 48 hours, BALF cellular composition does not show any 
significant trend for immune cell recruitment in hydrogel particle-treated mice.  C-D) 
BALF cellularity and composition was not significantly augmented seven days after 
hydrogel particle treatment. E) Histopathology analysis revealed no significant 
differences in lung architecture between PBS- and hydrogel particle-treated mice at 
either 2 or 7 days post-treatment. F) Histopathology scoring confirmed that no 
significant differences were seen between the lungs of PBS and hydrogel particle 
treated mice at any time points.   ***=p<0.001.  Experiments were performed using 
2-5 mice per group. Data shown are representative of at least two independent 
experiments. 
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Despite the absence of overt signs of inflammation, 6µm particles with their 
hallmark donut appearance could be viewed within the lung spaces of multiple mice 
after H&E staining 7 days post-challenge (Figure 2-5A).  The lack of immune cell 
recruitment or disruption of tissue architecture around these particles may suggest 
an immunologically inert deposition of particles within the alveolar spaces. Such a 
depot may provide sustained localized delivery of therapeutically attractive 
molecules.  Because the 80x320nm and 1.5µm particles were too small to see in 
lung histology samples, immunofluorescence imaging on BALF samples was 
performed to determine whether lung-localized cells took up particles.  As shown in 
Figure 2-5B, BALF cells contained hydrogel particles of all sizes at 48hrs (magnified 
view in Figure 2-5C).  The percentage of cells with particles decreases as particle 
size increased (Figure 2-5D).  Whether this is due to the quantitatively higher 
number of 80x320nm particles at the same dose weight of larger particles, the 
relatively easier ability for a cell to take up smaller particles as compared to larger 
ones, or an as yet unidentified size-dependent biological effect remains unanswered.  
Of note, BALF cells 7 days after particle instillation show particle uptake, albeit to a 
lesser extent than the 48 hour time point (Figure 2-5E).  Finally, the levels of pro-
inflammatory cytokines released into the BALF and serum of PEG particle-treated 
mice were quantified.  At both the 48 hour and 7 day time points, IL-1β, IL-6, and 
TNF-α were undetectable for any particle treatment (data not shown). In total, these 
data highlight the ability of PRINT particles to remain localized to the lung for long 
periods of time in an immunologically inert manner.   
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Figure 2-5. Sustained deposition of hydrogel particles in murine lungs. 
A) 6µm hydrogel particles (denoted by red arrows) are visible in the alveolar spaces 
of multiple mice 7 days after intratracheal installation. Lower insets are magnified 
views of particles.   B) Two days after treatment with hydrogel particles, BALF cells 
were stained and visualized for particle uptake via epifluorescence microscopy.  
Particles (Dylight 650, red); nuclei (DAPI, blue); F-actin (Phalloidin 488, green). C) 
Magnified views of BALF cells taking up hydrogel particles from Figure B images. D) 
Quantification of particle uptake indicates smaller particles are more readily taken up 
in BALF cells than larger particles.  E) All types of hydrogel particles can still be seen 
in BALF cells seven days after treatment, though there is a marked decrease in the 
number of particles present as compared to the 2 day time point. Scale bar is 20µm.  
Data shown are representative of at least two independent experiments.  
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2.4 DISCUSSION 
Given the diverse therapeutic potential of nano- and microscale particles, this 
study sought to define whether particles composed of either PLGA or PEG-
derivatives induced inflammatory responses in an in vitro and in vivo setting.  By 
making use of the highly controlled PRINT fabrication method, we were also able to 
determine whether particle size affected any ensuing innate immune responses.  
Our findings reveal that PRINT particles do not cause any obvious activation of the 
innate immune response in murine macrophages or the murine lung and maintain 
long term (7 day) immunologic stability in the lungs of mice.  
The wide array of polymers and particle fabrication techniques used in 
nanomedicine studies makes it difficult to reach definitive conclusions regarding 
particle effects on innate immune functions.  We initially used particles fabricated 
from PLGA as this is a commonly used polymer with attractive clinical potential given 
its F.D.A approval.  There is some discrepancy in the literature as to whether PLGA 
particles are inflammatory in situ.  Some groups suggest PLGA particles are 
inflammatory in vitro and in vivo, whereas others have not found this to be the case 
[72,73,203,276,277].  Our study reveals that PLGA particles of nano and micron 
range fabricated by PRINT technology do not synergize with a TLR ligand to cause 
inflammasome activation nor inflammation in general, and that in vivo delivery does 
not trigger an inflammatory reaction, contrary to a previous report [72].  The 
discrepancy between these findings may be due to differences in particle fabrication 
or experimental settings.  It has recently been shown that fabrication of particles with 
non-smooth surfaces can cause inflammasome activation, which may help explain 
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the discrepancy in the literature regarding PLGA nanoparticle-mediated IL-1β 
release [165].  However, given the long clinical history of PLGA and the broad 
literature reporting PLGA particle uses for biomedical applications, it seems unlikely 
that particles derived from PLGA would trigger potent inflammatory responses, yet 
this confusion is precisely why more research must be carried out to ensure such 
unwanted side-effects are avoided as fabrication methods or material sourcing may 
impact immune responses significantly [278-280].   
In addition, studies using PEG particles enabled us to broaden our 
understanding of innate immune activation by particles comprised of a polymer 
composition that enables wide-ranging chemical modifications for enhanced 
functionality, such as cell targeting, pH-specific cargo release and siRNA 
incorporation as previously reported by our group and others [258,259,281,282] .  
Interestingly, although these PEG particles are not considered biodegradable, they 
did not induce lung inflammation as seen with other non-degradable particles such 
as those comprised of polystyrene [276].  This suggests our PEG polymer 
composition may also be an attractive alternative from an environmental toxicology 
perspective in applications currently employing polystyrene particles. 
The issue of innate immune activation by particles is of central relevance to 
the translational application of nanotechnology.  While particulate vaccines against 
some pathogens and cancers will likely be designed to trigger localized inflammation 
as part of the general innate immune activation required for robust adaptive immune 
responses, most other biomedical applications for nano- and microparticles will 
benefit by avoiding such responses.  Additionally, a strong immune response might 
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lead to the undesirable outcome of rapid particle clearance as well as 
hypersensitivity responses.  Drug delivery, diagnostic imaging and physiological bio-
mimicry are examples of nanoengineering applications that may be impeded by 
innate immune activation. Importantly, many advances in immune modulation made 
available through rationally designed nano- and microscale particles such as 
tolerance induction in the setting of autoimmunity or organ transplantation, direct 
targeting of immune cell subsets and immune-skewing of pathological 
microenvironments such as tumors or sites of chronic inflammation, require that 
particles be designed initially from an inert immunological state 
[197,211,233,248,250,283,284].  To wit, if particles alone trigger inflammatory 
responses that skew towards any type of adaptive response (e.g., Th1, Th2), then 
many of these therapeutic goals will not be achieved.  For these reasons, we feel it 
is of utmost importance that baseline innate immune responses to particles be 
assessed as part of field standards [148]. 
Our in vivo studies reveal that particle size augments uptake into innate 
immune cells of the lungs, with larger particles taken up less than smaller particles.  
This finding suggests a duality in design considerations depending on therapeutic 
application.  For example, drug delivery to the lungs to ameliorate asthma would 
likely be best served by larger particles that can release their cargo to extracellular 
spaces.  Conversely, if trying to deliver a respiratory vaccine, smaller particles that 
are more readily taken up by antigen presenting cells and traffic to lymph nodes 
would be more appropriate.  The finding that particles of all tested sizes remain in 
the lungs up to 7 days post instillation also suggest the ability to provide sustained 
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localized delivery of therapeutically attractive molecules via particulate formulations.  
This is far different than the rapid clearance seen for smaller particles (<50nm 
diameter) and reflects the importance of particle design parameters when 
considering therapeutic interventions [285]. 
Having identified particles across the nano- and microscale that do not trigger 
inflammatory responses in mice while remaining in the lungs, we plan to next use 
these particles as delivery devices for a range of biologically relevant molecules, 
including siRNAs, anti-inflammatory agents, and immune-skewing compounds.  
These studies will test the hypothesis that targeted modulation of lung immunology 
via nanoengineering may enable a new class of therapeutics for lung disorders that 
avoid systemic side-effects while also reducing administration doses.  Importantly, 
we will move studies into human cells to provide much needed data regarding the 
immunological response to nanomaterials in our own species.  Using the design 
control inherent to PRINT technology, we will also be able to systematically address 
the role of particle size and shape during delivery of bioactive molecules.  Such 
results may be crucial to advancing next-generation respiratory vaccines and 
treatments for asthma, allergies and chronic disorders of lung function. 
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CHAPTER 3 
ANALYSIS OF THE HUMAN IMMUNE RESPONSE TO PRECISELY 
FABRICATED NANO- AND MICROSCALE PARTICLES WITH CROSS 
VALIDATION IN A HUMANIZED MOUSE MODEL 
 
Biocompatible particles at the nano- and micron scale are a promising 
platform for biological programming as they can be modularly designed to trigger 
specific cellular events in a variety of disease contexts.  Because the immune 
system is a major mediator of host homeostasis and pathology, avoidance of 
immune responses as well as directed and specific programming of immune 
responses will likely constitute a major clinical advance in the near future.  In order 
for this to occur, a clear understanding of the baseline human immune response to 
nano and microscale programming devices must be systematically characterized in 
order for the gamut of potential therapeutics to be achieved.  To this end, we make 
use of Particle Replication in Non-wetting Templates (PRINT) technology to 
precisely fabricate biocompatible particles across the nano- and micro-scale in order 
to address the role of size, shape and composition on human immune response.  
We first characterize the inflammatory response to particles in a human monocyte 
cell line and then identify resident immune cell populations which are passively 
targeted by nanoparticles in ex vivo human blood samples.  We uncover a role for 
PEGylation in modulation of particle uptake into human immune cells as well as a 
role for lipid incorporation in mitigating chemokine induction by PLGA nanoparticles 
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through global cytokine array screening.  Finally, we recapitulate our ex vivo human 
PBMC findings in a humanized mouse model and validate this as a whole animal 
approach for future nanomedicine studies with translational applications.  Our 
systematic methodology affirms the potential of biocompatible particles as biological 
programming devices for human use. 
3.1 INTRODUCTION 
Biocompatible materials when fabricated at the nano- and micro-scale enable 
interaction with the mammalian immune system where precise programming of host 
biology becomes feasible [74,148,201,214,246,247,283,286,287].  This has already 
been evidenced in mice for anti-microbial vaccines 
[73,120,123,124,178,195,196,203-205,212,224,253,288,289], cancer 
immunotherapy [137,231-233,236,245], induction of tolerance in autoimmune 
settings [248-250] and siRNA-mediated gene knockdown [231,232,245,260], with 
some promising pioneering examples also occurring in human studies [290].  
Concomitant with advances in molecular immunology, there is a widespread 
appreciation for the role of the immune system in modulating host homeostasis in 
every major disease category, including those of metabolic, neurologic, and 
oncogenic origin [17,129,147,291,292].   
While multiple efforts are underway to identify the molecular bases of these 
various diseases, a next generation of therapeutics will likely include the use of 
biocompatible materials fabricated at the nano- and micro-scale to deliver 
programming instruction to humans at the organ, tissue and cellular level [2,18,214].  
Nano- and micro-scale particles (NMP) will be designed to precise physical and 
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chemical specifications, as size, shape and composition of particulate matter clearly 
impacts host biology (reviewed in Chapter 1 and [148,156,214,246,247]).  However, 
our understanding of the impact of these particle design parameters on the human 
immune response is still in its infancy.  This is due in part to a lack of reproducible 
and well-controlled particle fabrication techniques, as well as a dearth of studies in 
human cells. 
In this report, we make use of the Particle Replication in Non-wetting 
Templates (PRINT) process to fabricate biocompatible, monodisperse nano- and 
micro-scale particles (NMP) with precise dimensions to probe the human immune 
response to such particulate matter [188,189,191,192,194,293].  NMP are 
comprised of polymers already used in clinical interventions, either poly(lactic-co-
glycolic acid) (PLGA) or polyethylene glycol (PEG) hydrogel derivatives [235].  
Particles can be fabricated across the nano (80x320nm) to micron scale (3μm) 
without inducing inflammatory responses in a human monocyte cell line.  In addition, 
we identify a subset of primary human peripheral blood mononuclear cells (PBMC) 
passively targeted by nanoparticles in a manner that correlates with CD14 
expression and identify PEGylation as a means to augment the specific quantity of 
particles taken up by these cells and ensuing biological responses.  Global cytokine 
profiling reveals a general lack of immune induction by hydrogel nanoparticles in 
human PBMC cultures.  This study also uncovered a role for lipid incorporation 
and/or surface charge in modulating induction of chemokine release in human 
immune cells by PLGA particles, while also revealing large differences in the 
magnitude of innate immune responses among donors.  Finally, to translate our 
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findings into a whole animal model, we show humanized mice recapitulate our ex 
vivo human PBMC results and make the first report of nanoparticle targeting of 
human plasmacytoid dendritic cells and bone marrow-resident immune populations 
in a humanized mouse.  These results may engender more appropriate models for 
nanomedicine studies aimed at eventual application in the clinic. 
 
3.2 MATERIALS AND METHODS 
Particle Materials 
Poly lactic co-glycolic acid (PLGA; 85:15 lactic acid/glycolic acid, MW= 55 000 
g/mol), poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoetheyl 
methacrylate hydrochloride (AEM), and Diphenyl (2,4,6-trimethylbenzoyl)-phosphine 
oxide (TPO) were all sourced from Sigma-Aldrich.  Tetraethylene glycol 
monoacrylate (HP4A) was synthesized in-house as previously described [263].  
Thermo Scientific maleimide-terminated Dylight 650 and Dylight 488, PTFE syringe 
filters (13mm membrane, 0.220 µm pore size), dimethylformamide (DMF), 
triethanolamine (TEA), pyridine, sterile water, borate buffer (pH 8.6), Dulbecco’s 1x 
phosphate buffered saline (DPBS) (pH 7.4), acetic anhydride and methanol were 
obtained from Fisher Scientific.  Rhodamine PolyFluor 570 was sourced from 
Polysciences.  Methoxy-PEG(5k)-succinimidyl carboxy methyl ester (mPEG5k-SCM) 
was purchased from Creative PEGWorks. Conventional filters (2 μm) were 
purchased from Agilent and polyvinyl alcohol (Mw 2000) (PVOH) was purchased 
from Acros Organics.  Liquidia Technologies kindly provided all PRINT molds used 
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in these studies (80 nm x 320 nm, 200 nm x 200nm, 1µm cylinder, 1.5µm and 3µm 
donuts). 
 
PRINT PLGA Particle Fabrication 
Fabricating PLGA particles using the PRINT process has been previously 
described in detail elsewhere [260,261] so a brief description is included here.  A 
preparticle solution (PPS) containing PLGA was prepared in a DMSO/DMF/water 
solvent mixture (4:16:1) and cast on a poly-(ethylene teraphthalate) (PET) sheet 
(delivery sheet) using a #5 Mayer Rod (R.D. Specialties). The delivery sheet was 
placed in contact with a PRINT mold with desired features patterned (e.g., 80 × 320 
nm, 200x200nm, 1.5µm donut). The delivery sheet and mold were then passed 
through a heated laminator (150 °C, 5.5 × 105 Pa) and separated at the nip. Heating 
enables the PLGA polymer solution to fill the molds through capillary forces, thereby 
forming nanoparticles of desired size and shape. Nanoparticles were then harvested 
from the PRINT mold by placing it in contact with a PET sheet coated with a 400nm 
layer of poly(vinyl alcohol) (PVOH, MW = 2000 g/mol). This ensemble of mold/PET-
PVOH was then passed through the laminator (150 °C, 5.5 × 105 Pa) to transfer the 
nanoparticles to the PVOH sheet. Both laminator steps - the filling of the mold and 
transfer of particles onto the PVOH-coated PET sheet - were performed at low 
humidity (∼20−30%). Particles were released from the PET/PVOH sheet by 
delivering ~1ml of sterile water via a bead harvester to dissolve the PVOH layer and 
remove particles from the PET sheet.  A typical yield of 80x320nm PLGA particles 
was ~0.4 mg particles/ft of PRINT mold, though this depended on the particle feature 
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size of the mold.  Tangential flow filtration (TFF; Spectrum Labs) was used to 
concentrate particles in sterile water (1-2mg/ml) and remove excess PVOH. For later 
use in particle characterization assays and experiments, mannitol and sucrose were 
used as cryoprotectants ((10× and 8× to mass of particles, respectively), particles 
were lyophilized, flash frozenand stored at -20 degrees. 
PRINT Hydrogel Fabrication 
The process of fabricating hydrogel particles was conceptually similar to 
PLGA fabrication, but with important differences as follows. For 80x320nm hydrogel 
particles, the pre-particle solution (PPS) contained a composition of 67.5 wt% HP4A, 
20 wt% AEM (functional monomer), 10 wt% PEG700DA (crosslinker), 1 wt% TPO 
(photo initiator) and 1.5 wt% Dylight 650 or Dylight 488 maleimide. This composition 
was then dissolved at 3.5 wt% in methanol and drawn as a thin film using a # 3 
Mayer rod (R.D. Specialties) onto a roll of corona treated PET using an in-house 
custom-made roll-to-roll lab line (Liquidia Technologies) running at 12 ft/min.  The 
solvent was evaporated from this delivery sheet by exposing the film to heat guns.  
The delivery sheet was laminated (80 PSI, 12 ft/min) to the patterned side of the 
mold, followed by delamination at the nip.  Particles were cured by passing the filled 
mold through a UV-LED (Phoseon, 395 nm, 3 SCFM N2, 12 ft/min).  A PVOH 
harvesting sheet was hot laminated to the filled mold (140 ºC, 80 PSI, 12 ft/min).  
Upon cooling to room temperature, particles were removed from the mold by splitting 
the PVOH harvesting sheet from the mold.  Particles were then harvested by 
dissolving the PVOH in a bead of water (1 mL of water per 5 ft of harvesting sheet).  
The particle suspension was passed through a 2 µm filter (Agilent) to remove any 
86  
large particulates.  To remove the excess PVOH, particles were centrifuged 
(Eppendorf Centrifuge 5417R) at 14000 rpm for 15 min, the supernatant was 
removed and the particles were re-suspended in sterile water.  This purification 
process was repeated 4 times prior to lyophilization as detailed above. The 
80x320nm particles were acetylated prior to experimental use to match negative 
charge of micron sized hydrogel particles. 
The 1.5 µm and 3 µm donut shaped hydrogel particles used in THP-1 studies 
were fabricated using a dropcast method.  The pre-particle solution (PPS) was 
composed of 20% PEG700-DA, 78% HP4A, 1% TPO (photoinitiator), and 1% 
rhodamine.  The solution was spread onto a fluorocur mold and a poly(ethylene 
terephthalate) (PET) sheet was laminated on top of the mold and polymer mixture 
and run through a heated, pressurized laminator to fill the molds.  The mold was 
then cured with a UV LED lamp for 30 seconds.  Particles were transferred out of the 
mold onto a Luvitec harvesting layer by laminating the mold and Luvitec sheet 
together and running them through a heated laminator nip.  The mold and harvesting 
sheet was separated, leaving free particles on the harvest layer.  Particles were 
collected from the harvest sheet by bead harvesting with water and pelleted by 
centrifugation.  The particles were re-suspended in tert-butanol and lyophilized 
overnight as detailed above. 
Particle Characterization 
Stock particle concentrations were determined using thermogravimetric 
analysis (TGA; TA Instruments Q5000 TGA).  Twenty µL of the stock nanoparticle 
solution was pipetted into a tared aluminum sample pan. The sample was heated at 
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30°C/min to 130°C and held at this temperature for 10 minutes. The sample was 
then cooled at 30°C/min down to 30°C and held for 2 minutes.  To account for the 
mass of any stabilizer remaining in each sample, TGA was performed on a 20 µL 
aliquot of supernatant from a centrifuged sample of the stock nanoparticle solution.  
By subtracting the concentration of the stabilizer from the concentration of the stock 
particle solution, the actual particle concentration was determined.  Particles were 
visualized with a Hitachi S-4700 scanning electron microscope (SEM).  Prior to 
imaging, SEM samples were coated with 1.5 nm of gold-palladium alloy using a 
Cressington 108 auto sputter coater.  A Zetasizer Nano ZS (Malvern Instruments, 
Ltd.) was used to measure particle size and zeta potential by dynamic light 
scattering (DLS). 
PEGylation of 80x320 nm hydrogel particles 
Purified 80x320 nm hydrogel particles were exchanged from water to DMF 
following the centrifugation.  The fabricated particles contained free primary amine 
groups which were used as chemical handles to react with a methoxy-PEG5K-SCM.  
The particles (1 mg/mL in DMF) were reacted with TEA (100 µL) for 10 min at room 
temperature on a shaker plate at 1400 rpm.  14 mg of methoxy-PEG5K-SCM was 
dissolved in DMF and added to the reaction mixture, shaken overnight and then 
quenched with borate buffer (100 μL). The nanoparticle solution was then 
centrifuged (14000 rpm; 15 minutes) and washed 5 times with DMF.   
To yield negatively charged nanoparticles following PEGylation, particles 
were acetylated with acetic anhydride to quench any unreacted amines.  
Nanoparticles (1 mg/mL in DMF) were reacted with an excess (10 µL) of pyridine 
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and acetic anhydride (7 µL) in a sonicator bath (Branson Ultrasonic Cleaner 1.4 A, 
160 W) for 15 min.  A second addition of acetic anhydride (7 µL) was added and the 
suspension was sonicated for another 15 min.  Following acetylation, particles were 
washed by centrifugation one time in DMF, one time in borate buffer to neutralize 
any acetic acid that had formed, and then washed four times with sterile water.  
Particles were analyzed by TGA, DLS and SEM after acetylation. 
In vitro Inflammation and Cell Death Assays 
The THP-1 human monocyte cells (ATCC) were cultured in RPMI 1640 
(Gibco) supplemented with 1% penicillin/streptomycin, 1% L-glutamine and 10% 
heat-inactivated fetal bovine serum. For experiments, THP-1 were plated at 200,000 
cells per well in a 96-well dish in 200µl of media. Some cells were primed with LPS  
or MPLA (100ng/ml; Invivogen) for 4 hours prior to particle treatment to provide 
signal 1 for inflammasome activation.  MSU (300μg/ml; Invivogen) or ATP (5mM) 
was used as a positive control for inflammasome activation. Particles were 
resuspended in PBS prior to dosing at various concentrations in triplicate.  After 
denoted incubation times, supernatants were harvested and analyzed by human IL-
1β ELISA (BD Biosciences) or a cytotoxicity detection kit (Roche) to determine cell 
death.   
NF-κB / AP-1 Activation Assay 
The THP1-XBlue reporter cells (Invivogen) were used to assay NF-κB and 
AP-1 activation by a panel of PRINT particles.  These cells stably express an NF-
κB/AP-1-inducible reporter secreted alkaline phosphatase system to facilitate the 
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colorimetric monitoring of NF-κB/AP-1 activation.  THP1-XBlue cells were plated at 
200,000 cells per well in a 96-well dish in 200µl of media and incubated with PRINT 
particles (10µg/ml) for 20 hours.  Supernatants were harvested and assayed for 
secreted alkaline phosphatase per manufacturer’s protocol.   
Particle Uptake in THP-1 
THP-1 cells that had been incubated with rhodamine-loaded 3.0 µm hydrogel 
donuts were fixed on slides in 2% paraformaldehyde (PFA) followed by 
permeabilization for 10 minutes in 0.1% Triton-PBS.  1:500 solution of Biotinylated 
Ricinius Communis Agglutinin (RCA, Vector Labs) was incubated with slides for 1 
hour at 37 degrees followed by 3 washes for 5 minutes each in PBS.  Avidin 
conjugated Alexa Fluor 594 (Invitrogen) was incubated 1:500 with slides for 45 
minutes at room temperature.  Slides were washed 3 times for 5 minutes each in 
PBS.  Slides were mounted in Vectashield with DAPI (Vector Labs).  Slides were 
viewed via immunofluorescence microscopy to assess particle uptake. 
Human PBMC Isolation and Culture 
Blood was donated by healthy donors in accordance with the University of 
North Carolina’s Office of Human Research Ethics (IRB #12-1858). Peripheral blood 
mononuclear cells were prepared from buffy coats by density gradient centrifugation 
using Lymphoprep (Cosmo Bio USA).  PBMC were cultured in AIMV medium 
(Gibco) supplemented with 1% penicillin/streptomycin, 1% L-glutamine and 10% 
heat-inactivated AB-human serum (Invitrogen).  PBMC were plated at 300,000 cells 
per well in a 96-well dish in 200µl of media and allowed to rest for 4 hours prior to 
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incubation with particles (10µg/ml) for 8 hours.  After experimental time point, plates 
were spun at 1500RPM for 5 minutes and supernatants were stored at -80 degrees 
until further cytokine human 30-plex analysis (Life Technologies) using the Luminex 
platform.  Cells were then stained and fixed for flow cytometry. 
Flow Cytometry of Human PBMC 
To differentiate immune cell subsets, cells were stained with fluorescent 
human antibodies as follows CD3-FITC, CD19-PacBlue, CD56-PerCP-Cy5, CD14-
PE, CD11b-APC-Cy7, and CD11c –PE-Cy7 (Becton Dickinson and eBiosciences).  
Live/Dead Fixable Dead Stain Kit was from Invitrogen. Flow cytometry was 
performed on a LSR II using FacsCalibur software (BD Biosciences).  Flow data was 
then analyzed via FlowJo (Tree Star, Inc.). 
Humanized Mice Experiments 
A detailed protocol for preparation of NRG-hu humanized mice has previously 
been published [294-297].  In brief, human CD34+ cells were isolated from 15- to 18-
week-old fetal liver tissues. The cell suspension released from the liver was filtered 
through a 70-µm cell strainer (BD Falcon) centrifuged at 150g for 5 minutes to 
remove hepatocytes. The mononuclear cells were purified through a Ficoll gradient 
(GE Healthcare Bio-science AB). Cells were labeled with the CD34 MicroBead Kit 
from Miltenyi Biotec, and then CD34+cells were positive selected with autoMACS by 
following the manufacturer’s instructions (Miltenyi Biotec).  After irradiating NRG 
mice at 200rad, a total of 0.5-1×106 CD34+ HSC cells were injected into the liver of 
each NRG mouse at 1-3 days of age.  Mice that received a transplant were bled 
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through tail vein at 3-4 months after transplantation to check human cell 
reconstitution by flow cytometry and gating on human CD45+ cells. All animal 
experiences were reviewed and approved by the University of North Carolina-
Chapel Hill Institutional Animal Care and Use Committee (IACUC). 
 Humanized mice were injected with 100µg of 80x320 nm hydrogel particles 
via tail vein injection in 100µl of sterile water.  Acetylated particles (HP4A Hydrogels) 
contained Dylight 650, while PEGylated versions of the same particle (PEG-
Hydrogel) contained Dylight 488. Twenty-four hours after particle injections, mice 
were euthanized for downstream analysis.  To assess particle distribution via flow 
cytometry, blood was drawn via retro-orbital bleed, spleens were homogenized and 
femurs were harvested using standard methods to access bone marrow.  Roughly 
1/3 of the spleen was processed via a tissue homogenizer and RNeasy Plus Minikit 
(Qiagen) for RNA analysis. 
Human cytokine expression in the spleen was assayed using RT-PCR and 
KiCqStart SYBR Green primers for Interleukin-1β, Interleukin-8, Interleukin-6, and 
TNF-α (Sigma Aldrich). Primer sequences (5’-3’) are as follows: IL-1β Forward - 
ACAGTGGCAATGAGGATGAC, IL-1β Reverse – CCATGGCCACAACAACTGA; IL-
6 Forward - GTGCCTCTTTGCTGCTTTCAC, IL-6 Reverse –
GGTACATCCTCGACGGCATCT; TNFα Forward – CTCTTCTGCCTGCTGCACTT, 
TNFα Reverse – GGCTACAGGCTTGTCACTC; IL-8 Forward – 
TCTCTTGGCAGCCTTCCTGA, IL-8 Reverse – TTCTGTGTTGGCGCAGTGTG. 
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Flow Cytometry of Humanized Mice 
 Cells were stained with the following human antibodies: CD11c-FITC, CD56-
FITC, CD14-PE, CD4-PE-Cy5, CD3-PE-Cy7, CD123-PE-Cy5, CD19-PB, CD11c-
APC, CD56-APC, CD45-APC-Cy7 (all from Biolegend); CD8-PE-TR and CD4-PE-
TR (Invitrogen).  Mouse CD45-Pacific Orange and Live/Dead Fixable Dead Stain Kit 
were from Invitrogen. All data were collected on CyAnTM (Beckman Coulter) and 
analyzedusing FLowJo (Treestar, Inc.) 
Statistical Analysis 
Statistical significance was analyzed using GraphPad Prism 5 software.  
Single data point comparisons were evaluated by Student’s two-tailed t-test, 
whereas multiple comparisons were evaluated for statistical significance using 
Analysis of Variance (ANOVA) followed by Tukey-Kramer HSD or Bonferroni post-
test.  All data are presented as mean +/- standard deviation (SD) or standard error of 
the mean (SEM) as noted, with a p-value less than 0.05 considered statistically 
significant. 
 
3.3 RESULTS 
Precise fabrication of monodisperse and homogenous particles with PRINT 
To address whether PRINT nano- and micro-particles are immunologically 
inert in human cells, we generated a panel of particles made of either PLGA or PEG, 
both biocompatible polymers which have a safe history in clinical use.   We used the 
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PRINT fabrication process to generate particles on the nano (80x320nm and 
200x200nm) and micron scale (1.5μm and 3.0 μm donuts).  In some cases, we 
incorporated fluorescent dyes to enable tracking of particles in downstream assays.  
Characterization via dynamic light scattering (DLS, measures size), zeta potential 
analysis (measures surface charge) and scanning electron microscopy (SEM) 
indicated monodisperse populations of particles that could be used to reproducibly 
probe the role of size and shape and composition on human immune responses to 
nano and microscale particles (Figure 3-1).  The polydispersity index (PDI), a 
measure of how similar in size particles within a batch are to one another, was below 
0.1 for all particles fabricated, reflecting the homogeneity of these preparations and 
the precision of PRINT fabrication.  Note that DLS analysis cannot be used on larger 
particles with nonspherous shapes, which explains why donut particles have no size 
values. Size was further verified for all particles via SEM.  All particles used in 
studies had a negative surface charge. 
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Figure 3-1. PRINT particle characterization. 
A-C) Size, polydispersity index (PDI) and surface charge data for PRINT particles 
used in these studies.  D-E) SEM images show homogenous particle populations in 
the appropriate size range (scale bars at lower right of each image). 
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PRINT particles do not induce inflammation in THP-1 cells 
We next carried out in vitro assays using the THP-1 human monocyte cell line 
as a surrogate for human innate immune cells of the monocyte and macrophage 
lineage.  Monocytes and macrophages, as part of the mononuclear phagocyte 
system (MPS), are the cell types primarily responsible for clearing NMP from 
circulation when delivered in vivo to mammals, including humans 
[235,245,293,298,299].  Previous studies have shown NMP made of PLGA and 
other materials can induce inflammatory responses [72,186].  As drug delivery, 
diagnostic and many immunoengineering applications would be precluded in 
humans if NMP trigger innate immune activation of inflammation, we deemed it 
important to address this issue using PRINT particles.   
Initial time course studies with the PRINT particles indicated an absence of 
inflammatory mediator release, as evidenced by the complete lack of IL-1β in culture 
media for all particles tested at the 10μg/ml dose (Figure 3-2A).  PRINT particles that 
ranged from 1-100μg/ml also failed to induce IL-1β secretion (Figure 3-2B).  As IL-1β 
secretion is largely dependent on activation of an inflammasome - typically requiring 
two signals to induce IL-1β secretion in THP-1 cells - we asked whether PRINT 
particles could synergize with a TLR4 ligand to cause IL-1β release [29,37,43,300].  
The TLR4 ligand LPS is used to provide signal 1 for inflammasome formation, which 
induces transcriptional upregulation of both IL-1β and NLRP3 [273].  For all particles 
tested, particles did not synergize with LPS to induce IL-1β secretion (Figure 3-2C).  
We also asked whether TRIF-mediated signaling events could synergize with PRINT 
particles to induce IL-1β secretion by using the TLR4 ligand monophosphoryl lipid A 
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(MPL), which preferentially engages the TRIF adapter as opposed to MyD88 [301].  
In concordance with the literature regarding soluble monophosphoryl lipid A (MPL) 
alone, there was no indication of inflammasome-mediated IL-1β release when 
particles were delivered in the presence of MPL (Figure 3-2C).  In these 
experiments, positive controls monosodium urate (MSU) and ATP+LPS induced IL-
1β secretion as expected.  These findings are different than published literature on 
the inflammatory potential of PLGA particles in mouse cells as well as literature 
showing inflammasome activation in THP-1 cells by silica nano- and microparticles 
[72,161].  This indicates that both particle fabrication and composition can augment 
inflammatory responses to NMP. 
PRINT particles do not activate pro-inflammatory transcription factors 
To gain a broader understanding of the potential for inflammation induction by 
particles, we made use of the THP1-XBlue reporter cell line (Invivogen) to enable 
colorimetric analysis of NF-κB and AP-1 transcriptional activation.  These cells 
encode the alkaline phosphatase gene downstream of NF-κB and AP-1 promoter 
sites, so activation of either of these transcription factors results in the secretion of 
alkaline phosphatase into the supernatant where it can be detected using 
colorimetric analysis.  For all particles tested, there was no indication of 
inflammatory transcriptional activation as measured by secreted alkaline 
phosphatase.  As a control, heat killed Listeria monocytogenes induced pro-
inflammatory transcription (Figure 3-2D).  This suggests PLGA and PEG particles do 
not activate the NF-κB or AP-1 transcriptional programs, a key finding given the 
desired use of these polymers in a broad array of nanomedicine efforts where NMP 
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carriers should preferably be immunologically inert. In line with these results, 
incubation with these particles for 24 hours did not induce cell death as measured by 
LDH assay (Figure 3-2E). The lack of a measurable immunologic effect is not due to 
a failure of uptake, as these particles were rapidly taken up by THP-1 cells (Figure 3-
2F). 
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Figure 3-2. PRINT particles are non-inflammatory in THP-1 human monocytes. 
A) PRINT particles (10μg/ml) comprised of PLGA or PEG do not cause IL-1β release 
at any time point tested when dosed on THP-1 cells.  B) PRINT particles dosed from 
1-100μg/ml to not cause IL-1β release at 6 hours post treatment with THP-1 cells.  
C) PRINT particles (10μg/ml) at the nano and micron scale do not synergize with 
either LPS or MPL to induce IL-1β release in THP-1 cells. D) PRINT particles 
(10μg/ml) do not activate NF-κB or AP-1 transcription in THP1-XBlue reporter cells 
as measured by alkaline phosphatase secretion.  E) PRINT particles (10μg/ml) do 
not induce cell death after 24 hours as measured by LDH assay.  F) Fluorescence 
microscopy images of THP-1 cells containing rhodamine-loaded 3.0μm PEG 
particles (red), with nuclei (DAPI-stained blue) and cell surface lectins (RCA-stained 
green) at two and four hours post treatment. All data are presented as mean values 
+/- SD. *** = p<0.001.  Experiments were performed in triplicate. Data shown are 
representative of at least three independent experiments. 
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Assessment of Nanoparticle uptake in Human PBMC 
With the ultimate goal of using nano and microscale particles in a broad range 
of clinical interventions, we first sought to identify which cells of the human immune 
system are targeted by particles, followed by global profiling of soluble immune 
mediators induced by particle delivery.  To our knowledge, this information is not 
readily available in the literature and thus we made use of the reproducibility of 
PRINT to address this gap in knowledge.  Peripheral blood mononuclear cells 
(PBMC) were prepared from two healthy females and two healthy males using 
standard procedures.  PBMC were treated with a panel of particles for 4 and 8 hours 
at 10µg/ml dose.  Supernatants were analyzed in a multiplex cytokine assay and 
cells were stained for flow analysis when fluorescent particles were used (hydrogel 
+/- PEGylation). 
We used particles of the same size, 80x320nm, but varied the composition 
between biocompatible polymers.  DC-Cholesterol is a cationic lipid commonly used 
in transfection reagents and was incorporated into PLGA particles to address 
whether surface charge affected ensuing immune responses (kindly provided by 
Liquidia Technologies).  For these studies, an improved hydrogel formulation 
published by our group using tetraethylene glycol monoacrylate (HP4A), a PEG 
derivative, as the base monomer afforded enhanced chemical conjugation 
opportunities.  We conjugated PEG chains (5K) to the surface of HP4A particles 
(termed PEGylation), which improves circulation times in vivo in mice [293].  
PEGylation has long been reported in mouse studies to augment uptake of 
nanoparticles, but little work has been done in primary human cells to address the 
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effects of this chemical modification.  Here, fluorescent dyes (Dylight 650) were 
incorporated into the HP4A series to identify which immune cells take up particles 
and whether PEGylation could modulate this to any extent. 
Forward scatter and side scatter were used to identify PBMC of the 
lymphocyte and myeloid lineage from all donors.  Lymphocytes (T, B and NK cells) 
did not undergo cell death in any donor nor could nanoparticles be detected in any of 
these cell populations (Figure 3-3A).  Conversely, roughly 14% myeloid cells were 
identified as dead and three discreet populations of myeloid cells based on CD14 
expression levels were detected (Figure 3-3B).  We termed these populations CD14-
High (Figure 3-3C), CD-14 Intermediate (Figure 3-3D), and CD-14 Low (Figure 3-
3E).  There was a clear correlation between particle uptake and CD14 expression 
levels.  This indicates 80x320nm hydrogel nanoparticles are selectively taken up by 
myeloid monocytic cells and not the lymphocytic subsets, a key finding that may 
enable more effective nanoparticle design strategies for a range of human diseases.  
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Figure 3-3. 80x320nm PRINT hydrogel particles target myeloid and not 
lymphocytic cells from freshly isolated human peripheral blood mononuclear 
cells. A) Hydrogel particles do not cause cell death or target human lymphocytes (T 
cells, B cells, and NK cells).  B) Hydrogel particle treatment induces a moderate cell 
death in myeloid cells (~14%).  Myeloid populations form three discreet populations 
based on CD14 expression.  C-E) Hydrogel particle uptake positively correlates with 
CD14 expression.  Flow plots from one donor are representative of all four donors. 
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By pooling data from all four donors, a number of interesting results regarding 
nanoparticle uptake were uncovered. First, CD14 expression distinctly correlates 
with particle uptake (Figure 3-4A).  Of the cells expressing the highest amount of 
CD14 (CD14 Hi), roughly 70% had taken up particles by the 8 hour time point, 
whereas those expressing the lowest amount of CD14 (CD14 Lo) took up particles 
to the same extent (~10%) as the phagocytosis control (cells kept at 4 degrees).  
Particle uptake is an active process, as keeping cells at 4 degrees greatly reduced 
the percentage of cells with particles.  In addition, the correlation between CD14 
expression levels and hydrogel particle uptake in human cells has not been reported 
to our knowledge and suggests a passive targeting of an innate immune cell 
population that is critical in mediating a variety of host functions.  There are reports 
noting CD14 receptor correlations with uptake of silver or iron-oxide nanoparticles in 
human PBMC, but those particles are potentially toxic and thus have limited 
therapeutic use [302-304].  As CD14 expression is a marker of monocytes, 
macrophages (M0) and dendritic cells (DC), CD11b (M0)  and CD11c (DC) staining 
were used to further verify these innate immune subsets take up particles (data not 
shown).  Passive targeting to these three CD14+ subsets may afford a wealth of 
therapeutic programming opportunities. 
Of note, while PEGylation of the particle surface does seem to impede the 
uptake of hydrogel particles at the 4 hour time point, an equivalent percentage of 
CD14 Hi cells take up particles regardless of PEGylation by 8 hours (compare HP4A 
to PEG group).  This is not the case for the intermediate CD14 expressing cells 
(CD14 Int) and may reflect phagocytosis differences intrinsic to these two cell 
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populations.  The CD14 Lo population did not take up an appreciable number of 
particles regardless of PEGylation status. 
While the percentage of cells taking up HP4A and PEG particles appears to 
be equivalent at 8 hours among CD14 Hi cells, PEGylation greatly impedes the 
quantity of particles taken up by a given cell as measured by mean fluorescence 
intensity (MFI) (Figure 3-4B).   Because the MFI of PEG treated groups at both 37 
degrees and 4 degrees are similar, this may suggest that PEGylated particles 
decorate the surface of CD14 cells as opposed to becoming internalized, though 
imaging studies are needed to validate this interpretation. These trends are 
consistent regardless of CD14 expression levels and indicate a simple chemical 
modification, PEGylation, may quantitatively restrict particle internalization but not 
particle interactions with the cell surface.  This may be an important design 
consideration when developing nanoparticles for either targeted or systemic drug 
delivery.  Effective dosing concentrations may be adjusted via surface modification 
with PEG chains to enable autocrine and paracrine delivery of immunomodulators or 
other therapeutics if these particles remain bound to the cell surface. 
There was a clear correlation with uptake of HP4A particles and cell death in 
the CD14 population (Figure 3-4C).  Those cells which took up the most HP4A 
particles (CD14 Hi) had higher levels of cell death than the CD14 Int and CD14 Lo 
populations.  This was phagocytosis dependent as cells kept at 4 degrees did not 
have appreciable levels of cell death.  PEGylation of HP4A particles entirely 
abrogated the cell death seen with HP4A particles alone.  This could be due to the 
larger quantity of HP4A particles taken up by a given cell as compared to the 
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PEGylated form (Figure 3-4B) or the possibility that PEGylated particles remain 
surface bound.  Further analysis of the mechanism by which HP4A particles induce 
cell death is necessary though preliminary data suggest particle surface charge may 
be a critical driver of cell death in response to particle uptake. 
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Figure 3-4. Human PBMC differentially process PRINT particles depending on 
CD14 expression and PEGylation. 
A) Particle uptake correlates with CD14 expression levels in human PBMC.  B) 
PEGylation of HP4A particles (PEG) decreases the absolute number of particles 
taken up by CD14+ human PBMC as measured by MFI.  C) PEGylation abrogates 
HP4A particle-induced cell death in CD14+ human PBMC as measured by Live/ 
Dead staining.  All data are presented as mean values +/- SEM from four blood 
donors. * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Global Cytokine Profiling in NP-treated Primary Human Immune Cells 
Having addressed which human PBMC take up particles, we next assessed 
the immune environment of PBMC after 8 hours of incubation with our particle panel 
(Table 3.1).  We used a 30-plex human cytokine array (Invivogen) in an attempt to 
capture the soluble immune profile from all donors.  Immune changes induced by 
particles - such as cytokine, chemokine and growth factors alterations - could be 
revealed through this method.  For all particles tested, there was no induction of a 
number of immune mediators at the 8 hour time point, including growth factors, 
interferons and cytokines associated with Th1, Th2, and Th17 immune responses 
(Figure 3-5A). The lack of induction of numerous cytokines from multiple classes of 
immune response may reflect a general inactivation of innate immunity by the 
particles tested herein.  Given that HP4A particles were able to induce considerable 
cell death in CD14 expressing cells (Figure 3-4C), we were surprised to see no 
differences in any of the 30 cytokines assayed between the untreated, HP4A  and 
PEGylated-HP4A treatment groups (Figure 3-5B).  This suggests that HP4A particle-
induced cell death may be immunologically inert and thus may lend itself to potential 
therapeutic interventions where transient depletion of circulating phagocytes is of 
use.   
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Figure 3-5. Hydrogel nanoparticles do not induce a broad spectrum of 
cytokines in human PBMC. 
A) Table listing soluble mediators not detectable by multiplex array analysis from 
human PBMC after 8 hours of treatment with 80x320nm PLGA particles (+/- DC-
Cholesterol) or 80x320nm hydrogel particles (+/- PEGYlation).  B) HP4A particle 
treatment and subsequent cell death (Figure 3-4C) does not induce cytokine release 
from human PBMC.  All data are presented as mean values +/- SD from all four 
blood donors. 
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Heterogeneity in Human Immune Responses to Nanoparticles 
Among the different particles tested, 80x320nm PLGA particles were the only 
one to induce any cytokines over untreated controls.  In this experiment, PLGA 
particles induced a subset of inflammatory mediators, namely TNF-α and the 
chemokines CCL3 and CCL4 (Figure 3-6).  Interestingly, complexation of PLGA with 
DC-cholesterol was sufficient to abrogate this modest inflammatory response 
through an as yet undetermined mechanism that may depend on surface charge.  
However, subsequent analysis of 80x320nm PLGA particles did not show induction 
of TNF-α, suggesting this may have been a single batch fabrication issue with 
unidentified contaminant(s).   Nonetheless, we think these data are noteworthy and 
include it here because there was considerable inter-donor variation in the 
magnitude of cytokines detected by the same particle treatment.  This was 
recapitulated in separate work we recently published where the immune status of 
primary human macrophages augmented uptake of nanoparticles [305].  Polarizing 
CD14+ monocytes from human donors towards the M2 phenotype significantly 
enhanced particle uptake, whereas polarizing towards the M1 phenotype reduced 
particle phagocytosis.  In line with our findings, another group recently found 
tremendous donor variability in the innate immune response of humans to carbon-
based nanoparticles [306].  We suggest that future ex vivo studies addressing 
nanoparticle use in humans should employ multiple blood donors so that individual 
immune variation can be revealed.  In total, these findings highlight the need for a 
systematic analysis of the human immune response to biocompatible particles as 
simple modifications may augment the immune response in profound ways. 
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Figure 3-6. Heterogeneity in the Human Immune Response to Nanoparticles. 
A-C) There are large differences in the magnitude of nanoparticle-induced 
production of pro-inflammatory cytokines and chemokines among healthy human 
blood donors.  Coating PLGA particles with DC-Cholesterol (DC-Chol) may dampen 
these inflammatory responses.  All data are presented as mean values +/- SD. 
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Cross-Validation of ex vivo PBMC findings in a Humanized Mouse Model 
Having characterized the resident immune cells which take up hydrogel 
particles in human PBMC and captured the global immune profile via cytokine array, 
we next sought to determine whether our findings were translatable to emerging 
models of human disease that employ humanized mice, such as infection with 
human immunodeficiency virus (HIV) or hepatitis C virus (HCV) [294-297].  As 
nanomedicine is increasingly sought out as a means for therapeutic improvement, 
we aimed to recapitulate aspects of human immune interactions with nanoparticles 
in humanized mouse models in order to help translate basic research to the clinic.   
To this end, humanized mice were generated using established protocols that 
repopulate immune-deficient mice with a human immune system derived from fetal 
liver cells [294-297].  After reconstitution, mice were injected with 100µg of dye-
loaded 80x320 HP4A particles or PEGylated-HP4A particles via the tail vein.  
Twenty four hours after injection, flow cytometric studies were performed on the 
spleen, blood and bone marrow of mice to identify resident human immune cells 
which took up particles.  Anti-human CD45 antibodies distinguished human and 
murine immune cells.  All major human immune cell subsets were identified in 
humanized mice.  These include CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ 
NK cells, CD14+ monocytes and macrophages, CD11c+ myeloid dendritic cells 
(mDC) and CD123+ plasmacytoid dendritic cells (pDC) (Figure 3-7).  
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Figure 3-7. Humanized mice reconstitute major types of human immune cells. 
Gating example used to characterize human immune cells in humanized mice. 
Human CD45 was used to gate on human immune cells only, followed by specific 
gating schemes for individual immune cell subsets.  These include CD3+CD4+ T 
cells, CD3+CD8+ T cells, CD19+ B cells, CD56+ NK cells, CD14+ monocytes and 
macrophages, CD11c+ myeloid dendritic cells (mDC) and CD123+ plasmacytoid 
dendritic cells (pDC).  Representative flow plot shown from one of 14 humanized 
mice used in studies. 
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In the spleens of humanized mice the cell types which took up the most 
particles, regardless of PEGylation status, were the CD14+ monocytes and 
macrophages as well as CD11c+ myeloid dendritic cells (Figure 3-8A).  This is 
similar to the human PBMC findings which showed uptake primarily in CD14+ cells.  
PEGylation of particles reduced uptake into CD14+ human immune cells of the 
spleen by about half, while modestly decreasing uptake in CD11c+, which also 
recapitulates the ex vivo human PBMC findings.  Like the human PBMC studies, 
CD14 expression levels in humanized mice correlated with particle uptake 
regardless of PEGylation status (Figure 3-8B).  Though more thorough analysis is 
needed, PEGylation may also enhance targeting of nanoparticles to pDC (Figure 3-
8A). As pDC are a primary interferon producing cell of the immune system, this 
could be a useful nanoparticle design strategy for therapeutic targeting of this cell 
population during viral infection in humanized mouse models [110,296,307-312].   
A low level of hydrogel particles were seen in lymphocyte subsets of the 
spleen, such as CD4+ T cells.  As lymphocytes did not take up particles in the ex 
vivo PBMC studies, this difference may be due the complexity of in vivo physiology 
and/or the longer time course of the in vivo studies.  Alternatively, the possibility of 
particle drainage to the spleen and lymphocyte sampling of particles directly or 
through passive transfer by myeloid cells is a potential explanation.  If true, then 
lymphocyte targeting with nanoparticles in vivo may also be feasible.   
Hydrogel particles failed to elicit inflammatory responses during the human 
PBMC as measured by cytokine production.  Because the number of human 
immune cells in humanized mice is relatively small, the levels of human cytokine 
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production are often too low to be detectable using ELISA.  Therefore, we assayed 
human mRNA levels of four pro-inflammatory cytokines form the spleens of 
humanized mice.  As seen in Figure 3-8C, the expression levels of human IL-8, 
TNF-α, IL-6 and IL-1β were indistinguishable between mock treatment groups and 
mice treated with hydrogel nanoparticles +/- PEGylation, which recapitulates the 
human PBMC data. 
We were somewhat surprised to see that PEGylation of hydrogels did not 
abrogate uptake into immune cells of the blood because this chemical modification 
has been published as reducing particle uptake.  In both blood and spleen, CD14+ 
and CD11c+ cells are the primary targets of particles yet no difference in uptake is 
seen between the two particle types in the blood population (Figure 3-8D).  This may 
reflect the fact that PEGylation enhances circulation times of these same 
nanoparticles in normal mouse strains [293].  Over the course of 24 hours, 
circulating immune cells have more time to encounter and process PEGylated 
particles and uptake differences seen between hydrogels and PEGylated hydrogels 
may be diminished.  The ex vivo PBMC data reflects this, where the only difference 
in particle uptake for CD14 Hi expressing cells occurred at 4 hours but not at 8 hours 
(Figure 3-4A).     
When assessing nanoparticle uptake in human immune cells resident in the 
bone marrow of humanized mice, we found a small but measurable amount of 
hydrogel particles in innate immune cells (CD14+ and CD11c+) as well as T cells 
(Figure 3-8E).  PEGylation abrogated this effect entirely, revealing nanoparticle 
design principles that enable selective targeting of the bone marrow niche.  To our 
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knowledge, this is the first report of nanoparticle targeting of human cells in the bone 
marrow compartment of humanized mice and may enable therapeutic modulation of 
hematopoietic niches.   
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Figure 3-8. Humanized mice recapitulate human PBMC nanoparticle studies. 
A) Particle uptake in the spleens of humanized mice 24 hours after tail vein injection 
is most pronounced in CD14+ human monocyte/macrophage population and 
CD11c+ dendritic cells (mDC).  PEGylation of particles reduces uptake into these 
populations while potentially enhancing targeting to pDC, an attractive cell 
population for antiviral therapeutics.  B) As seen with human PBMC, CD14 
expression levels in humanized mice correlates with particle uptake regardless of 
PEGylation status. C) Expression levels of human pro-inflammatory cytokines are 
unchanged over mock in the spleens of nanoparticle-treated humanized mice.  D)  
CD14+ and CD11c+ cells are the primary targets of particles in the blood.  
PEGylation does not alter uptake in these cells.  E)  Hydrogels show enhanced 
targeting to immune cell subsets in the bone marrow as compared to PEGylated 
hydrogels. Mock (n=2), Hydrogel (n=3), PEG-Hydrogel (n=3). All data are presented 
as mean values +/- SEM. .  * = p< 0.05, ** = p<0.01, *** = p<0.001. Data shown are 
representative of at least two independent experiments.  
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3.4 DISCUSSION  
 The goal of these studies is to identify baseline human immune responses to 
nano and microparticles (NMP).  This information is critical to eventual translational 
applications of nanomedicines in humans yet is grossly understudied.  As the 
immune system is supremely sensitive to the host environment but also a central 
integrator of host physiology, clinical application and efficacy of NMP will ultimately 
depend on our ability to understand and control immune responses to NMP. 
Using the PRINT system to fabricate particles comprised of biodegradable 
and biocompatible polymers across the nano and micron scale, we observed no 
activation of inflammatory pathways in a human monocyte cell line as evidenced by 
cytokine release and inflammatory transcriptional activation.  To provide physiologic 
relevance to these studies, primary human immune cells isolated from four healthy 
individuals were studied.  Using these cells, we found that 80x320nm particles were 
not targeted to lymphocyte subsets but instead preferentially targeted cells that 
express CD14.  Particle uptake correlated with the level of CD14 on the surface of 
cells and this was impeded by PEGylating particles.  PEGylation also inhibited the 
modest cell death seen after uptake of hydrogel particles.  Neither the mechanisms 
of hydrogel-induced cell death nor how PEGylation abrogates cell death and uptake 
into human immune cells are clear at this time. 
Next, we employed a 30-plex cytokine array to generate a global picture of 
the inflammatory state induced by nanoparticle treatment of human PBMC.  These 
results indicated that 80x320nm hydrogel particles +/-PEGylation are 
immunologically inert because none of the 30 assayed cytokines were different in 
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any donors as compared to untreated controls.  Therefore, the hydrogel cell death 
identified by flow cytometry may thus be considered ‘silent’ in the sense that no 
indication of immune activation was found. 
We were surprised to find an increase of the inflammatory mediators TNF-α, 
CCL3 and CCL4 by 80x320nm PLGA particles.  In all our extensive in vitro and in 
vivo experiments using mouse and human cells with PLGA particles (Chapter 2, 3, 4 
and data not shown), this was the only instance an inflammatory response to PLGA 
particles was observed.  One explanation is that the single particle batch used in the 
cytokine array may have been inadvertently contaminated during fabrication as other 
particle batches do not show activation of inflammation in human cells.  Regardless, 
we include the data here because of the insight it reveals about the heterogeneity of 
human immune response to nanoparticles.  Though all four donors received the 
same dose of PLGA particles, the magnitude of cytokine production among them 
varies considerably.  One donor consistently had the highest amount, one donor 
consistently had the lowest amount, and two donors had comparable amounts of 
detected cytokines.  Coupled with our findings in a recently published paper that 
macrophage polarization differentially affects nanoparticle uptake in primary human 
CD14+ cells (M2>M1) [305], we believe this might reflect heterogeneity in human 
immune responses to nanoparticles that may suggest a one-size-fits-all approach to 
NMP clinical interventions is too simplistic a model.  A recent paper showing 
tremendous human variability in innate immune responses to carbon-based 
nanoparticles validates our conclusions [306].  
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 As a means to further the translational relevance of these studies, we 
generated humanized mice to assess the human immune response to hydrogel 
nanoparticles in a more dynamic in vivo system.  Many of our ex vivo human PBMC 
findings were recapitulated in this mouse model,including preferential targeting of 
nanoparticles to CD14+ monocyte/macrophages and CD11c+ dendritic cells (DC), 
and CD14 expression levels correlating with particle uptake.  PEGylation was able to 
reduce particle uptake in vivo, though this effect was greater in the spleen than in 
the blood.  Splenic mRNA analysis of the human cytokines IL-8, TNF-α, IL-6 and IL-
1β may indicate hydrogel particles do not cause inflammation, which replicates 
results from the human PBMC global cytokine array data.  However, studies using 
more humanized mice are necessary to control for variation in reconstituted human 
immune systems between animals. 
Interestingly, we see evidence of particle-specific uptake into immune cell 
subsets, with PEGylated hydrogels preferentially targeting plasmacytoid DC (pDC) in 
the spleen and the blood while hydrogels access bone marrow niches including T 
cells.  As humanized mice are primarily used to model viral infection, targeting 
interferon-producing pDC with NP may be a means to enhance our basic 
understanding of these human cells types during an in vivo infection.  Because pDC 
are a primary interferon producing cell of the immune system and interferon is a key 
anti-viral and anti-cancer defense, this could be a useful nanoparticle design 
strategy for therapeutic targeting of this cell population during viral infection and 
cancer [110,140,296,307-312].   Accessing the bone marrow niche via nanoparticles 
may also have relevance for studying and treating hematopoietic abnormalities.  To 
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our knowledge, this is the first report of nanoparticle targeting of human pDC and 
bone-marrow resident immune cells in a humanized mouse model. 
Ideally, NMP will be fabricated from polymers that are immunologically inert at 
baseline.  This would enable diagnostic and drug delivery applications without 
concern for unwanted immune activation.  In addition, the ultimate goal of 
immunoengineering is the ability to design NMP that can program all types of 
immune responses.  Therefore, using a NMP platform that is perceived as a blank 
canvas by the immune system would enable the full spectrum on immunological 
‘colors’ to be painted in any combination.  We believe these studies indicate NMP 
composed of PLGA or hydrogel polymers may be perceived by the human immune 
system as relatively inert, thus bolstering their use as a blank canvas for therapeutic 
immune painting. 
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CHAPTER 4 
LESSONS IN IMMUNE PROGRAMMING WITH PRECISELY FABRICATED 
NANO- AND MICROSCALE PARTICLES 
 
Programming biological responses with nanomaterials has the potential to 
transform clinical care in the 21st century, in particular through control of immune 
responses in situ.  In order to help make this a reality, we reported in Chapters 2 and 
3 on the generation of precisely fabricated biocompatible and biodegradable 
particles using the PRINT process across the nano and micron scale (NMP) that are 
immunologically inert in two mammalian species,  mouse and human.  Here, we 
probe the programming landscape for engineering immune responses in mammals 
by rational design of PRINT NMP.  We identify NMP design features that enable 
control of uptake into immune cells, activation and silencing of inflammatory 
responses, and the induction of immune tolerance.  These findings may have 
bearing on the clinical treatment of many pressing diseases, including types 1 and 2 
diabetes, allergies and asthma, organ transplantation and autoimmune disorders. 
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4.1 INTRODUCTION 
As detailed extensively in Chapter 1, the immune system is exquisitely 
sensitive to the environment.  Thus, if one is trying to program immune responses 
through rational design of NMP, it is absolutely imperative that the starting material 
be as immunologically inert as possible so as not to inadvertently trigger unwanted 
signaling pathways.  In effect, we desire a blank canvas on which to paint (i.e., 
program). 
As presented in Chapters 2 and 3, our own careful analysis of the murine and 
human immune response to PRINT nano and microparticles (NMP) composed of 
PLGA and hydrogels established these particles are inert from an immunological 
perspective.  This is precisely the desired finding, as the ultimate goal of these 
particles is to design them into programming devices that can modulate immune 
functions in mammals.   
In this Chapter, we present a compilation of findings over the course of our 
studies that reflect not only the complexity of innate immune responses to NMP, but 
also highlight potential immunoengineering directions using rationally designed 
particles we have generated.  Studies discussed herein address: 1) the role of 
surface modification on augmenting nanoparticle uptake into human cells; 2) particle 
design parameters to control the kinetics and magnitude of inflammasome 
activation; 3) anti-inflammatory NMP designs; and 4) NMP designs which may 
enable programming of immune tolerance through two separate pathways.  These 
findings have direct relevance to the development of microbial and cancer vaccines, 
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reducing inflammatory damage in a range of disease settings, and offering new 
treatments for autoimmune disorders.   
4.2 MATERIALS AND METHODS 
Particle Materials 
Poly(D,L-lactide-co-glycolide) (PLGA) (lactide:glycolide 85:15, 0.65 dL/g 
Inherent Viscosity at 30 °C)  was purchased from Sigma-Aldrich. Chloroform and 
solvents (acetonitrile and water) for high performance liquid chromatography (HPLC) 
were purchased from Fisher Scientific.  Poly(ethylene terephthalate) (PET) sheets 
(6” width) were purchased from KRS plastics. Fluorocur®, d = 80 nm; h = 320 nm; all 
prefabricated molds and 2000 g/mol polyvinyl alcohol (PVOH) coated PET sheets 
were kindly provided by Liquidia Technologies. 
PRINT PLGA Particle Fabrication 
Fabricating PLGA particles using the PRINT process has been previously 
described in detail elsewhere [260,261] so a brief description is included here.  A 
preparticle solution (PPS) containing PLGA was prepared in a DMSO/DMF/water 
solvent mixture (4:16:1) and cast on a poly-(ethylene teraphthalate) (PET) sheet 
(delivery sheet) using a #5 Mayer Rod (R.D. Specialties). The delivery sheet was 
placed in contact with a PRINT mold with desired features patterned (e.g., 80 × 320 
nm, 200x200nm, 1.5µm donut). The delivery sheet and mold were then passed 
through a heated laminator (150 °C, 5.5 × 105 Pa) and separated at the nip. Heating 
enables the PLGA polymer solution to fill the molds through capillary forces, thereby 
forming nanoparticles of desired size and shape. Nanoparticles were then harvested 
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from the PRINT mold by placing it in contact with a PET sheet coated with a 400nm 
layer of poly(vinyl alcohol) (PVOH, MW = 2000 g/mol). This ensemble of mold/PET-
PVOH was then passed through the laminator (150 °C, 5.5 × 105 Pa) to transfer the 
nanoparticles to the PVOH sheet. Both laminator steps - the filling of the mold and 
transfer of particles onto the PVOH-coated PET sheet - were performed at low 
humidity (∼20−30%). Particles were released from the PET/PVOH sheet by 
delivering ~1ml of sterile water via a bead harvester to dissolve the PVOH layer and 
remove particles from the PET sheet.  A typical yield of 80x320nm PLGA particles 
was ~0.4 mg particles/ft of PRINT mold, though this depended on the particle feature 
size of the mold.  Tangential flow filtration (TFF; Spectrum Labs) was used to 
concentrate particles in sterile water (1-2mg/ml) and remove excess PVOH. For later 
use in particle characterization assays and experiments, mannitol and sucrose were 
used as cryoprotectants ((10× and 8× to mass of particles, respectively), particles 
were lyophilized, flash frozen and stored at -20 degrees. 
Quantum Dot, Docosahexaenoic acid and Phosphatidylserine Particle Fabrication 
Particles were fabricated using the same techniques as described in detail in 
Chapters 2 and 3.  Details unique to the studies reported in this chapter are included 
here.  Q-Dot (655 ITK Organic, Invitrogen) were incorporated into the pre-particle 
PLGA solution at 3% by weight.  Docosahexaenoic Acid (DHA; 90310, Cayman 
Chemicals) and phosphatidylserine (PS; 840032, Avanti Polar Lipids) and PLGA 
were dissolved separately in chloroform. The solutions of DHA or PS and PLGA 
were mixed at ratios of 30:70 (DHA:PLGA) or 10:90 (PS:PLGA), and the sample was 
diluted to 2 wt% (mass/mass) solution with chloroform. A thin film of DHA or PS and 
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PLGA was deposited on a 6”x12” sheet of PET by spreading 200 μL of solution 
using a #5 Mayer Rod (R.D. Specialties). The solvent was evaporated with heat. The 
PET sheet with the film was then placed in contact with the patterned side of a mold 
and passed through heated nips (ChemInstruments Hot Roll Laminator) at 130 °C 
and 80 psi. The mold was split from the PET sheet as they both passed through the 
hot laminator. The patterned side of the mold was then placed in contact with a 
sheet of PET sheet coated with 2000 g/mol PVOH. This was then passed through 
the hot laminator to transfer the particles from the mold to the PET sheet. The mold 
was then peeled from the PET sheet. The particles were removed by passing the 
PVOH coated PET sheet through motorized rollers and applying water to dissolve 
the PVOH to release the particles. To remove excess PVOH, the particles were 
purified and then concentrated by tangential flow filtration (Spectrum Labs).  
Particles were lyophilized, flash frozen and stored at -20 prior to use in experiments. 
HPLC Analysis of Ligand Incorporation into Particles 
Ligand encapsulation (DHA, and PS) was quantified via HPLC in a similar 
fashion.  DHA or PS incorporation into PLGA particles was measured using an 
Agilent Technologies Series 1200 HPLC with a C18 reverse phase column (Zorbax 
Eclipse XDB-C18, 4.6×100 mm, 3.5 micron). A linear gradient from 85:15 of 
methanol with 0.1% trifluoroacetic acid (TFA): water with 0.1% TFA to 100% 
methanol with 0.1% TFA was run over 25 minutes.  The flow rate was 1 mL/min and 
an ELSD detector was used for quantification. Particle samples were prepared by 
diluting the sample with a 50:50 acetonitrile:water solution and mixing the sample to 
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break down the particle and dissolve the PVOH. Standards of PS and DHA were 
prepared in 50:50 acetonitrile:water. 
PRINT Hydrogel Fabrication 
The process of fabricating hydrogel particles was conceptually similar to 
PLGA fabrication, but with important differences as follows. For 80x320nm hydrogel 
particles, the pre-particle solution (PPS) contained a composition of 67.5 wt% HP4A, 
20 wt% AEM (functional monomer), 10 wt% PEG700DA (crosslinker), 1 wt% TPO 
(photo initiator) and 1.5 wt% Dylight 650 or Dylight 488 maleimide. This composition 
was then dissolved at 3.5 wt% in methanol and drawn as a thin film using a # 3 
Mayer rod (R.D. Specialties) onto a roll of corona treated PET using an in-house 
custom-made roll-to-roll lab line (Liquidia Technologies) running at 12 ft/min.  The 
solvent was evaporated from this delivery sheet by exposing the film to heat guns.  
The delivery sheet was laminated (80 PSI, 12 ft/min) to the patterned side of the 
mold, followed by delamination at the nip.  Particles were cured by passing the filled 
mold through a UV-LED (Phoseon, 395 nm, 3 SCFM N2, 12 ft/min).  A PVOH 
harvesting sheet was hot laminated to the filled mold (140 ºC, 80 PSI, 12 ft/min).  
Upon cooling to room temperature, particles were removed from the mold by splitting 
the PVOH harvesting sheet from the mold.  Particles were then harvested by 
dissolving the PVOH in a bead of water (1 mL of water per 5 ft of harvesting sheet).  
The particle suspension was passed through a 2 µm filter (Agilent) to remove any 
large particulates.  To remove the excess PVOH, particles were centrifuged 
(Eppendorf Centrifuge 5417R) at 14000 rpm for 15 min, the supernatant was 
removed and the particles were re-suspended in sterile water.  This purification 
129  
process was repeated 4 times prior to lyophilization as detailed above. The 
80x320nm particles were acetylated prior to experimental use to match negative 
charge of micron sized hydrogel particles. 
OVA-Conjugated Hydrogel Fabrication 
Fabrication of the base hydrogel particle is the same as reported above. 
Conjugation of ovalbumin is as follows.  Ovalbumin (OVA) is attached to the surface 
of hydrogel particles using a bifuncational PEG linker, which contains a maleimide 
group that reacts with thiols present in cysteines in the protein. HP4A AEM-
containing particles are first reacted with maleimide-PEG5k-succinimidyl carboxy 
methyl ester (MAL-PEG5k-SCM, Creative PEGWorks).  Amine groups in the 
nanoparticle are activated with triethylamine in DMF for 10 minutes prior to the 
addition of MAL-PEG5k-SCM. For a high surface PEG density maintaining a brush 
conformation, 14mgs of MAL-PEG5k-SCM is added per 1 mg of NP as previously 
reported [293].  This reaction is left overnight (~12 hr) on a shaker at room 
temperature. Particles are then centrifuged at 14000 rpm for 15 minutes three times 
to remove excess reagents. This results in the reaction of surface amine groups 
PEG5k with a functional terminal maleimide handle. Unreacted amine groups are 
then quenched through the addition of acetic anhydride in the presence of pyridine 
for 30 minutes. Centrifuge wash steps are carried out in DMF and 1x borate buffer 
pH 9.5, with particles ultimately resuspended in 2x Borate Buffer: 1x PBS + 0.1% 
PVOH.  OVA is added to the particles at a ratio 1:1 by mass and left on a shaker 
overnight at room temperature.  Conjugated particles are then washed three times in 
water to remove excess OVA. HP4A-PEG5k-OVA particles are confirmed by DLS, 
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TGA and SEM, with OVA loadings determined through a colorimetric BCA Protein 
Assay (Thermo Scientific Pierce Protein Assay Kit). The difference in absorbance 
between a known amount of conjugated HP4A-PEG5k-OVA particles from 
unconjugated PEG5k-OVA control particles is attributed to bound OVA, quantified 
through the use of an OVA standard curve. 
Particle Characterization 
Thermogravimetric analysis (TGA) was used to determine stock particle 
concentrations (TA Instruments Q5000 TGA).  Briefly, 20 µL of the stock 
nanoparticle solution was pipetted into a tared aluminum sample pan. The sample 
was heated at 30°C/min to 130°C and held at this temperature for 10 minutes. The 
sample was then cooled at 30°C/min down to 30°C and held for 2 minutes.  A 
Hitachi S-4700 scanning electron microscope (SEM) was used to visualize particles.  
Prior to imaging, the SEM samples were coated with 1.5 nm of gold-palladium alloy 
using a Cressington 108 auto sputter coater.  Particle size and zeta potential were 
measured by dynamic light scattering (DLS) on a Zetasizer Nano ZS (Malvern 
Instruments, Ltd.).   
Particle uptake in THP-1 cells 
THP-1 cells were seeded at 500K/ml media and particles were dosed in 
triplicate at 100µg/ml over the time course (1, 4, 24 hours).  Analysis of PLGA-QDot 
and hydrogel particle uptake in THP-1 cells was performed on an LSR II (BD 
Biosciences) using scatter gating and analyzed via Flow Jo (Treestar, Inc.) 
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THP-1 inflammasome activation assays 
THP-1 human monocyte cells (ATCC) were cultured in RPMI 1640 (Gibco) 
supplemented with 1% penicillin/streptomycin, 1% L-glutamine and 10% heat-
inactivated fetal bovine serum. For experiments, THP-1 were plated at 200,000 cells 
per well in a 96-well dish in 200µl of media. Some cells were primed with 0.5µM 
PMA for 3 hours prior to particle treatment to provide signal 1 for inflammasome 
activation.  MSU (300μg/ml; Invivogen) or ATP (5mM) was used as a positive control 
for inflammasome activation. Particles were resuspended in PBS prior to dosing at 
various concentrations in triplicate.  For adjuvant coated particle studies, particles 
were harvested in water with LPS or MPL at 1mg/ml concentration and filtered by 
TFF (50nm pore, Spectrum labs) at least 3x prior to use in experiments   After 
denoted incubation times, supernatants were harvested and analyzed by human IL-
1β ELISA (BD Biosciences).   
Murine inflammasome activation assays 
Bone marrow macrophages were isolated from the femurs of C57Bl/6 and 
BALB/c mice using standard procedures. Bone marrow-derived macrophages were 
cultured for six days in DMEM supplemented with 10% fetal bovine serum, L-
Glutamine, pen/strep and 20% L929-conditioned medium prior to use in particle 
experiments.  Adherent cells were isolated and plated in complete Dulbecco’s 
Modifed Eagle Medium (Gibco) with 10% fetal calf serum, 1% penicillin/streptomycin 
and 1% L-glutamine at 200,000 cells per well in a 96-well dish for 24 hours prior to 
treatment with particles.  Some cells were primed with LPS (50ng/ml) for 24 prior to 
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particle treatment to provide signal 1 for inflammasome activation.  MSU (300μg/ml; 
Invivogen) or ATP (5mM) was used as a positive control for inflammasome 
activation. Particles were resuspended in PBS prior to dosing at various 
concentrations.  After 24 hours of particle treatment in triplicate, supernatants were 
harvested and analyzed by murine IL-1β ELISA (BD Biosciences).  50µM doses 
were used for cells pre-treated with particle-delivered ligand or soluble ligand (DHA 
and PS).  Blank particle controls were dosed at the same concentration of particle 
required to deliver a 50µM dose of ligand. Coated particles were generated by 
resuspending lyophilized PLGA particles in a water solution containing 50µM of the 
coated ligand DHA, PS, or DOTAP/DOPE (Avanti Polar Lipids). 
Mouse Model of Asthma 
The OVA-alum murine model of asthma has been used extensively by 
multiple laboratories and details have been previously reported by us [105].  Briefly, 
C57/Bl6 mice were immunized with interperitoneal (i.p.) injections of a 200µl 
emulsion of OVA and alum (20µg OVA per dose) on day 1 and day 7. Starting on 
Day 13, mice were challenged with intratracheal instillations of 1µg/50µl dose OVA 
in either soluble form or conjugated to hydrogel particles.  PBS and PEGylated 
hydrogels were used as controls.  After 5 days of challenge, mice were euthanized 
and harvested for analysis.  Serum was collected from animals by cardiac puncture 
and centrifuged at 15,000 RPM for 10 minutes.  The serum supernatant was 
collected and used for ELISA analysis of antibody production.  OVA-specific 
antibody ELISAs were sourced from Biolegend, BD and Invitrogen. 
133  
Bronchoalveolar lavage fluid (BALF) was also collected to evaluate local 
leukocyte levels in the lungs.  For this purpose, lungs were lavaged three times with 
1ml Hanks Balanced Salt Solution (HBSS; Gibco).  After centrifugation at 1500 RPM 
for 5 minutes, RBC were lysed via brief hypotonic saline treatment and the cell pellet 
was resuspended in PBS.  Total BALF cellularity was assessed with a 
hemacytometer.  The cellular composition was determined by cytospin of BALF 
aliquots onto slides and staining with Diff-Quik (Dade Behring) for differential cell 
counts. Leukocytes were identified based on the morphology of ≥200 cells per 
sample. Following BALF harvest, the lungs were fixed by inflation (20-cm pressure) 
and immersed in 10% buffered formalin. 
Histopathological examination 
Inflammation was evaluated in 5µm sections of the left lung lobe after 
hematoxylin and eosin (H&E) staining.  Serial paraffin-embedded sections were set 
and cut to reveal maximum longitudinal visualization of the intrapulmonary main 
axial airway and inflammation was scored blinded to genotype and treatment.  As 
previously described, histology images were evaluated on each of the following 
inflammatory parameters and scored between 0 (absent) to 3 (severe): mononuclear 
cell infiltration, polymorphonuclear cell infiltration, airway epithelial cell 
hyperplasia/injury, extravasation, perivascular cuffing, and estimated percentage of 
the lung involved with inflammation [48,265]. Scores for each parameter were 
averaged for a total histology score. 
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DC-2D2 Co-culture assays 
Bone-marrow dendritic cells (DC) were isolated from murine femurs and 
differentiated for 6 days in 20ug/mL GM-CSF. Anti-CD11c beads (Miltenyi Biotec) 
were used to isolate DC, which were plated in 96 well plates at 40,000 cells per well.  
T cells were isolated from 2D2 mouse spleens using anti-CD4 beads (Miltenyi 
Biotec) and were plated at 200,000 cells per well in co-culture with DC.  2-4 hours 
prior to adding T cells, DC were incubated with soluble phosphatidylserine (PS) or 
PRINT particles fabricated with or without PS.  DC-T cell cultures were then 
incubated for 2 days at 37 degrees prior to supernatant harvesting for cytokine 
analysis by ELISA or cell fixing and staining for flow cytometry analysis using 
antibodies to IFN-γ, IL-10 and FOXP3+ (eBiosciences). 
Experimental animals 
All studies were conducted in accordance with National Institutes of Health 
guidelines for the care and use of laboratory animals and approved by the 
Institutional Animal Care and Use Committee (IACUC) of the University of North 
Carolina at Chapel Hill. All animals were maintained in pathogen-free facilities at the 
University of North Carolina at Chapel Hill.  
Statistical Analysis 
GraphPad Prism 5 software was used to identify statistical significance.  
Single data point comparisons were evaluated by Student’s two-tailed t-test, 
whereas multiple comparisons were evaluated for statistical significance using 
Analysis of Variance (ANOVA) followed by Tukey-Kramer HSD post-test.  Data are 
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presented as mean +/- standard deviation (SD) or standard error of the mean (SEM), 
with a p-value less than 0.05 considered statistically significant. 
 
4.3 RESULTS 
Inside or Out? – Design Considerations for Particle Uptake 
 There are a multitude of therapeutic applications for NMP that require control 
over the location of NMP deposition depending on the desired outcome.  For 
example, drug delivery may yield better results if NMP remain in extracellular spaces 
to target more tissues and cells.  Conversely, targeting NMP to specific cells is 
desirable in vaccine settings or when targeting specific tumors.  Thus, underlying 
principles which can modulate uptake into cells is an important area of basic 
research in the nanomedicine field [74,163,251,256,313-315].  By making use of 
fluorescent 80x320nm PRINT particles comprised of either PLGA or hydrogels, we 
addressed how composition affects cell uptake of NP in the THP-1 human monocyte 
cell line in a quantitative manner using flow cytometry.  We chose THP-1 as a 
surrogate for phagocytic cells responsible for clearance of NMP in vivo. It has been 
difficult in the past to ensure fluorescent dyes remain within PLGA NMP.  To remedy 
this, quantum dots (QD) - ~5-15nm diameter metallic alloys which auto-fluoresce at 
the 650nm wavelength – were incorporated into the pre-particle solution in order to 
fabricate PLGA NP that could be tracked as recently reported (Figure 4-1A) [316].  
Hydrogel particles were fabricated with Dylight 488 to enable fluorescent monitoring.  
To further the impact of our studies, we looked at the role of a lipid coating on 
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modulating PLGA particle uptake, as well as the role of PEGylation and conjugation 
with a model antigen (ovalbumin, OVA) on the uptake of hydrogel particles. 
For 80x320nm PLGA particles, there was very little to no uptake into THP-1 
cells.  Even after 24 hours, only 12% of cells were positive for particle uptake (Figure 
4-1B).  As these particles have a slightly negative surface charge (-5 mV), we 
proposed coating these NP with a cationic lipid after fabrication would alter particle 
uptake.  As coating PLGA particles with the common transfection reagent 
DOTAP/DOPE is known to make the nanoparticle surface positively charged and 
enhance siRNA delivery, DOTAP/DOPE was selected for these studies [260].  
Within 1 hour after particle dosing, nearly 100% of THP-1 cells had taken up 
particles and this held constant through 24 hours of treatment (Figure 4-1C). 
It is not clear whether this robust enhancement is strictly due to a change 
from negative to positive surface charge or whether the lipid coating itself aids in 
masking other physical or chemical PLGA surface properties that impede THP-1 
uptake.  Studies are underway to tease this apart.  However, preliminary in vivo 
studies suggest uncoated 80x320nm PLGA-QDot particles may not be readily taken 
up by immune BALF resident cells in the lungs of mice as they cannot be found in 
these cells by flow analysis after intratracheal instillation, whereas hydrogel particles 
are (Figure 2-5 and data not shown).  From a translational perspective, design 
features which can impede NP uptake into phagocytic cells may enhance in vivo 
circulation times of the NP as well as promote extracellular delivery of cargo.  A lipid 
coating would thus be used for applications where uptake into phagocytes is more 
desirable, such as immunoengineering approaches targeting macrophage function. 
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Figure 4-1. Design control of PLGA particle uptake in THP-1 cells. 
A) Particle characterization details.  B) Uncoated 80x320nm PLGA particles are not 
taken up by THP-1 cells to any significant extent across a 24 hour time course.  C) 
Coating 80x320nm PLGA particles with the cationic lipid DOTAP/DOPE results in 
rapid and complete uptake by all THP-1 cells.  Data are representative of two 
independent experiments. 
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We next carried out similar uptake assays using the 80x320nm hydrogel 
system.  THP-1 cells were incubated with three types of 80x320nm hydrogels: 
acetylated, PEGylated and acetylated, and PEGylated and conjugated to the model 
antigen OVA to mimic a vaccine application (see Figure 4-7 for characterization).  
Acetylation confers a negative surface charge to the hydrogels and ensured all three 
particle types had similar charges.  As seen in Figure 4-2A, acetylated hydrogels 
were taken up by nearly all THP-1 cells as soon as 1 hour after treatment.  By 
modifying the surface of these particles with either OVA or PEG chains, uptake was 
entirely blocked through 4 hours of treatment.  Even after 24 hours, OVA-particles 
were present in only half the cells, while PEGylated particles were found in only 25% 
of cells (Figure 4-2B and C). 
The PEGylation finding is perhaps not surprising given the published literature 
regarding surface decoration with PEG impeding uptake of NMP [293].  However, 
the 24 hour result in THP-1 cells is somewhat at odds with our own findings in 
human PBMC where PEGylation does not seem to confer great masking of uptake 
by cells per se, but does impede the quantity of particles per cell (Figure 3-4).  This 
may also reflect differences between primary human cells and those derived from 
immortalized cell lines, a further testament to the importance of validating in vitro 
findings in primary cells.  In addition, simply conjugating OVA to the surface of 
hydrogels impeded uptake.  Because of the intricacies of antigen processing through 
either MHC I or MHC II pathways discussed in the introduction chapter, more 
detailed experiments are underway to address how conjugation strategies can 
modify the processing of antigen from hydrogel particles. 
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Figure 4-2. Design control of hydrogel particle uptake in THP-1 cells. 
A) Within 1 hour, nearly all THP-1 cells are positive for 80x320nm hydrogel particles.  
B) Conjugating the model antigen OVA to the surface of these particles impedes 
their uptake entirely at early time points and to roughly half that seen with blank 
hydrogels at 24 hours. C) PEGylating the surface of hydrogels greatly reduces 
uptake into THP-1 cells at all time points tested. Data are representative of two 
independent experiments. 
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Design control over the kinetics and magnitude of immune signaling 
 As discussed at length in the introduction, triggering immune signaling 
pathways via NMP is a potent means for programming biological responses.  There 
is a large field of literature which indicates the magnitude and duration of biological 
signaling events are interpreted by dynamic cellular networks to fundamentally alter 
the cell response to environmental stimuli [317].  Thus, as NMP technology 
advances and our knowledge of immune principles increases, it likely will be 
desirable to impart control over the kinetics and magnitude of signaling events 
programmed by NMP devices.  It is already clear that particle parameters such as 
size, shape and density of surface-displayed ligands can affect the biological output 
induced by NMP [168,178,206,217-219,246].  Because of the importance of 
controlled inflammatory responses to host physiology [34], we sought to address 
whether the kinetics and magnitude of inflammasome activation by NMP could be 
controlled through varying the size, shape and composition of PRINT particles.  
Such findings may have relevance to vaccine design and Th17 immune skewing 
applications [47,48,54,68,69,84,94].   
As our previous studies indicated PRINT particles alone or in the presence of 
the soluble TLR4 ligands LPS and MPL did not activate the inflammasome to 
release IL-1β (Figures 2-2 and 3-2), these TLR4 ligands were coated onto PRINT 
particles to adjuvant them.  Initial studies focused on the TLR4 ligand 
lipopolysaccharide (LPS), a bacterial cell wall component known to synergize with 
other signals to activate the NLRP3 inflammasome [29,49,50,159].  The same 
PRINT particles fabricated in Chapter 3 studies - a series of PRINT particles across 
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the nano and micron range composed of either PLGA or PEG - were coated with 
LPS during the harvesting phase.  Using the established THP-1 inflammasome 
activation model, we were able to screen a number of parameters as regards their 
impact on inflammatory activation. 
As show in in Figure 4-3A, particles alone did not cause release of IL-1β 
across a range of doses.  Unlike what was seen when particles were delivered with 
soluble LPS (Figure 3-2C), simply coating these particles with LPS was sufficient to 
generate an inflammatory response (Figure 4-3A).  In addition, the magnitude and 
kinetics of the response depended not only on the size of the particle (1.5 µm more 
efficient than 3.0µm), but also the composition.  PLGA particles induced a 
comparable level of IL-1β at 1/10 the dose of PEG particles.  In all cases, LPS-
coated particles were more inflammatory than MSU crystals. 
When carrying out kinetic studies, it was clear that the inflammatory response 
was hastened when LPS-coated particles were composed of PLGA as opposed to 
PEG (Figure 4-3B), with 80x320nm particles leading to more rapid inflammatory 
induction than those in the micron range.  This could be due to the fact that at the 
same dose weight (10µg/ml) there will be far more 80x320nm particles than micron 
size particles.  Thus, more cells may be exposed to particles or take them up 
compared to larger particles.  Regardless, these findings point to the possibility that 
altering the size, shape or composition of adjuvanted-NMP can enable control over 
the kinetics and magnitude of inflammatory immune responses. 
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To verify these particles were causing IL-1β release through inflammasome 
activation, we made use of previously reported THP-1 cell lines that stably 
knockdown the inflammasome components, NLRP3 and ASC [106,318,319].  As 
shown in Figure 4-3C, IL-1β release induced by 80x320nm PLGA particles coated 
with either LPS or MPL is mediated by the NLRP3 inflammasome, as knockdown of 
either NLRP3 or ASC completely abrogates IL-1β production.  Similar results were 
seen for 200x200nm PLGA, 1.5µm PLGA, 1.5µm PEG and 3.0µm PEG particles 
coated with LPS (data not shown).   
It is interesting to note that coating particles with MPL also induces a modest 
inflammasome-dependent IL-1β release.  This is somewhat surprising as MPL has a 
more favorable clinical profile than LPS and is not thought to activate the 
inflammasome.  The reduced toxicity of MPL is thought to occur because it signals 
primarily through the TRIF adaptor of TLR4 as opposed to LPS, which uses the 
MyD88-adaptor [301,320].  It has been reported that TRIF activation is less potent at 
priming inflammasome events than MyD88, but these studies were done using 
soluble forms of these ligands [301].  To our knowledge, the effect of particulate 
MPL on inflammatory responses has not been studied, thus these studies are 
clinically relevant.  Along these lines, the data revealed a size- and shape-
dependent sensitivity to the inflammatory response induced by particulate MPL 
(Figure 4-3D).  At the same dose of MPL-coated particles, 200x200nm PLGA 
cylinders induce a significantly greater amount of IL-1β as compared to 80x320nm 
particles.  This effect is not seen when these same particles are coated with LPS.   
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One could hypothesize that the receptor clustering events that occur upon 
TLR4 activation are differentially sensitive to shape and size depending on whether 
TRIF or MyD88 is enlisted as the adaptor.  In order to carry out well-controlled 
experiments to address this issue, absolute quantification of the amount of biological 
ligands complexed with particles is necessary.  This is a difficult task that many 
groups fail to carry out in their published reports as it requires technically challenging 
analytical chemistry assays.  However, given our own findings, we strongly believe 
that these types of exhaustive particle characterizations are absolutely required in 
order to move the field forward.  As soon as these techniques became available to 
us, we made use of analytical chemistry assays during the remainder of our 
dissertation studies.  
While the mechanism of particle shape differences in MPL-induced 
inflammatory responses is not clear, this finding exemplifies the molecular details of 
immune signaling that can be uncovered by NMP studies, in particular when using 
the PRINT platform’s inherent control over particle size and shape.  Design control 
of inflammasome activation may have therapeutic relevance, such as enhancing the 
efficacy of microbial vaccines against fungal and respiratory infections through 
generation of Th17 adaptive immunity [46,48,54,94].  In addition, these studies 
reflect the concept that emergent biological properties can manifest when a soluble 
ligand is particularized.  This is a common theme we see in the studies detailed 
below. 
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Figure 4-3. Design control over the kinetics and magnitude of inflammasome 
activation. 
A) Dose studies using a panel of PRINT particles reveals coating NMP with LPS 
induces IL-1β release in a manner that depends on both particle size and 
composition.  B) Kinetic studies using a panel of PRINT particles reveals coating 
NMP with LPS induces IL-1β release in a manner that depends on both particle size 
and composition. C) IL-1β release induced by LPS- and MPL-coated 80x320nm 
PLGA particles depends on the inflammasome components NLRP3 and ASC.  D) 
MPL-dependent signaling events show sensitivity to particle size and shape at the 
nanoscale not seen for LPS signaling.  Data are representative of at least three 
independent experiments. 
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Turning off Inflammation using Endogenous Pathways in a Targeted Manner 
Having addressed design features which can activate inflammatory pathways, 
we next sought to develop a series of particles that could be used to dampen or 
inhibit inflammatory signaling cascades.  Inflammation is a major cause of disease 
pathology in a multitude of clinical settings, from driving cancer to exacerbating the 
detrimental effects of heart attacks and strokes, and acting as a prime instigator in 
type 2 diabetes [17,34,127,137,241,321-323].  Therefore, therapeutics which inhibit 
inflammatory signaling pathways have tremendous clinical merit.  By coupling anti-
inflammatories with NMP, we may also gain translational advantages through the 
modular freedoms inherent to this delivery platform. 
The body has numerous endogenous signaling networks to resolve 
inflammation, as tight control over this physiologic response is critical to ensure the 
long term health of the host [34].  These include down regulation of PRRs and the 
production of anti-inflammatory mediators such as resolvins, protectins and lipoxins 
[324-327].   The latter classes of molecules are metabolic by-products of poly 
unsaturated fatty acids, such as the omega-3 fatty acids eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA).  Long known for their beneficial effects on 
human health, omega-3 fatty acids are derived entirely from the diet, with seafood 
providing the lion share for most people.  Recently, the report of GPR120 as the cell 
surface receptor for omega-3 fatty acids has helped unmask the molecular 
mechanisms explaining the anti-inflammatory effects of these molecules [328].  We 
thus sought to address whether incorporating DHA into PLGA NMP would generate 
an anti-inflammatory programming device. 
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As part of these studies, we also generated a separate panel of PLGA NMP 
containing one of two lipids.  One set were coated with DOTAP/DOPE, as this 
enhanced uptake into cells (Figure 4-1) and could control for the role of lipids on any 
ensuing cell response.  The second lipid we fabricated PLGA particles with was 
phosphatidylserine (PS).  PS is an endogenous lipid known to have unique immune 
signaling properties [329,330].  It is located on the inner surface of the plasma 
membrane and is exposed on the surface of cells which are undergoing apoptosis.  
This informs phagocytes that they are engulfing ‘self’, so they are tempered from 
activating inflammatory responses or presenting antigen from the apoptotic cell in a 
manner that would cause an autoimmune response.  This occurs in part through PS 
triggering release of TGF-β and IL-10, potent immunoregulatory cytokines involved 
in tempering immune activation and inducing tolerance [26,329-332].  We reasoned 
that PS NMP could dampen inflammation and/or potentially skew the immune 
environment towards immunoregulatory conditions, which would be of great use in 
autoimmune disorders.  In support of our reasoning, recent papers reveal PS NMP 
preparations can dampen pro-inflammatory cytokine release and promote production 
of the anti-inflammatory cytokines IL-10 and TGF- β [333-335].   
An inflammasome activation model in bone-marrow derived mouse 
macrophages (BMDM) was used to address the anti-inflammatory potential of this 
panel of particles.  Given our previous studies with TLR agonists (Figure 4-3), high 
performance liquid chromatography (HPLC) analysis of all particle types was used to 
determine the explicit amount of encapsulated ligand to carry out well-controlled 
experiments (details in Figure 4-4).  Cells were pre-treated overnight with soluble 
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DHA, soluble PS or PLGA NMP containing ligands encapsulated or coated on the 
surface (all doses were 50µM of ligand).  After treating cells with the inflammasome-
activating signals LPS+ATP, IL-1β release was assessed.   
As seen in Figure 4-5, nearly all particle types were able to significantly 
dampen IL-1β release as compared to the untreated, blank particle or soluble ligand 
controls.  Coating or encapsulating particles with DHA resulted in significant 
inhibition of IL-1β, with the 80x320nm DHA particles having comparable effects as 
the 1µm particles.  Similarly, all PS particles significantly inhibited IL-1β release 
regardless of particle size.  In addition, neither soluble form of DHA or PS inhibited 
inflammation.  It is also worth noting that coating a 1µm particle with DOTAP/DOPE 
was able to significantly inhibit IL-1β release whereas DOTAP/DOPE-coated 
80x320nm particles did not, though the mechanism of how this occurs is unclear.  
These findings support a previous comment regarding the emergent properties that 
occur when biological ligands are delivered in particulate fashion and reflect how 
control over size and shape afforded by the PRINT system unmasks emergent 
biological details that may otherwise be missed.  A final point is the attractive clinical 
feature of using anti-inflammatory programming devices that are both biodegradable 
and composed of natural compounds (PS or DHA).  Studies are underway to tease 
out molecular mechanisms and test the in vivo efficacy of these devices in mice. 
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Figure 4-4. Characterization Details for Anti-Inflammatory PRINT particles. 
 A) Blank 80x320nm PLGA particles.  B) 80x320nm PLGA and phosphatidylserine 
(PS) particles.  C) 80x320nm PLGA and docosahexaenoic acid (DHA) particles. 
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Figure 4-5.Biodegradable PRINT Particles Complexed with Natural Ligands are 
Anti-inflammatory Programming Devices. 
A) Inflammasome activation in bone marrow derived mouse macrophages is 
significantly inhibited by PLGA nano- and microparticles containing the natural 
ligands phosphatidylserine (PS) and docosahexanoiec acid (DHA) (50µM doses). 
Inhibition by DOTAP/DOPE coating is only effective at the 1µm particle size.  
Experiments were performed in triplicate.  Data are representative of three 
independent experiments. 
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Inducing Immune Tolerance through Particle Design 
 An immunoengineering area that has the potential to entirely change the 
clinical outcomes for those with allergies, autoimmune disorders or organ 
transplantations is the ability to induce tolerance to antigens which trigger undesired 
or overactive immune responses.  This is based on the principle that immune 
responses have inherent plasticity, meaning responses to an antigen can be shifted 
among the various classes of adaptive immunity depending on the context in which 
the antigen is presented [111]. This principle has already shown efficacy in treating 
food allergies to either peanuts or eggs.  By delivering escalating doses of allergen 
over multiple months, tolerance to peanut and egg allergen is induced in children 
[336-338].   
In a similar fashion, rationally designed NMP that deliver antigens and/or 
immunoregulatory signals have the potential to switch pathological immune 
responses off and replace them with tolerance [197].  This has recently been 
demonstrated in a mouse model of multiple sclerosis, where simply coupling the 
triggering antigen, PLP, to a PLGA particle induced anergy of effector T cells and 
promoted a tolerizing immune response that reduced clinical severity [250].  Soluble 
delivery of PLP exacerbated disease, which suggests the particulate delivery of 
antigen on an inert particle is able to access and induce immunoregulatory 
pathways. 
 To test this principle, we made use of an established mouse model of asthma 
we have previously published [105].  Mice are immunized against the model antigen 
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OVA through co-delivery into the intraperitoneal (i.p.) space with the vaccine 
adjuvant alum and then challenged intratracheally (i.t.) with soluble OVA for 5 days 
to induce an allergic response in the lungs.  Because we were interested in how the 
immune response to an allergen is affected by particulate delivery of that antigen, 
we challenged the lungs of immunized mice with equivalent doses of either soluble 
OVA (n=5) or OVA conjugated to the surface of 80x320nm hydrogel particles (PEG-
OVA, n=3), as well as PBS controls (n=3).  As OVA was conjugated to PEG chains 
on the surface of PEGylated 80x320nm particles, PEGylated 80x320nm particles 
alone (PEG) were used as controls for particle delivery. Particle characterization and 
an asthma model schematic are show in Figure 4-6.   OVA-conjugation to hydrogel 
particles was quantified using BCA Protein assay to ensure equivalent dosing with 
soluble OVA. 
 To assess the immune response of challenged mice, we carried out a number 
of assays including assessment of cell recruitment to bronchoalveolar lavage fluid 
(BALF), OVA-specific antibody ELISAs and histopathology analysis of mouse lungs 
to visualize the extent of allergic responses.  As compared to PBS treated mice, 
there was a small increase in the number of cells recruited to the lungs regardless of 
how OVA was delivered, as to be expected when encountering an allergen (Figure 
4-7A).  For total IgG as well as OVA-specific IgG1 and OVA-specific IgG2a, there 
were no differences among any treatment groups (data not shown).   
We next assessed the level of IgE production in the serum of mice, as IgE is 
an antibody class associated with allergic responses [339].  For total IgE, there was 
no statistically significant difference between OVA-sensitized groups, though there 
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was a trend for soluble OVA to increase the total amount of IgE (Figure 4-7B).  The 
high level of total IgE seen even in PBS treated mice reflects the role of the alum-
OVA immunization in boosting production of this antibody class, as the unsensitized 
mice treated only with PEGylated particles (PEG- No OVA IP) show no IgE in the 
serum.  When assaying for OVA-specific IgE production, a statistically significant 
increase was seen only in the groups treated with soluble OVA (Figure 4-7C).  The 
relatively lower OVA-specific IgE seen in PEG-OVA treated groups may reflect the 
fact that particulate OVA would not necessarily encounter the same number of cells 
or tissue regions as soluble OVA.  The sequestration of the antigen may thus restrict 
the amount of immune activation otherwise seen in soluble delivery. 
 Perhaps most telling from these studies is histopathology analysis of the 
lungs of asthma-induced mice (Figure 4-7D).  A robust allergic response induced by 
soluble OVA can be seen, with numerous infiltrating immune cells and general 
widespread damage to the air spaces as seen at both 1.25x and 10x magnification.  
Surprisingly, mice treated with PEG-OVA do not show lung pathology and in fact 
have histopathology scores no different than mice treated with either PBS or PEG 
particles alone (Figure 4-7E).  This finding suggests particulate delivery of an 
allergen (here, OVA) significantly reduces an inflammatory allergic response to that 
allergen.  Clearly, more work needs to be done to further characterize the immune 
response to OVA in these mice, such as cytokines present as well as T cell 
responses to OVA.   
It is known that many allergens are particulate in nature, pollen being a prime 
example, so that cannot explain the lack of an inflammatory response to PEG-OVA 
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entirely.  However, the answer may be due to the uptake pathway which PEG-OVA 
accesses in comparison to soluble OVA, a pathway that may promote less robust 
allergic responses through as yet undefined mechanisms.  As an example, 
preliminary work in our lab indicates that OVA conjugated to hydrogels is presented 
by DC to T cells, though the kinetics and dosing are different than soluble OVA (data 
not shown).  Given literature in the NMP field where modulating the duration or 
uptake pathway of an antigen can augment ensuing adaptive responses, we believe 
that this may help explain our findings in this asthma model [219].  It may also be 
useful to address the binding affinity of OVA-specific antibodies when OVA is 
conjugated to a particle, as this may also affect immune responses to an antigen 
through reduced Fc receptor activation on mast cells and eosinophils for example.  
Future studies employing NMP-delivery of known allergens, such as food products 
and environmental substances that trigger asthma, may enable low-cost 
immunomodulatory therapeutics to help treat the increasing number of people with 
allergies and asthma [12,340,341].  This approach also has clear relevance for 
autoimmune disorders, as published recently [250]. 
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Figure 4-6. OVA Asthma Study Details. 
A) Characterization of OVA-conjugated and PEGylated 80x320nm hydrogel 
particles. B) Asthma model schematic where mice are immunized by i.p. injection 
with prime and boost doses of 20µg of OVA in an alum emulsion.  For the challenge 
phase, mice were given 1µg doses of OVA in either soluble form or OVA-conjugated 
particles via intratracheal instillation. 
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Figure 4-7. Particulate delivery of OVA reduces allergic responses to an 
allergen. 
A) Cell recruitment in the bronchoalveolar lavage fluid (BALF) of mice reveals a 
modest increase when OVA is delivered in either soluble or particulate form. B) No 
significant differences were seen in total IgE production among immunized mice, 
though soluble OVA trends higher than other groups.  C) OVA-specific IgE levels are 
significantly higher than PBS-treated mice when OVA is delivered in soluble form, a 
finding not seen with PEG-OVA delivery (* = p < 0.05). D) Histopathology analysis 
reveals soluble OVA induces widespread lung damage through immune cell 
recruitment and inflammation.  Similar to PBS and PEG treated mice, PEG-OVA 
treatment does not cause histopathology.  E) Histopathology scores indicate only 
soluble OVA significantly increases lung pathology, whereas particulate delivery 
does not. PBS, n=3; Soluble OVA, n=5; PEG-OVA, n=3; PEG, n=3; PEG (No OVA-
IP), n=1. Data represent a single experiment. 
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Inducing Immune Tolerance through Particle Design – Part 2 
 It is known that there are many different types of immune tolerance and that 
the pathways eliciting each are unique and appropriate to certain circumstances 
[24,115,342].  For example, aggressive T cells may be directly turned off or 
dampened through anergic mechanisms, or a population of regulatory T cells can be 
induced to feedback on other immune cells and ‘change the message’ towards 
tolerance.  Many of these pathways depend explicitly on the context by which 
dendritic cells encounter and present antigen [24].  As discussed in Chapter 1, other 
pathways to tolerance also exist, so identifying means of programming various 
qualities of tolerance with NMP may be a boon to human health.   
As mentioned previously, one group recently demonstrated an approach 
where coupling the PLP antigen to PLGA particles induced a tolerizing immune 
response and protected mice against experimental autoimmune encephalomyelitis 
(EAE), a mouse model of multiple sclerosis.  The mechanism did not depend on 
production of regulatory T cells (FOXP3+) or IL-10 production, but instead occurred 
through anergizing effector T cell responses [250].  As shown in Figure 4-7, we have 
preliminary in vivo data suggesting a diminution of an allergic immune response to 
an antigen by conjugating OVA to a NP which supports the published finding that 
coupling antigen to inert NP may promote tolerance.  However, we sought to design 
NMP that may program alternative tolerance pathways, in particular the production 
of regulatory T cells. 
158  
To achieve these goals, we hypothesized that phosphatidylserine (PS) could 
program tolerizing signals when delivered via nano- and microparticles.  PS is a 
natural lipid exposed on the surface of apoptotic cells of the host that signals 
phagocytes not to mount an immune response against the contents of the engulfed 
apoptotic cell in order to reduce autoimmune pathology that would otherwise ensue 
[26,329-331,343].  PS is also known to trigger TGF-β and IL-10 release, critical 
immunoregulatory cytokines that drive production of FOXP3+ regulatory T cells 
[329,332,335,342].  In order to assess the potential for PS-NMP to program 
regulatory immune responses, a panel of PLGA-encapsulating PS particles was 
produced as described earlier (Figure 4-4).  
We used a co-culture system with bone marrow-derived murine dendritic cells 
(BMDC), the myelin oligodendrocyte glycoprotein (MOG) and 2D2 T cells, which are 
transgenically engineered to encode T cell receptors (TCR) specific for the MOG 
peptide (amino acids 35-55) [344,345].  2D2 T cells are specific for MOG antigen 
and are skewed towards Th1 responses (low IL-10, low FOXP3 expression, and 
high IFN-γ).  Therefore, this experimental system addressed whether PS-NMP could 
modulate the functions of 2D2 T cells in the presence and absence of MOG antigen 
presentation.  As show in in Figure 4-8A, delivery of PS (50µM) via 80x320nm PLGA 
particles (PS PAR) is able to significantly (p < 0.05) increase the production of 
FOXP3+ regulatory T cells (~20% of total T cells) in the presence or absence of 
MOG.  Neither blank 80x320nm PLGA particles (BLK PAR) nor soluble PS (PS SOL, 
50µM) could induce such high levels of FOXP3+ T cells.  In addition, IFN-γ 
production by T cells, a hallmark of Th1 effector immune responses, was 
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significantly (p < 0.05) impeded by both soluble and NP-delivery of PS during 
antigen stimulation with MOG.  This latter finding is interesting because it shows a 
bifurcation in programming requirements for PS signaling events: PS in either 
soluble or particulate form can inhibit IFN-γ production, whereas FOXP3+ induction 
requires that PS is presented on a particle. 
This bifurcation of PS signaling also holds true for production of the anti-
inflammatory cytokine IL-10 by FOXP3+ T cells (Figure 4-8B).  Only NP-delivered 
PS significantly (p < 0.05) increased the percentage of IL-10 and FOXP3 double 
positive T cells (>20% of T cells).  Blank particles and soluble PS were equally 
ineffective at generating this population of regulatory T cells.  These preliminary 
findings show induction of robust amounts of regulatory T cells that inhibit pro-
inflammatory cytokines while increasing anti-inflammatory cytokines in a 
nanoparticle-dependent fashion.  Current studies to delineate the role of particle size 
and ligand density on these effects indicate 1µm PLGA-PS particles also induce 
regulatory T cell populations, though 80x320nm particles are more potent.  In vivo 
studies in an EAE mouse model with PS particles will determine whether these 
regulatory responses are antigen-specific and sustainable in vivo. 
Through NP-mediated programming, we show evidence of skewing Th1 
adaptive immune responses towards regulatory T responses, a finding that has clear 
translational implications for autoimmune disorders, allergies and the field of organ 
transplantation.   A recent paper identified phosphatidylserine and other natural fatty 
acid-derivatives as therapeutic targets in humans with multiple sclerosis, giving 
further credence to the translational relevance of data presented herein [291].   
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Figure 4-8. Programming Regulatory T cells with Phosphatidylserine 
Nanoparticles. 
A) Flow plots of 2D2 T cells after co-stimulation with bone-marrow derived dendritic 
cells +/- the MOG peptide.  Incubation with 50µM of soluble phosphatidylserine (PS 
SOL) or 50µM of phosphatidylserine encapsulated in 80x320nm PLGA particles (PS 
PAR) is able to inhibit IFN-γ production by T cells in the presence of MOG, whereas 
blank 80x320nm PLGA particles (BLK PAR) have no effect.  PS PAR induce a 
significant increase in FOXP3+ T cells, not seen in the BLK PAR or PS SOL groups. 
B) Only particulate delivery of PS (PS PAR) is capable of inducing significant 
percentages of IL-10 and FOXP3 double positive T cells. * = p<0.05.  Data are 
representative of at least three independent experiments. 
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4.4 DISCUSSION 
 In the studies detailed in this chapter, we have explored potential particle 
parameters that may enable broad programming of immune responses through 
modular and rational design of NMP.  While this is by no means an exhaustive list of 
the potential signaling events that can be designed into NMP, we believe it reflects 
the merit in pursuing basic science studies addressing the potential of biological 
programming through NMP.  As evidenced by our findings, there is a tremendous 
space for discovery through basic probing using size and shape specific delivery of 
biological ligands.  Given the potential to control the kinetics and magnitude of 
biological responses through size, shape and composition of NMP, there are 
multiple levels of program control afforded by this approach (Figure 4-3).  It should 
also be noted how well suited the PRINT platform is for these studies. 
These studies not only enable more thoughtful interpretation of experimental 
data, but also open up the possibility of uncovering unique signaling events that 
have translational merit.  For example, our findings uncovered a bifurcation between 
the signaling events downstream of phosphatidylserine signaling (Figure 4-8).  
Inhibition of IFN-γ production is insensitive to how PS is delivered, whereas 
generation of IL-10 and FOXP3 regulatory T cells requires particulate delivery of PS.  
Whether this is because particulate PS enables receptor clustering on immune cells 
to drive this regulatory switch is currently unclear, but as discussed throughout this 
dissertation, emergent properties occur when biological ligands are presented in 
particulate fashion [1].   
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It is an added benefit that the majority of these studies were performed using 
PLGA as the base composition of our particles, as this polymer is biodegradable, 
biocompatible and F.D.A approved for use in humans.  In addition, we have 
purposefully designed NMP with biological ligands that are endogenously produced 
in the body to generate entirely biodegradable and natural programming devices that 
modulate mammalian biology in clinically relevant fashion. 
A last note regards the potential for modular perturbation of signaling 
networks through NMP design.  There is much literature showing the potential of 
NMP as vaccines through incorporation of TLR agonists 
[73,74,123,124,201,203,204,211,214,246,247].  Yet, TLRs are but one class of 
pattern recognition receptor (PRR) and there are multiple other network families 
beyond PRRs that have yet to be explored.  As cells integrate cues from all aspects 
of their environment in every moment, we deem it judicious to consider combinatorial 
approaches to network perturbation.  
Coupled with our studies using natural lipids and fatty acids, one could 
envisage a combinatorial programming device at the nano and microscale that 
triggers multiple biological networks simultaneously to generate unique and, ideally, 
clinically useful outcomes.  Given the modularity of NMP, this combinatorial signaling 
need not necessarily occur on a single device.  One could envisage targeting NMP 
to certain tissues or cell types that program responses which promote or enhance 
the efficacy of the ultimate payload delivered by a separate NMP.  The feasibility of 
this general concept has already been proven using nanoparticles which 
communicate in vivo to amplify tumor targeting of drugs [346]. 
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CHAPTER 5 
GENERAL CONCLUSIONS 
 
Given that cellular function is both sensitive and malleable in response to 
environmental input, we sought to demonstrate the utility of a platform capable of 
programming cellular function for therapeutic benefit as a paradigm shift in how we 
treat disease.  This requires the use of biocompatible devices that can be modularly 
designed at the physical scale which cellular networks communicate: the nano (10-9) 
and micron (10-6) scale.  These devices are termed nano- and microparticles (NMP). 
As discussed at length throughout this dissertation, the immune system 
constitutes a vast communication network that integrates cues from within and 
without the body in a coordinated fashion with all organ and tissue systems to 
ensure the maintenance of health for the entire organism.  Given its direct and 
commanding role in host survival, it is not surprising that immune network signaling 
is implicated in all major disease categories.  This spans microbial infections, 
neurodegenerative and autoimmune disorders, cancer, organ transplantation 
rejection, metabolic abnormalities such as type 2 diabetes, and other non-
communicable diseases (NCD).  In addition, it is the immune system that naturally 
recognizes and responds to NMP devices.  Therefore, we have direct access to one 
of the most important and powerful communication networks in the body and the 
166  
potential to program the immune system in a targeted manner to evoke cellular 
functions that may have benefit in all major disease categories. 
A new and promising scientific field, termed immunoengineering, merges the 
disciplines of materials science, chemistry, immunology, and bioengineering to 
pursue the ultimate goal of harnessing the full potential of the human immune 
system to treat disease [214,246,247].  Early results from this nascent field suggest 
rationally designed NMP programming devices can make this goal a reality in the 
foreseeable future.  Some major highlights include: generation of highly potent 
microbial and cancer vaccines [73,123,124,195,203,204,207,211,227,253,289]; 
inhibition of inflammatory immune cell recruitment in vivo with associated 
improvement in multiple mouse models of disease [245]; inhibition of cancer-
mediated immune suppression and activation of T cell mediated tumor killing [231-
233,236,284]; induction of potent mucosal immunity [224,225,347]; skewing of 
adaptive immune classes [196,197];  and tolerance induction in mouse models of 
autoimmunity [248-250]. 
While these results are very promising, they all used different methods of 
particle fabrication and design with no overall consideration of a platform approach 
to immunoengineering.  In particular, programming the full spectrum of immune 
responses will be greatly abetted by a NMP platform that offers precise control over 
particle fabrication, as even slight differences in size, shape or chemistry can have 
profound biological implications (reviewed in Chapter 1 and [148-150,246,247]).  
Recent breakthroughs in materials science have resulted in development of a 
precise fabrication technique, termed Particle Replication in Non-wetting Templates 
167  
(PRINT), which offers complete control over the size, shape, composition and 
chemistries of nano- and microscale particles (NMP) 
[188,189,191,192,194,257,348].  Using PRINT technology, this dissertation sought 
to systematically and reproducibly address the feasibility and potential of 
programming mammalian biology through rational design of NMP. 
As our ultimate goal is the ability to program all types of immune response in 
vivo, it is critical that we use NMP that are immunologically inert at baseline.  To use 
a metaphor, we want to use NMP that are a blank canvas to the immune system so 
that we can paint with all colors.  Thus, the initial work we performed was systematic 
analysis of the mammalian immune response to PRINT-fabricated NMP.  For all 
studies, we fabricated NMP with biodegradable and biocompatible polymers with a 
safe history of use in humans to lend the most translational relevance to our studies 
(PLGA, PEG or PEG derivatives).   
PRINT Particles are Immunologically Inert in Mice 
In chapter 2, we presented evidence that PRINT NMP do not cause 
inflammatory responses in vitro or in vivo in mice.  As the mouse is the most 
common mammal used in biomedical research, we initiated our studies in this 
species so that we could help clarify confusion in the field as to the inflammatory 
potential of PLGA NMP [72,73].  In addition, future murine studies employing PRINT 
NMP for therapeutic purposes now have a baseline of data to guide design 
strategies.   We were able to show sustained deposition (7 days) of NMP in the 
lungs of mice without immune cell recruitment, inflammation or evidence of 
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pathology.  This suggests that PRINT NMP are immunologically inert in mice, and 
can reside in the lung for extended periods of time, a desirable attribute for drug 
delivery efforts.  In addition, modulating particle size corresponded with differential 
uptake into lung cells.  This particle design parameter may enable differential 
targeting to the intracellular and extracellular space, a feature that could be exploited 
if one wanted to deliver cytokines locally to the lung while also delivering an antigen 
into innate immune cells so that the ensuing immune response could be skewed in a 
targeted manner.  Unexpectedly, particle deposition in the lungs may have direct 
relevance to treatments for autoimmune disorders such as multiple sclerosis and 
type 1 diabetes or other CNS and intestinal abnormalities.  This is because the lung 
serves as a network hub where circulating T cells are licensed to enter the CNS or 
the intestines depending on the cues in the lung environment [349,350]. 
PRINT Particles are Immunologically Inert in Humans 
In chapter 3, we performed a systematic analysis of the human immune 
response to PRINT NMP.  We did this to address the gap in literature regarding 
human immune responses to nanomaterials, as most studies are performed in mice.  
Of mice and men, there are large immunological differences [351,352].  In the 
human monocyte cell line, THP-1, we found no signs of inflammatory responses to 
PRINT NMP, nor an ability to synergize with soluble TLR ligands to activate the 
inflammasome, as assessed by cytokine production.  More broadly, we also found 
PRINT NMP do not activate the pro-inflammatory transcription networks NF-κB or 
AP-1.  This is a critical finding as it suggests a large part of the canvas we so desire 
to paint is blank.   
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For direct analysis of human immune responses to a series of 80x320nm 
PRINT NP, we acquired blood from four healthy donors and identified immune cell 
subsets which are targeted by particles.   Using dye-loaded hydrogels, we found no 
uptake into lymphocyte subsets (T, B and NK) and targeting to CD14+ innate 
immune cells.  Particle uptake correlated with the level of CD14+ expression and 
could be abrogated by PEGylation to the particle surface.  In addition, the cells 
which took up the most particles stained positive for a marker of cell death, a 
response that was entirely diminished by PEGylation.   
When we performed a global cytokine screen to capture a portrait of the 
human immune response to PRINT 80x320nm hydrogels, we found no differences 
between treated and untreated donor samples for any of the 30 cytokines tested.  
This reflects the broad immunological inertness of these particles and suggests the 
cell death we identified via flow cytometry for hydrogels is itself non-
immunostimulatory.  While the mechanism needs more analysis, broad depletion of 
innate immune populations for transient periods of time may be of clinical merit in 
certain settings.  For example, many NMP applications are limited by their rapid 
clearance from the circulatory system by innate immune cells [235,287,353].  By first 
treating patients with particles that deplete this same population transiently, 
subsequent delivery of a therapeutic or diagnostic NMP may show prolonged 
circulation times and enhanced efficacy, as published in mouse studies [354]. 
In conjunction with our with our published data on the role of human 
macrophage polarization on particle uptake [305], our uncovering of heterogeneity in 
the human innate immune response to nanoparticles points to the complexity of 
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future clinical nanomedicine interventions and suggests humans may have 
differential responses to NMP programming depending, in part, on their immune 
status.  Some evidence exists for this already [299,306].  In future, pre-screening of 
patients for known immune parameters (e.g., allergies, asthma, autoimmune 
disorders, recent sickness, age, gender) may be an important aspect of ensuring 
appropriate dosing and delivery strategies of NMP therapeutics. 
We translated our ex vivo findings into a humanized mouse model to gain a 
better appreciation of the complexities of human immune cell targeting in a whole 
animal.  Our findings were largely recapitulated, with hydrogel particles taken up 
primarily by human CD14+ myeloid cells and CD11c+ DC, with PEGylation impeding 
this process.  CD14 expression levels also correlated with particle uptake in this in 
vivo setting.  We did not find any indication of an inflammatory response to NP 
treatment as assessed by mRNA analysis for human cytokines.  Interestingly, we 
noted enhanced targeting of PEGylated particles to human plasmacytoid dendritic 
cells (pDC), which may be an attractive cell population to program in applications 
related to viral infection, such as vaccines.  .   
In the absence of PEGylation, hydrogels showed a modest  uptake into 
human CD4 and CD8 T cells in the bone marrow.  This is also an exciting finding, as 
access to T cells by NP may enable direct programming of these very potent 
adaptive immune cells.  As the bone marrow contains T cell precursors as well as 
memory and regulatory T cell subsets, further characterization of which classes are 
targeted by particles is necessary [355].  However, targeting any, or all, of these 
populations could confer unique therapeutic opportunities in a variety of disease 
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spaces.  Clearly, more work needs to be done to show the low level of in vivo 
targeting we see is sufficient for therapeutic instruction.  Alternative targeting 
strategies, such as T cell specific antibody conjugation on the particle surface, may 
enable more robust efficacy in downstream applications.  The general cross-
validation of our ex vivo PBMC studies and humanized mouse work further validates 
each study and suggests the humanized mice may be a more clinically relevant 
model for NMP translational applications. 
Programming Immune Responses with PRINT Particles 
Having systematically characterized the immune response to PRINT NMP in 
both mouse and humans, we felt confident in the general immunologic inertness of 
our particle platform.  Thus, in Chapter 4, we turned to early sketches on this blank 
canvas to reveal some of the potential programming opportunities available through 
rationally designed NMP.  Through the fabrication control inherent to PRINT, we 
were able to uncover biological details relevant to programming immunity that would 
have been masked using other fabrication systems.  They are summarized here as 
testament to the power of the PRINT platform for probing basic biology  
We first identified simple surface modifications to particles that could 
modulate uptake in a model human immune cell (THP-1).  80x320nm PLGA 
particles could be programmed to remain outside or enter these cells simply by 
adding a cationic lipid to the surface.  This may be a powerful yet low-tech means of 
delivering cargos to extracellular or intracellular spaces, depending on the 
therapeutic need.   
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In a similar fashion, PEGylation of the surface of hydrogels or conjugation of a 
model antigen (OVA) reduced uptake.  Control of the kinetics of uptake and duration 
of antigen presentation are key parameters in modulating adaptive immune 
responses, in part through differential targeting of MHC I or MHC II pathways 
[24,115,178,246].  As has been shown in other particle systems, this is a potentially 
simple yet powerful approach to skewing vaccine responses towards CD4+ or CD8+ 
effector cells [246,356]. 
By coating the TLR4 ligand LPS onto PRINT NMP, we identified differences 
in the timing and magnitude of inflammasome activation based on particle size, 
shape and composition.  This provides evidence for the ability to control both the 
kinetics and intensity of biological signaling pathways with NMP.  These are two 
critical components of cell network communication and will likely be a boon to 
programming efforts in the immunoengineering space [317].  In addition, design 
control over inflammasome activation may itself enhance vaccine efficacy, such as 
for those targeting fungal infections or induction of Th17 responses. 
As inflammation drives pathology in numerous diseases including cancer, 
metabolic syndrome, atherosclerosis, stroke and neurodegenerative disorders 
[17,34,127,137,241,321-323], we sought design features that would enable NMP to 
program anti-inflammatory responses.  To this end, we fabricated PLGA particles 
with the omega-3 fatty acid docosahexaenoic acid (DHA), as literature supports its 
potent anti-inflammatory properties [326,328].  In addition, we incorporated the lipid 
phosphatidylserine (PS) into particles as it is known to have strong 
immunoregulatory functions, in part through production of anti-inflammatory and 
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immunoregulatory cytokines [329,333,335].  Both particles compositions were able 
to significantly inhibit inflammasome activation in vitro, whereas soluble controls 
were ineffective at the same dose.  Size-dependent differences in the magnitude of 
inflammation inhibition may reflect the power of PRINT to tease out small biological 
details and the complex role of ligand presentation on ensuing biological responses.   
This theme of emergent properties manifesting when bioactive ligands are 
delivered via NMP is one we cannot stress enough, as any small molecule may have 
its own unique properties when made particulate. These NMPs are entirely natural 
and biodegradable anti-inflammatory devices that we are now testing in in vivo 
models with inflammatory sequelae.  We also note the modularity and fabrication 
ease of incorporating fatty acids and lipids into PLGA particles with the PRINT 
process.  This is a research space worth pursuing given the potent biological 
properties of commercially available endogenous fatty acids and lipids.   
Work we would like to see undertaken involves combinatorial delivery of 
ligands for multiple receptor families.  A prime example is the design of vaccine 
carriers which would contain adjuvants for multiple classes of pattern recognition 
receptors.  For example, this could include TLR, NLR and/or RLR ligands to potently 
augment innate immune activation.  It is known that multiple TLR ligands when 
delivered by NMP show synergistic effects and enhance adaptive immune response 
to co-delivered antigens [204,207], thus it is likely that combinatorial signaling 
between PRRs will be even more advantageous as this more closely mimics the 
cellular response to natural infection.  To our knowledge, this is a design space that 
has not been studied to date. 
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Our final studies in Chapter 4 focused on programming immune tolerance, as 
this has immediate relevance to a number of poorly treated diseases that afflict 
millions of people, including allergies, asthma, organ transplantation and 
autoimmune disorders.  We believe we have identified NMP design parameters that 
may enable the programming of two immune tolerance pathways.  In the first, we 
simply conjugated the model antigen OVA onto the surface of our previously 
identified inert 80x320nm hydrogel particles (Chapters 2 and 3).  In a mouse model 
of asthma where mice are sensitized to OVA as an allergen, particle delivery of OVA 
to the lungs completely abrogates the allergy response.  The mechanism for this has 
not been elucidated as of yet.  However, we are bolstered in our findings by a paper 
published after our studies showing induction of tolerance in a mouse model of 
multiple sclerosis by simply conjugating the antigen at issue to a PLGA particle 
[250].  The study authors identified anergy of effector T cells as the primary 
mechanism of tolerance induction by antigen-conjugated PLGA particles with no 
evidence for a role of regulatory T cells (Treg).   
Because there are different pathways to generate tolerance and Treg are 
critical to maintaining immune tolerance throughout the body, we deemed it useful to 
identify NMP design parameters that could program expansion of the Treg 
population.  We hypothesized that particles fabricated with PLGA and 
phosphatidylserine (PS) would be processed similarly to apoptotic cells (which have 
PS exposed on their surface), namely in an immunosuppressive manner 
characterized by production of IL-10 and TGF-β [329,330,332,335].  In support of 
our reasoning and during the course of our dissertation work, two groups published 
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that delivery of liposomal PS could indeed produce these immunoregulatory 
cytokines [333,334].  However, they did not address the potential of their PS 
particles to modulate tolerance, which is our main interest.  
Using a co-culture system with mouse DC and Th1-skewed MOG-specific 
2D2 T cells, 80x320nm PLGA-PS NP dampened production of IFN-γ from T cells 
while significantly increasing production of IL-10 and FOXP3 expression.  At the 
same dose, soluble PS was unable to induce IL-10 or FOXP3 expression in T cells, 
exemplifying the theme of emergent properties when using particulate ligands.  
These exciting findings may suggest that an entirely natural and biodegradable 
PLGA-PS NP can reprogram T cells with effector-skewed responses to an antigen 
into Treg cells with tolerizing responses to that same antigen.  While much work 
remains, this may be a powerful and clinically unheralded means of treating 
autoimmune disorders and improving clinical outcomes after organ transplantation.  
In addition, it epitomizes our belief that rationally designed NMP have the potential to 
fundamentally change treatment and clinical outcomes for the panoply of modern 
diseases while also serving as immensely detailed probes of biology.   
We have glimpsed only a small spectrum of the potential of NMP for 
immunoengineering approaches.  Given their modularity, these devices can be 
designed to include small molecules, siRNAs, expression vectors, proteins, 
antibodies, in short anything one could possibly want to paint with.  The possibilities 
for biological programming are truly awe-inspiring. 
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Final Thoughts 
The prevailing realization one has when considering the complexity of 
biological systems is how impossibly simple it all is: input<->output.  Of course, 
there’s a lot that goes on in the in between space!  What is absolutely clear is the 
tremendous amount of integration and collaboration that must occur within and 
between cells in order for the higher organism to exist.  This integration and 
collaboration goes beyond the cellular level, as collaboration between organisms is a 
prerequisite for life; without peaceful coexistence with the 100 plus trillion bacteria 
that cohabit our body, we quickly fall into disrepair [8,10,12,80,147,357,358].   
Through collaboration, higher functions manifest.  We take this to heart, as 
the work presented in this dissertation required collaborations with at least 16 
scientists across multiple disciplines.  We also benefited from knowledge 
collaborations with thousands of scientists, referenced throughout this dissertation, 
whose research laid the ground work and intellectual framework for our studies.  
 Only through massive collaboration across disparate disciplines will scientists 
and non-scientists alike solve the world’s most pressing problems.  By learning 
about biology, we must also learn from it. We, and all the other living things among 
us, will be better for it. 
 
“There’s a natural mystic blowing through the air…”  
-Bob Marley 
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